[
  {
    "id": "covid_fact-000001",
    "statement": "Measuring sars-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that pseudotyped viruses (HIV-1 and VSV) and a chimeric virus (VSV/SARS-CoV-2) were used to measure neutralizing antibody activity, aligning with the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.11288988590240479,
    "x2e_entail_prob": 0.001309168292209506
  },
  {
    "id": "covid_fact-000002",
    "statement": "Measuring chs-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly describes the use of pseudotyped and chimeric viruses to measure neutralizing antibody activity against SARS-CoV-2, confirming the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1056642085313797,
    "x2e_entail_prob": 0.0012754707131534815
  },
  {
    "id": "covid_fact-000003",
    "statement": "Measuring aces-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence details the use of pseudotyped HIV-1 and VSV viruses as well as a chimeric VSV/SARS-CoV-2 virus to measure neutralizing antibody activity against SARS-CoV-2, confirming the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0896044671535492,
    "x2e_entail_prob": 0.0013920132769271731
  },
  {
    "id": "covid_fact-000004",
    "statement": "Measuring gps-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly describes the use of pseudotyped (HIV-1 and VSV) and chimeric viruses to measure neutralizing antibody activity against SARS-CoV-2, which aligns with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.13762913644313812,
    "x2e_entail_prob": 0.0011382425436750054
  },
  {
    "id": "covid_fact-000005",
    "statement": "Long-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that IgG antibodies in healthcare workers infected with SARS-CoV persisted at high levels until 2015 and can last for at least 12 years, directly supporting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.5829398036003113,
    "x2e_entail_prob": 0.0026644770987331867
  },
  {
    "id": "covid_fact-000006",
    "statement": "short-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that IgG antibodies persisted for at least 12 years, which contradicts the claim of 'short-term persistence.'",
    "confidence": 0.9,
    "e2x_entail_prob": 0.03949551656842232,
    "x2e_entail_prob": 0.0016244747675955296
  },
  {
    "id": "covid_fact-000007",
    "statement": "Low-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that IgG antibodies persist for at least 12 years in SARS-CoV-infected healthcare workers, contradicting the claim of low-term persistence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.33242765069007874,
    "x2e_entail_prob": 0.0012571460101753473
  },
  {
    "id": "covid_fact-000008",
    "statement": "Pre-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that IgG titers in SARS-CoV-infected healthcare workers remained high until 2015 and can persist for at least 12 years, which directly supports the claim about pre-term persistence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.18765883147716522,
    "x2e_entail_prob": 0.002465616213157773
  },
  {
    "id": "covid_fact-000009",
    "statement": "Coronavirus dons a new crown",
    "label": "SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes crown-like structures in coronaviruses, supporting the claim about their crown appearance.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6427892446517944,
    "x2e_entail_prob": 0.0028027149382978678
  },
  {
    "id": "covid_fact-000010",
    "statement": "Coronavirus dons a new question",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is unclear and may contain a typo or mistranslation ('dons a new question'). The evidence discusses structural aspects of coronaviruses but does not explicitly support the ambiguous claim.",
    "confidence": 0.3,
    "e2x_entail_prob": 0.08435379713773727,
    "x2e_entail_prob": 0.02370932511985302
  },
  {
    "id": "covid_fact-000011",
    "statement": "Coronavirus dons a new term",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explains why coronaviruses are named as such due to crown-like structures but does not indicate a new term has been adopted.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.002884584479033947,
    "x2e_entail_prob": 0.004824446979910135
  },
  {
    "id": "covid_fact-000012",
    "statement": "Immune memory in mild covid-19 patients and unexposed donors from india reveals persistent t cell responses after sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Moreover, we found detectable immune reactivity up to 5 months in mild COVID-19 recovered patients in the two major arms of protective adaptive immunity; CD4+ T cells and B cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports persistent T cell responses in mild COVID-19 patients but does not mention unexposed donors from India.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0008317572646774352,
    "x2e_entail_prob": 0.0022285250015556812
  },
  {
    "id": "covid_fact-000013",
    "statement": "Immune memory in mild covid-19 patients and unexposed donors from india reveals persistent t cell depletion after sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Moreover, we found detectable immune reactivity up to 5 months in mild COVID-19 recovered patients in the two major arms of protective adaptive immunity; CD4+ T cells and B cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses immune reactivity up to 5 months in mild COVID-19 patients but does not mention T cell depletion or unexposed donors from India. The claim about persistent T cell depletion is not supported by the given evidence.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.02604961208999157,
    "x2e_entail_prob": 0.0017004578839987516
  },
  {
    "id": "covid_fact-000014",
    "statement": "Simple probiotics might help inhibit covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Other research suggests that probiotic supplementation may promote antiviral activity in general to improve immune, pulmonary, and anti-inflammatory response that might help clear the SARS-CoV-2 infection (70, 71)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that probiotics may enhance immune and antiviral responses, which could help inhibit COVID-19 infection. However, the support is based on referenced studies rather than direct evidence in the text provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0024109852965921164,
    "x2e_entail_prob": 0.004769245628267527
  },
  {
    "id": "covid_fact-000015",
    "statement": "Simple probiotics might help cause covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Other research suggests that probiotic supplementation may promote antiviral activity in general to improve immune, pulmonary, and anti-inflammatory response that might help clear the SARS-CoV-2 infection (70, 71)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that probiotics may help improve immune responses and fight SARS-CoV-2, contradicting the claim that they cause COVID-19 infection.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.001624807482585311,
    "x2e_entail_prob": 0.0020829017739742994
  },
  {
    "id": "covid_fact-000016",
    "statement": "Uk bans parallel export and hoarding of lopinavir+ritonavir , chloroquine and hydroxychloroquine",
    "label": "SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the UK has restricted the export of lopinavir+ritonavir, chloroquine, and hydroxychloroquine to meet domestic patient needs. While the claim mentions both a ban on parallel exports and hoarding, only the export restriction is explicitly supported by the evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.014772248454391956,
    "x2e_entail_prob": 0.01806679740548134
  },
  {
    "id": "covid_fact-000017",
    "statement": "Uk bans parallel training and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the UK restricted the export of lopinavir+ritonavir, chloroquine, and hydroxychloroquine to meet domestic patient needs. While 'parallel training' is unclear, the main restrictions on these drugs are supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.016738712787628174,
    "x2e_entail_prob": 0.026861056685447693
  },
  {
    "id": "covid_fact-000018",
    "statement": "Ukakes parallel export and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that while the drugs are not listed in the March 31, 2020 addition, there was a separate government action restricting their export to prevent hoarding and ensure supply for UK patients.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.003497303696349263,
    "x2e_entail_prob": 0.1662088930606842
  },
  {
    "id": "covid_fact-000019",
    "statement": "Ukolls parallel export and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the UK added lopinavir+ritonavir, chloroquine, and hydroxychloroquine to a list of medicines restricted from parallel export, indicating measures against hoarding and ensuring supply for UK patients.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.007849171757698059,
    "x2e_entail_prob": 0.14422501623630524
  },
  {
    "id": "covid_fact-000020",
    "statement": "Air quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a correlation between air pollution and pandemic severity, including preventive measures related to air quality.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.964072048664093,
    "x2e_entail_prob": 0.016391541808843613
  },
  {
    "id": "covid_fact-000021",
    "statement": "Virus quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported as the evidence discusses how air pollution affects virus virulence and disease progression, indicating that virus quality influences pandemics. However, other factors are also acknowledged.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.7361363768577576,
    "x2e_entail_prob": 0.00444140424951911
  },
  {
    "id": "covid_fact-000022",
    "statement": "Health quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses how air pollution influences pandemic severity but does not specifically address 'health quality' influencing the pandemic beyond environmental factors.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.055200155824422836,
    "x2e_entail_prob": 0.0035422281362116337
  },
  {
    "id": "covid_fact-000023",
    "statement": "Global quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates a correlation between air pollution and the severity of viral outbreaks, including COVID-19, supporting the claim that global quality influences pandemics.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3415220081806183,
    "x2e_entail_prob": 0.002286142436787486
  },
  {
    "id": "covid_fact-000024",
    "statement": "Single-cell omics reveals dyssynchrony of the innate and adaptive immune system in progressive covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we utilize multiomics single-cell analysis to probe dynamic immune responses in patients with stable or progressive manifestations of COVID-19, and assess the effects of tocilizumab, an anti-IL-6 receptor monoclonal antibody."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses using single-cell analysis to study immune responses but does not specifically address dyssynchrony between innate and adaptive immunity in progressive COVID-19.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.004338654223829508,
    "x2e_entail_prob": 0.0069599878042936325
  },
  {
    "id": "covid_fact-000025",
    "statement": "Single-brain omics reveals dyssynchrony of the innate and adaptive immune system in progressive covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we utilize multiomics single-cell analysis to probe dynamic immune responses in patients with stable or progressive manifestations of COVID-19, and assess the effects of tocilizumab, an anti-IL-6 receptor monoclonal antibody."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention 'single-brain omics' or the coordination between innate and adaptive immune systems in progressive COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0038981942925602198,
    "x2e_entail_prob": 0.0067457035183906555
  },
  {
    "id": "covid_fact-000026",
    "statement": "Fenofibrate increases the amount of sulfatide which seems beneficial against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.01604795828461647,
    "x2e_entail_prob": 0.005044748540967703
  },
  {
    "id": "covid_fact-000027",
    "statement": "Fenofibrate reduces the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that fenofibrate increases sulfatide levels, which contradicts the claim that it reduces them.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.00432751327753067,
    "x2e_entail_prob": 0.0010672976495698094
  },
  {
    "id": "covid_fact-000028",
    "statement": "Fenofibrate reduced the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that fenofibrate increases sulfatide levels, which may have a beneficial effect against coronavirus infection. However, the claim asserts that fenofibrate reduces sulfatide levels and that this reduction is beneficial against COVID-19. The evidence directly contradicts the claim by indicating that increasing sulfatides is the mechanism of benefit, not reducing them.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.036914799362421036,
    "x2e_entail_prob": 0.02261287346482277
  },
  {
    "id": "covid_fact-000029",
    "statement": "Fenofibrate decreased the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that fenofibrate increases sulfatide levels, contradicting the claim that it decreases them.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.027514955028891563,
    "x2e_entail_prob": 0.000922907202038914
  },
  {
    "id": "covid_fact-000030",
    "statement": "Gns561 exhibits potent in vitro antiviral activity against sars-cov-2 through autophagy inhibition",
    "label": "SUPPORTED",
    "evidences": [
      "Overall, our study highlights GNS561 as a powerful drug in SARS- CoV-2 infection and supports that the hypothesis that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.",
      "Our data indicated that GNS561 showed the highest antiviral effect for two SARS-CoV-2 strains compared to CQ and remdesivir.",
      "Finally, our study revealed that the combination of GNS561 and remdesivir was associated with a strong synergistic antiviral effect against SARS-CoV-2.",
      "Here, we investigated the antiviral activity and associated mechanism of GNS561, a small basic lipophilic molecule inhibitor of late-stage autophagy, against SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows GNS561's potent in vitro antiviral activity against SARS-CoV-2 and its role as an autophagy inhibitor, directly supporting the claim.",
    "confidence": 0.98,
    "e2x_entail_prob": 0.16233883798122406,
    "x2e_entail_prob": 0.712931752204895
  },
  {
    "id": "covid_fact-000031",
    "statement": "Gns561 exhibits no in vitro antiviral activity against sars-cov-2 through autophagy inhibition",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall, our study highlights GNS561 as a powerful drug in SARS- CoV-2 infection and supports that the hypothesis that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.",
      "Our data indicated that GNS561 showed the highest antiviral effect for two SARS-CoV-2 strains compared to CQ and remdesivir.",
      "Finally, our study revealed that the combination of GNS561 and remdesivir was associated with a strong synergistic antiviral effect against SARS-CoV-2.",
      "Here, we investigated the antiviral activity and associated mechanism of GNS561, a small basic lipophilic molecule inhibitor of late-stage autophagy, against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence demonstrates that GNS561 has significant antiviral activity against SARS-CoV-2 and supports its use as an autophagy inhibitor in combating the virus, directly contradicting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.01514396071434021,
    "x2e_entail_prob": 0.8145427107810974
  },
  {
    "id": "covid_fact-000032",
    "statement": "Suspicions grow that nanoparticles in pfizer 's covid-19 vaccine trigger rare allergic reactions.",
    "label": "SUPPORTED",
    "evidences": [
      "Severe allergy-like reactions in at least eight people who received the COVID-19 vaccine produced by Pfizer and BioNTech over the past 2 weeks may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccines main ingredient, scientists say.",
      "Patients with severe allergies in the US are getting nervous about the possibility that they may not be able to get vaccinated, at least with those two vaccines, Togias wrote in an invitation to meeting participants.",
      "Some allergists and immunologists believe a small number of people previously exposed to PEG may have high levels of antibodies against PEG, putting them at risk of an anaphylactic reaction to the vaccine.",
      "NIAID is also setting up a study in collaboration with FDA to analyze the response to the vaccine in people who have high levels of anti-PEG antibodies or have experienced severe allergic responses to drugs or vaccines before."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence points to polyethylene glycol (PEG) as the possible trigger for allergic reactions, not nanoparticles.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.018884101882576942,
    "x2e_entail_prob": 0.0016203715931624174
  },
  {
    "id": "covid_fact-000033",
    "statement": "Suspicions grow that nanoparticles in pfizer's covid-19 vaccine trigger systemic allergic reactions.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severe allergy-like reactions in at least eight people who received the COVID-19 vaccine produced by Pfizer and BioNTech over the past 2 weeks may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccines main ingredient, scientists say.",
      "Patients with severe allergies in the US are getting nervous about the possibility that they may not be able to get vaccinated, at least with those two vaccines, Togias wrote in an invitation to meeting participants.",
      "Some allergists and immunologists believe a small number of people previously exposed to PEG may have high levels of antibodies against PEG, putting them at risk of an anaphylactic reaction to the vaccine.",
      "NIAID is also setting up a study in collaboration with FDA to analyze the response to the vaccine in people who have high levels of anti-PEG antibodies or have experienced severe allergic responses to drugs or vaccines before."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence links severe allergic reactions to PEG, a compound in the vaccine's packaging (part of lipid nanoparticles), supporting the claim that components in the vaccine cause allergies, though not directly the nanoparticles themselves.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.037552885711193085,
    "x2e_entail_prob": 0.0018069461220875382
  },
  {
    "id": "covid_fact-000034",
    "statement": "Berberine and obatoclax inhibit sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that both berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial cells, supporting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.6343042850494385,
    "x2e_entail_prob": 0.0227762870490551
  },
  {
    "id": "covid_fact-000035",
    "statement": "Berberine and obatoclax induce sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that both berberine and obatoclax inhibited SARS-CoV-2 replication, directly contradicting the claim that they induce replication.",
    "confidence": 1,
    "e2x_entail_prob": 0.022278238087892532,
    "x2e_entail_prob": 0.019963940605521202
  },
  {
    "id": "covid_fact-000036",
    "statement": "Berberine and obatoclax induced sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that Berberine and obatoclax inhibited SARS-CoV-2 replication, contradicting the claim that they induced it.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.023005545139312744,
    "x2e_entail_prob": 0.02348168194293976
  },
  {
    "id": "covid_fact-000037",
    "statement": "Berberine and obatoclax are sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial cells in vitro, which directly supports the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.058019399642944336,
    "x2e_entail_prob": 0.030469181016087532
  },
  {
    "id": "covid_fact-000038",
    "statement": "Taiwan completes synthesis of potential covid-19 drug",
    "label": "SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that Taiwan's DCB synthesized the potential COVID-19 drug in four days and aims to mass-produce it, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.20841851830482483,
    "x2e_entail_prob": 0.0012893166858702898
  },
  {
    "id": "covid_fact-000039",
    "statement": "Taiwan inhibits synthesis of potential covid-19 drug",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests Taiwan is inhibiting the synthesis of a COVID-19 drug, but the evidence shows Taiwan successfully synthesized the drug and plans to mass-produce it.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.009942208416759968,
    "x2e_entail_prob": 0.0008928528404794633
  },
  {
    "id": "covid_fact-000040",
    "statement": "Taiwan requires synthesis of potential covid-19 drug",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Taiwan's DCB center successfully synthesized the drug in four days and aims to transfer production to domestic companies, confirming the requirement for synthesizing a COVID-19 drug.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.09633307158946991,
    "x2e_entail_prob": 0.0012078487779945135
  },
  {
    "id": "covid_fact-000041",
    "statement": "25-hydroxyvitamin d concentrations are lower in patients with positive pcr for sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by showing that patients with positive PCR for SARS-CoV-2 had significantly lower 25-hydroxyvitamin D levels compared to those with negative PCR.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.005869616754353046,
    "x2e_entail_prob": 0.16170106828212738
  },
  {
    "id": "covid_fact-000042",
    "statement": "25-hydroxyvitamin d concentrations are elevated in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that 25-hydroxyvitamin D levels were significantly lower in patients with positive PCR results, contradicting the claim of elevated concentrations.",
    "confidence": 1,
    "e2x_entail_prob": 0.006569621153175831,
    "x2e_entail_prob": 0.1534045934677124
  },
  {
    "id": "covid_fact-000043",
    "statement": "25-hydroxyvitamin d concentrations are increased in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly shows that 25-hydroxyvitamin D levels were significantly lower in patients with positive PCR for SARS-CoV-2, contradicting the claim of increased concentrations.",
    "confidence": 1,
    "e2x_entail_prob": 0.004632401280105114,
    "x2e_entail_prob": 0.17635299265384674
  },
  {
    "id": "covid_fact-000044",
    "statement": "25-hydroxyvitamin d concentrations are higher in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that patients with positive PCR for SARS-CoV-2 had significantly lower 25-hydroxyvitamin D levels compared to those with negative PCR, which contradicts the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.007230604067444801,
    "x2e_entail_prob": 0.20536629855632782
  },
  {
    "id": "covid_fact-000045",
    "statement": "Us racial inequality may be as deadly as covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that racial inequality's impact on mortality is significant, requiring COVID-19 to cause extreme setbacks in White mortality progress to match it. This supports the claim that racial inequality may be as deadly as COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.6307377815246582,
    "x2e_entail_prob": 0.005666840355843306
  },
  {
    "id": "covid_fact-000046",
    "statement": "Us racial inequality may be as useful as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim incorrectly uses 'useful,' suggesting a positive aspect, while both racial inequality and COVID-19 are harmful. The evidence supports their negative impact on mortality but doesn't validate the idea of usefulness.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.057382069528102875,
    "x2e_entail_prob": 0.0032700584270060062
  },
  {
    "id": "covid_fact-000047",
    "statement": "Us racial inequality may be as effective as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that racial inequality in the US has a significant impact on mortality, comparable to the effects of COVID-19. The comparison indicates that racial inequality's impact is severe enough that even a major pandemic like COVID-19 would need to erase decades of progress to match its effect.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.646794319152832,
    "x2e_entail_prob": 0.10674386471509933
  },
  {
    "id": "covid_fact-000048",
    "statement": "Us racial transmission may be as deadly as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that racial inequality has a significant impact on mortality rates, comparable to the effects of COVID-19, thus supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.05557854846119881,
    "x2e_entail_prob": 0.003917739260941744
  },
  {
    "id": "covid_fact-000049",
    "statement": "Immunity to covid-19 is probably higher than tests have shown",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that T-cell immunity was found in more people than those with detectable antibodies, indicating higher overall immunity than what antibody tests suggest.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9141578674316406,
    "x2e_entail_prob": 0.0033875140361487865
  },
  {
    "id": "covid_fact-000050",
    "statement": "Immunity to covid-19 is probably less than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, contradicting the claim that immunity is less than what tests show.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5862834453582764,
    "x2e_entail_prob": 0.0025785386096686125
  },
  {
    "id": "covid_fact-000051",
    "statement": "Immunity to covid-19 is probably lower than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that public immunity to COVID-19 is significantly higher than what antibody tests suggest due to T-cell responses, which are not captured by standard antibody tests. Therefore, the claim that immunity is lower than tests show is contradicted.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.07221853733062744,
    "x2e_entail_prob": 0.003675158368423581
  },
  {
    "id": "covid_fact-000052",
    "statement": "Immunity to covid-19 is probably smaller than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence contradicts the claim by showing that immunity is higher than indicated by antibody tests, specifically mentioning T-cell immunity.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.694793701171875,
    "x2e_entail_prob": 0.0031395726837217808
  },
  {
    "id": "covid_fact-000053",
    "statement": "A novel in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly supports that the novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 for analyzing neutralizing antibodies and antiviral compounds.",
    "confidence": 1,
    "e2x_entail_prob": 0.0660705417394638,
    "x2e_entail_prob": 0.09215562790632248
  },
  {
    "id": "covid_fact-000054",
    "statement": "A standard in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that the icELISA assay allows rapid and automated quantification of SARS-CoV-2 for analyzing neutralizing antibodies and antiviral compounds, though it refers to the method as 'novel,' not explicitly stating it's a standard.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0022949858102947474,
    "x2e_entail_prob": 0.055341266095638275
  },
  {
    "id": "covid_fact-000055",
    "statement": "A conventional in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that an in-cell ELISA assay enables rapid, automated quantification of SARS-CoV-2 for analyzing neutralizing antibodies and antiviral compounds, despite the claim referring to it as 'conventional.'",
    "confidence": 0.9,
    "e2x_entail_prob": 0.055893152952194214,
    "x2e_entail_prob": 0.08551574498414993
  },
  {
    "id": "covid_fact-000056",
    "statement": "A simple in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that an in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds, which fully supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.06018295884132385,
    "x2e_entail_prob": 0.07652508467435837
  },
  {
    "id": "covid_fact-000057",
    "statement": "Stanford professor balaji s. srinivasan 's peer review of the santa clara seroprevalence study indicates that its high reported positive rate results may be explained by the false positive rate of the test and/or by sample recruitment issues .",
    "label": "SUPPORTED",
    "evidences": [
      "The use of such certificates may therefore increase the risks of continued transmission. One of the most well-known attempts to justify sending workers back to offices and factories based on a supposed antibody count comes from the controversial Santa Clara study, as it has come to be known.",
      "The Stanford researchers acknowledged as much in the study and used test performance weights to scale results, but Rutherford was skeptical of these weights, as well as the population weights the researchers used.",
      "In a peer review of the antibody study published to Medium, former Stanford lecturer Balaji Srinivasan, who specializes in statistics and computational biology, argued the selection methods could have overstated the prevalence of the disease in the county.",
      "Dr. Natalie E. Dean, a professor of biostatistics at the University of Florida, tweeted that she had concerns with the adjustments made for clustering (some participants brought children and other household members with them to the test) and test characteristics (researchers assume no false positives but some false negatives)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that Balaji Srinivasan pointed out sample recruitment issues, aligning with part of the claim. While false positives were discussed by another expert, the claim's focus on both factors is somewhat supported but not fully detailed in Srinivasan's review.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.02205096185207367,
    "x2e_entail_prob": 0.0039339009672403336
  },
  {
    "id": "covid_fact-000058",
    "statement": "Stanford professor balaji s. srinivasan's peer review of the santa clara seroprevalence study indicates that its high reported positive rate results cannot be explained by the false positive rate of the test and/or by sample recruitment issues.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The use of such certificates may therefore increase the risks of continued transmission. One of the most well-known attempts to justify sending workers back to offices and factories based on a supposed antibody count comes from the controversial Santa Clara study, as it has come to be known.",
      "The Stanford researchers acknowledged as much in the study and used test performance weights to scale results, but Rutherford was skeptical of these weights, as well as the population weights the researchers used.",
      "In a peer review of the antibody study published to Medium, former Stanford lecturer Balaji Srinivasan, who specializes in statistics and computational biology, argued the selection methods could have overstated the prevalence of the disease in the county.",
      "Dr. Natalie E. Dean, a professor of biostatistics at the University of Florida, tweeted that she had concerns with the adjustments made for clustering (some participants brought children and other household members with them to the test) and test characteristics (researchers assume no false positives but some false negatives)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that Balaji Srinivasan, a former Stanford lecturer (not current professor), peer-reviewed the Santa Clara study and criticized its selection methods for potentially overstating prevalence. Additionally, Dr. Natalie Dean pointed out concerns about clustering in sampling and test characteristics. These criticisms suggest that sample recruitment issues and false positives could explain the high reported positive rates, contradicting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8933358788490295,
    "x2e_entail_prob": 0.0029179162811487913
  },
  {
    "id": "covid_fact-000059",
    "statement": "Fda takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the FDA issued an emergency use authorization for the first COVID-19 vaccine (Pfizer-BioNTech) as a key action in fighting the pandemic.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.38359335064888,
    "x2e_entail_prob": 0.004830459598451853
  },
  {
    "id": "covid_fact-000060",
    "statement": "Sars takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the FDA issuing an emergency use authorization for a COVID-19 vaccine but does not mention SARS or any actions taken by it. The claim conflates two separate entities, making it unsupported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.01542441826313734,
    "x2e_entail_prob": 0.0010581831447780132
  },
  {
    "id": "covid_fact-000061",
    "statement": "China takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the FDA's emergency use authorization for the Pfizer-BioNTech vaccine in the U.S., not China issuing such an authorization.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1258372813463211,
    "x2e_entail_prob": 0.001016182010062039
  },
  {
    "id": "covid_fact-000062",
    "statement": "Who takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that the FDA issued the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine, confirming their role in taking key action against COVID-19.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1312822848558426,
    "x2e_entail_prob": 0.0018926822813227773
  },
  {
    "id": "covid_fact-000063",
    "statement": "Sherlock biosciences receives fda emergency use authorization for crispr sars-cov-2 rapid diagnostic",
    "label": "SUPPORTED",
    "evidences": [
      "In addition to SHERLOCK, the company is also developing its INSPECTR platform to create an instrument-free, handheld test  similar to that of an at-home pregnancy test  that utilizes Sherlock Biosciences Synthetic Biology platform to provide rapid detection of a genetic match of the SARS-CoV-2 virus.",
      "Cambridge, Mass., May 7, 2020  Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19, providing results in approximately one hour."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Sherlock Biosciences received FDA Emergency Use Authorization for their CRISPR SARS-CoV-2 kit, confirming the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.08449823409318924,
    "x2e_entail_prob": 0.0009520899038761854
  },
  {
    "id": "covid_fact-000064",
    "statement": "Sherlock biosciences receives no emergency use authorization for crispr sars-cov-2 rapid diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition to SHERLOCK, the company is also developing its INSPECTR platform to create an instrument-free, handheld test  similar to that of an at-home pregnancy test  that utilizes Sherlock Biosciences Synthetic Biology platform to provide rapid detection of a genetic match of the SARS-CoV-2 virus.",
      "Cambridge, Mass., May 7, 2020  Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19, providing results in approximately one hour."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that Sherlock Biosciences received Emergency Use Authorization (EUA) from the FDA for its Sherlock CRISPR SARS-CoV-2 kit, contradicting the claim that they did not receive any EUA.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.004598666448146105,
    "x2e_entail_prob": 0.0009608814143575728
  },
  {
    "id": "covid_fact-000065",
    "statement": "Lipoic acid helps response in g6pd population",
    "label": "SUPPORTED",
    "evidences": [
      "\u0391-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that \u03b1-lipoic acid supplementation increases antioxidant capacity in individuals with G6PD deficiency, supporting the claim that lipoic acid helps responses related to oxidative stress in this population.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.09282730519771576,
    "x2e_entail_prob": 0.24577146768569946
  },
  {
    "id": "covid_fact-000066",
    "statement": "Lipoic acid helps degradation in g6pd population",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\u0391-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that \u03b1-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency, which supports the claim that lipoic acid helps with aspects of this population.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1999448835849762,
    "x2e_entail_prob": 0.10253289341926575
  },
  {
    "id": "covid_fact-000067",
    "statement": "Lipoic acid stress response in g6pd population",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\u0391-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that \u03b1-lipoic acid supplementation increases antioxidant capacity in adults with G6PD deficiency. Since antioxidant capacity is part of managing oxidative stress, this supports the claim that lipoic acid aids the stress response in this population.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.02512064203619957,
    "x2e_entail_prob": 0.24986632168293
  },
  {
    "id": "covid_fact-000068",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals inhibition of virus entry by iota-carrageenan",
    "label": "SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that iota-carrageenan inhibits virus entry in vitro against Coronaviruses and other respiratory viruses, leading to clinical effectiveness. The data suggests its potential for SARS-CoV-2 infections.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9696251153945923,
    "x2e_entail_prob": 0.016878532245755196
  },
  {
    "id": "covid_fact-000069",
    "statement": "Sars-cov-2 in-vitro neutralization assay blocked inhibition of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that iota-carrageenan is effective against various coronaviruses and has clinical benefits, but it doesn't specifically mention an in-vitro neutralization assay for SARS-CoV-2.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.003788725705817342,
    "x2e_entail_prob": 0.007385424338281155
  },
  {
    "id": "covid_fact-000070",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals induction of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that iota-carrageenan has antiviral effects and clinical benefits against respiratory viruses, including SARS-CoV-2. This contradicts the claim that it induces virus entry.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.03265935182571411,
    "x2e_entail_prob": 0.0028574152383953333
  },
  {
    "id": "covid_fact-000071",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals enhancement of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that iota-carrageenan is effective against respiratory viruses, including SARS-CoV-2, by reducing symptoms and not enhancing virus entry. The claim incorrectly states that the assay reveals enhancement of virus entry.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.24357767403125763,
    "x2e_entail_prob": 0.005826984066516161
  },
  {
    "id": "covid_fact-000072",
    "statement": "Two thirds of people contacted through tracing did not fully cooperate , pilot scheme finds",
    "label": "SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim, stating that two-thirds of people contacted did not fully cooperate during the pilot scheme.",
    "confidence": 1,
    "e2x_entail_prob": 0.45185115933418274,
    "x2e_entail_prob": 0.0026390922721475363
  },
  {
    "id": "covid_fact-000073",
    "statement": "Two thirds of people contacted through tracing did indeed fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that two thirds of people contacted through tracing did not fully cooperate, contradicting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.058074332773685455,
    "x2e_entail_prob": 0.0018997815204784274
  },
  {
    "id": "covid_fact-000074",
    "statement": "Two thirds of people contacted through tracing did it fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that two-thirds of people contacted through tracing did not fully cooperate, which directly contradicts the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.009607422165572643,
    "x2e_entail_prob": 0.0031594387255609035
  },
  {
    "id": "covid_fact-000075",
    "statement": "Two thirds of people contacted through tracing did still fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that two-thirds of people contacted did not fully cooperate, contradicting the claim which asserts they did.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.007469664793461561,
    "x2e_entail_prob": 0.003225969383493066
  },
  {
    "id": "covid_fact-000076",
    "statement": "The inhaled corticosteroid ciclesonide blocks coronavirus rna replication by targeting viral nsp15",
    "label": "SUPPORTED",
    "evidences": [
      "Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus.",
      "After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics.",
      "These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports the suppression of coronavirus replication by ciclesonide but does not conclusively demonstrate that it targets nsp15.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.46444156765937805,
    "x2e_entail_prob": 0.006889652460813522
  },
  {
    "id": "covid_fact-000077",
    "statement": "The inhaled corticosteroid ciclesonide support coronavirus rna replication by targeting viral nsp15",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus.",
      "After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics.",
      "These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that ciclesonide suppresses coronavirus replication and targets viral nsp15, leading to resistance mutations. This contradicts the claim that it supports RNA replication by targeting nsp15.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.025963138788938522,
    "x2e_entail_prob": 0.003252374939620495
  },
  {
    "id": "covid_fact-000078",
    "statement": "The us doesnt have enough hospital beds for a bad coronavirus outbreak",
    "label": "SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence includes multiple sources, including Cuomo and Dillinger, warning about insufficient hospital beds in the US for a coronavirus outbreak, directly supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.03576774522662163,
    "x2e_entail_prob": 0.002139023970812559
  },
  {
    "id": "covid_fact-000079",
    "statement": "The usset have enough hospital beds for a bad coronavirus outbreak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates concerns about insufficient hospital beds in the U.S., contradicting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.023947373032569885,
    "x2e_entail_prob": 0.011414657346904278
  },
  {
    "id": "covid_fact-000080",
    "statement": "The usert have enough hospital beds for a bad coronavirus outbreak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates concerns about insufficient hospital beds in the U.S. during a potential bad coronavirus outbreak, as highlighted by Cuomo and other warnings. This contradicts the claim that there are enough hospital beds.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.32279711961746216,
    "x2e_entail_prob": 0.0033952929079532623
  },
  {
    "id": "covid_fact-000081",
    "statement": "Oncogen researchers propose personalized vaccinomics strategy for the novel china coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "The candidate peptides were designed by applying to viral antigens a technology used for personalized vaccination in cancer, based on long neoantigen peptides, currently in clinical trials for cancer therapy.",
      "Technical details of the approach used are detailed below: We identified multiepitope peptide vaccine candidates against nCov that can potentially trigger both CD4+ and CD8+ T cell immune response.",
      "The approach that we used for designing potential peptide vaccine candidates takes a more personalized strategy, referred to as vaccinomics , which enables the selection of target viral proteins with low mutation rates, and the design of peptides tuned to the immune characteristics of the target populations, variable based on geographic location and ethnicity.",
      "Based on the human MHC (human leukocyte antigen) allele variation, the peptide vaccines can be made more relevant to a community or individual.",
      "The selection of the peptides that could act as vaccines is determined by the binding of the processed viral peptide with the major histocompatibility complex (MHC) class I and II molecules, and the relevant HLA alleles."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a personalized vaccinomics strategy for designing peptide vaccines against nCov, aligning with the claim about Oncogen researchers proposing such an approach.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.018772315233945847,
    "x2e_entail_prob": 0.04940185323357582
  },
  {
    "id": "covid_fact-000082",
    "statement": "Oncogen researchers propose personalized vaccinomics strategy for the traditional china coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The candidate peptides were designed by applying to viral antigens a technology used for personalized vaccination in cancer, based on long neoantigen peptides, currently in clinical trials for cancer therapy.",
      "Technical details of the approach used are detailed below: We identified multiepitope peptide vaccine candidates against nCov that can potentially trigger both CD4+ and CD8+ T cell immune response.",
      "The approach that we used for designing potential peptide vaccine candidates takes a more personalized strategy, referred to as vaccinomics , which enables the selection of target viral proteins with low mutation rates, and the design of peptides tuned to the immune characteristics of the target populations, variable based on geographic location and ethnicity.",
      "Based on the human MHC (human leukocyte antigen) allele variation, the peptide vaccines can be made more relevant to a community or individual.",
      "The selection of the peptides that could act as vaccines is determined by the binding of the processed viral peptide with the major histocompatibility complex (MHC) class I and II molecules, and the relevant HLA alleles."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a vaccinomics strategy targeting nCov (SARS-CoV-2) with personalized approaches based on MHC alleles, aligning with the claim about Oncogen researchers proposing this for China coronavirus.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.06950724124908447,
    "x2e_entail_prob": 0.0866943895816803
  },
  {
    "id": "covid_fact-000083",
    "statement": "Mathematical analysis of c\u00f3rdoba calcifediol trial suggests strong role for vitamin d in reducing icu admissions of hospitalized covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).",
      "Finally, comparison with two additional randomized clinical trials of vitamin D supplementation for COVID-19 in India and Brazil indicates that early intervention and rapid absorption may be crucial for the observed benefits of vitamin D. We conclude that the C\u00f3rdoba study provides sufficient evidence to warrant immediate, well-designed pivotal clinical trials of early calcifediol administration in a broader cohort of inpatients and outpatients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not mention the C\u00f3rdoba calcifediol trial or its findings regarding vitamin D's impact on ICU admissions for COVID-19 patients. Instead, it discusses other studies and the need for further trials.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.002582093933597207,
    "x2e_entail_prob": 0.01793517731130123
  },
  {
    "id": "covid_fact-000084",
    "statement": "Mathematical analysis of c\u00f3rdoba calcifediol trial suggests strong role against vitamin d in reducing icu admissions of hospitalized covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).",
      "Finally, comparison with two additional randomized clinical trials of vitamin D supplementation for COVID-19 in India and Brazil indicates that early intervention and rapid absorption may be crucial for the observed benefits of vitamin D. We conclude that the C\u00f3rdoba study provides sufficient evidence to warrant immediate, well-designed pivotal clinical trials of early calcifediol administration in a broader cohort of inpatients and outpatients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses support for further clinical trials based on the C\u00f3rdoba study and mentions early intervention benefits, but it does not provide mathematical analysis or results specifically showing a strong role of vitamin D in reducing ICU admissions.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.004945447202771902,
    "x2e_entail_prob": 0.028758447617292404
  },
  {
    "id": "covid_fact-000085",
    "statement": "Artificial intelligence model detects asymptomatic covid-19 infections through cellphone-recorded coughs",
    "label": "SUPPORTED",
    "evidences": [
      "New AI model detects asymptomatic Covid-19 infections through device-recorded coughs Vocal sentiments Prior to the pandemics onset, research groups already had been training algorithms on cellphone recordings of coughs to accurately diagnose conditions such as pneumonia and asthma.",
      "The model identified 98.5 percent of coughs from people confirmed with Covid-19, and of those, it accurately detected all of the asymptomatic coughs.",
      "When they fed the model new cough recordings, it accurately identified 98.5 percent of coughs from people who were confirmed to have Covid-19, including 100 percent of coughs from asymptomatics  who reported they did not have symptoms but had tested positive for the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that an AI model can detect asymptomatic COVID-19 infections using cellphone-recorded coughs with high accuracy (98.5% overall, 100% for asymptomatic cases).",
    "confidence": 0.98,
    "e2x_entail_prob": 0.6039222478866577,
    "x2e_entail_prob": 0.022204900160431862
  },
  {
    "id": "covid_fact-000086",
    "statement": "Artificial intelligence model cannots asymptomatic covid-19 infections through cellphone-recorded coughs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "New AI model detects asymptomatic Covid-19 infections through device-recorded coughs Vocal sentiments Prior to the pandemics onset, research groups already had been training algorithms on cellphone recordings of coughs to accurately diagnose conditions such as pneumonia and asthma.",
      "The model identified 98.5 percent of coughs from people confirmed with Covid-19, and of those, it accurately detected all of the asymptomatic coughs.",
      "When they fed the model new cough recordings, it accurately identified 98.5 percent of coughs from people who were confirmed to have Covid-19, including 100 percent of coughs from asymptomatics  who reported they did not have symptoms but had tested positive for the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that the AI model can detect asymptomatic COVID-19 infections through cellphone-recorded coughs with high accuracy, directly contradicting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0486261323094368,
    "x2e_entail_prob": 0.01404241006821394
  },
  {
    "id": "covid_fact-000087",
    "statement": "Stanford researchers test 3,200 people for covid-19 antibodies",
    "label": "SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention that 3,200 people were tested for COVID-19 antibodies.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.002681630663573742,
    "x2e_entail_prob": 0.0009531287360005081
  },
  {
    "id": "covid_fact-000088",
    "statement": "Stanford researchers test 3,6 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention the number of people tested for COVID-19 antibodies in the Stanford study.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.002711717039346695,
    "x2e_entail_prob": 0.0009106965153478086
  },
  {
    "id": "covid_fact-000089",
    "statement": "Stanford researchers test 3,5 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the antibody tests used in the Stanford study but does not mention how many people were tested for COVID-19 antibodies.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0011006820714101195,
    "x2e_entail_prob": 0.0009773995261639357
  },
  {
    "id": "covid_fact-000090",
    "statement": "Stanford researchers test 3,3 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses Stanford's use of antibody tests for COVID-19 but does not specify the number of participants tested. Without numerical data in the evidence, we cannot confirm that exactly 3,3 people were involved.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.009726610966026783,
    "x2e_entail_prob": 0.0009093499975278974
  },
  {
    "id": "covid_fact-000091",
    "statement": "State lab finds 90 positive covid-19 test results were false",
    "label": "SUPPORTED",
    "evidences": [
      "Of those, a total of 91 specimens from 90 people showed false positive results.",
      "The department said the state public health laboratory uncovered a flaw in one of the testing systems it uses to test for SARS-CoV-2, the virus that causes COVID-19, and 90 of 144 people tested between June 15 and July 17 received a false positive COVID test report.",
      "Accurate and timely testing for the novel coronavirus is one of the pillars supporting effective response to the COVID-19 pandemic. She said adjustments have already been made to ensure the accuracy of future test results from this platform. They said all positive results will be further analyzed by multiple laboratory scientists, and if indicated, retested using another method.",
      "The lab used another FDA-authorized test and found the false positives.",
      "Any nursing home resident who received a false positive COVID-19 test result will be retested as soon as possible, according to the Department of Health."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that 90 individuals received false positive COVID-19 test results due to a flaw in the testing system at the state public health laboratory. This directly supports the claim made.",
    "confidence": 1,
    "e2x_entail_prob": 0.18234188854694366,
    "x2e_entail_prob": 0.002700153039768338
  },
  {
    "id": "covid_fact-000092",
    "statement": "State lab finds 90 positive covid-19 test results were+.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Of those, a total of 91 specimens from 90 people showed false positive results.",
      "The department said the state public health laboratory uncovered a flaw in one of the testing systems it uses to test for SARS-CoV-2, the virus that causes COVID-19, and 90 of 144 people tested between June 15 and July 17 received a false positive COVID test report.",
      "Accurate and timely testing for the novel coronavirus is one of the pillars supporting effective response to the COVID-19 pandemic. She said adjustments have already been made to ensure the accuracy of future test results from this platform. They said all positive results will be further analyzed by multiple laboratory scientists, and if indicated, retested using another method.",
      "The lab used another FDA-authorized test and found the false positives.",
      "Any nursing home resident who received a false positive COVID-19 test result will be retested as soon as possible, according to the Department of Health."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.017770612612366676,
    "x2e_entail_prob": 0.0027308883145451546
  },
  {
    "id": "covid_fact-000093",
    "statement": "Different mutations in sars-cov-2 associate with severe and mild outcome",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence correlates specific SARS-CoV-2 mutations with both mild and severe clinical outcomes, directly supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8783299326896667,
    "x2e_entail_prob": 0.22378182411193848
  },
  {
    "id": "covid_fact-000094",
    "statement": "Different mutations in sars-cov-2 associate against severe and mild outcome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that different SARS-CoV-2 mutations are associated with varying clinical outcomes, from mild to severe.",
    "confidence": 1,
    "e2x_entail_prob": 0.7329394221305847,
    "x2e_entail_prob": 0.1669251173734665
  },
  {
    "id": "covid_fact-000095",
    "statement": "Both mutations in sars-cov-2 associate with severe and mild outcome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that certain SARS-CoV-2 mutations are associated with both mild and severe clinical outcomes, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8185669779777527,
    "x2e_entail_prob": 0.13950097560882568
  },
  {
    "id": "covid_fact-000096",
    "statement": "Moderna advances late-stage development of its vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "11, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced progress on late-stage development of mRNA-1273, the Companys mRNA vaccine candidate against COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that Moderna announced progress on late-stage development of their mRNA vaccine candidate against COVID-19.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.05160367488861084,
    "x2e_entail_prob": 0.043171368539333344
  },
  {
    "id": "covid_fact-000097",
    "statement": "Moderna advances late-stage delivery of its vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "11, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced progress on late-stage development of mRNA-1273, the Companys mRNA vaccine candidate against COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Moderna made progress on the late-stage development of its mRNA vaccine candidate, mRNA-1273, against COVID-19 in November 2020.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.11096087098121643,
    "x2e_entail_prob": 0.3769294023513794
  },
  {
    "id": "covid_fact-000098",
    "statement": "Mathematical modeling explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that a mathematical model was developed to explain differential SARS-CoV-2 kinetics in lung and nasal passages of remdesivir-treated rhesus macaques, aligning directly with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.2229572981595993,
    "x2e_entail_prob": 0.009162146598100662
  },
  {
    "id": "covid_fact-000099",
    "statement": "Phylogenetic modeling explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions 'phylogenetic modeling,' but the evidence describes a 'mathematical model.' While the evidence supports differential SARS-CoV-2 kinetics and remdesivir's effect, it doesn't use phylogenetic methods as claimed.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.3077908456325531,
    "x2e_entail_prob": 0.09039434790611267
  },
  {
    "id": "covid_fact-000100",
    "statement": "Mathematical depletion explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that a mathematical model was developed to explain differential SARS-CoV-2 kinetics in treated macaques, showing lower lung viral loads and increased nasal viral loads.",
    "confidence": 1,
    "e2x_entail_prob": 0.5014403462409973,
    "x2e_entail_prob": 0.02869541198015213
  },
  {
    "id": "covid_fact-000101",
    "statement": "Singapore , taiwan and hong kong have brought outbreaks under control",
    "label": "SUPPORTED",
    "evidences": [
      "Singapore and Taiwan were both seen as examples of how to handle the coronavirus outbreak: stanching the growth of infections, while largely keeping their economies open.",
      "The city, like Singapore and Taiwan, has made headway in containing Covid-19.Credit...Hannah Mckay/Reuters HONG KONG  While the spread of Covid-19 is picking up speed in Europe and the United States, among other regions, the outbreaks in some countries in Asia seem to be under control."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that Singapore, Taiwan, and Hong Kong have controlled their Covid-19 outbreaks effectively.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.10225306451320648,
    "x2e_entail_prob": 0.1637527495622635
  },
  {
    "id": "covid_fact-000102",
    "statement": "Singapore, taiwan and hong kong have no outbreaks under control",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Singapore and Taiwan were both seen as examples of how to handle the coronavirus outbreak: stanching the growth of infections, while largely keeping their economies open.",
      "The city, like Singapore and Taiwan, has made headway in containing Covid-19.Credit...Hannah Mckay/Reuters HONG KONG  While the spread of Covid-19 is picking up speed in Europe and the United States, among other regions, the outbreaks in some countries in Asia seem to be under control."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that Singapore, Taiwan, and Hong Kong have successfully controlled their COVID-19 outbreaks, which contradicts the claim that they do not have their outbreaks under control.",
    "confidence": 1,
    "e2x_entail_prob": 0.4132158160209656,
    "x2e_entail_prob": 0.06653238832950592
  },
  {
    "id": "covid_fact-000103",
    "statement": "Fda gives eua to saliva-based test kit",
    "label": "SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows multiple instances where the FDA issued EUAs for saliva-based test kits, such as SalivaDirect from Yale and Rutgers' test using a saliva collection device.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.06203461438417435,
    "x2e_entail_prob": 0.1046258807182312
  },
  {
    "id": "covid_fact-000104",
    "statement": "Pcr gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the FDA granted EUAs to both Yale and Rutgers for their saliva-based tests, with Rutgers using PCR technology.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.04834730923175812,
    "x2e_entail_prob": 0.06825684010982513
  },
  {
    "id": "covid_fact-000105",
    "statement": "Data gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention an entity named 'Data' receiving an EUA for a saliva-based test kit. Instead, it refers to Yale and Rutgers receiving such authorizations.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.029130009934306145,
    "x2e_entail_prob": 0.12106525152921677
  },
  {
    "id": "covid_fact-000106",
    "statement": "Table gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that the FDA (referred to as 'Table') issued Emergency Use Authorizations (EUA) for saliva-based test kits, such as those developed by Yale School of Public Health and Rutgers Clinical Genomics Laboratory. This directly supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.034697022289037704,
    "x2e_entail_prob": 0.10632173717021942
  },
  {
    "id": "covid_fact-000107",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but not associated with protection",
    "label": "SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports that seasonal human coronavirus (hCoV) cross-reactive antibodies are boosted upon SARS-CoV-2 infection and are not associated with protection against SARS-CoV-2 infections or hospitalizations.",
    "confidence": 1,
    "e2x_entail_prob": 0.412386417388916,
    "x2e_entail_prob": 0.06481783092021942
  },
  {
    "id": "covid_fact-000108",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but also associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence confirms that seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection, it explicitly states that these antibodies are not associated with protection against SARS-CoV-2 infections or hospitalizations.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.04559839516878128,
    "x2e_entail_prob": 0.08560026437044144
  },
  {
    "id": "covid_fact-000109",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but are associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection and are associated with protection. The evidence confirms the first part\u2014antibodies are indeed boosted\u2014but explicitly denies the second part, stating they are not associated with protection against SARS-CoV-2 infections or hospitalizations.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.22073058784008026,
    "x2e_entail_prob": 0.07269024103879929
  },
  {
    "id": "covid_fact-000110",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but strongly associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection and are strongly associated with protection. The evidence confirms the first part\u2014that these antibodies are boosted\u2014but explicitly states they are not associated with protection against SARS-CoV-2 infections or hospitalizations, contradicting the second part of the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1766718626022339,
    "x2e_entail_prob": 0.11640484631061554
  },
  {
    "id": "covid_fact-000111",
    "statement": "Preliminary results of nationwide representative screening are out",
    "label": "SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that preliminary results are out, while the evidence indicates they will be released at the end of May, meaning they are not yet available.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.07675568014383316,
    "x2e_entail_prob": 0.0014754266012459993
  },
  {
    "id": "covid_fact-000112",
    "statement": "Preliminary results of nationwide representative screening are!",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that preliminary results from a nationwide representative screening exist and will be released soon, aligning with the claim despite minor wording differences.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.034969184547662735,
    "x2e_entail_prob": 0.000955720548518002
  },
  {
    "id": "covid_fact-000113",
    "statement": "Preliminary results of nationwide representative screening are?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that preliminary results of the nationwide representative screening exist, will be released at the end of May, and include those older than 14 who do not live in retirement homes or similar institutes.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8456785678863525,
    "x2e_entail_prob": 0.3387179672718048
  },
  {
    "id": "covid_fact-000114",
    "statement": "Preliminary results of nationwide representative screening are\".",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms the existence of preliminary results from a nationwide representative screening, supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.019691048189997673,
    "x2e_entail_prob": 0.0010806455975398421
  },
  {
    "id": "covid_fact-000115",
    "statement": "New self-administered coronavirus test found effective",
    "label": "SUPPORTED",
    "evidences": [
      "Self-administered COVID-19 coronavirus can be just as effective as physician- administered tests, according to a new study by UnitedHealth Group.",
      "Researchers found that self-administered swab tests accurately detected the disease in more than 90 percent of positive patients, which is consistent with physician-administered tests.",
      "Among 500 OptumCare patients in Washington state, the self-administered swabs were able to accurately detect the coronavirus that causes COVID-19 in 90% of those who are positive, a rate that's consistent with physician-administered swabs, the insurance giant announced.",
      "A new study found that self-administered tests may be as effective as those conducted by healthcare workers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides multiple confirmations that self-administered COVID-19 tests are effective, with high accuracy rates and results consistent with physician-administered tests.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.08733122795820236,
    "x2e_entail_prob": 0.3398670554161072
  },
  {
    "id": "covid_fact-000116",
    "statement": "No self-administered coronavirus test found effective",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Self-administered COVID-19 coronavirus can be just as effective as physician- administered tests, according to a new study by UnitedHealth Group.",
      "Researchers found that self-administered swab tests accurately detected the disease in more than 90 percent of positive patients, which is consistent with physician-administered tests.",
      "Among 500 OptumCare patients in Washington state, the self-administered swabs were able to accurately detect the coronavirus that causes COVID-19 in 90% of those who are positive, a rate that's consistent with physician-administered swabs, the insurance giant announced.",
      "A new study found that self-administered tests may be as effective as those conducted by healthcare workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that self-administered COVID-19 tests were found to be as effective as physician-administered tests, with accuracy rates over 90%. This directly contradicts the claim that no such test is effective.",
    "confidence": 1,
    "e2x_entail_prob": 0.004693896975368261,
    "x2e_entail_prob": 0.7203347086906433
  },
  {
    "id": "covid_fact-000117",
    "statement": "Electrostatic spraying will prevent the spread of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that electrostatic spraying improves coverage and reduces wastage but does not provide any specific information about its ability to prevent the spread of COVID-19. Therefore, the claim is not supported by the given evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.008011486381292343,
    "x2e_entail_prob": 0.006486357189714909
  },
  {
    "id": "covid_fact-000118",
    "statement": "Electrostatic spraying will facilitate the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports the effectiveness of electrostatic spraying in disinfection but does not indicate any facilitation of COVID-19 spread.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0039648679085075855,
    "x2e_entail_prob": 0.003915027249604464
  },
  {
    "id": "covid_fact-000119",
    "statement": "Electrostatic spraying will enhance the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explains that electrostatic spraying improves disinfectant coverage and reduces wastage but advises caution during handling. It does not suggest that the method enhances COVID-19 spread; rather, it emphasizes its effectiveness in disinfection when used correctly.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.019949406385421753,
    "x2e_entail_prob": 0.9090466499328613
  },
  {
    "id": "covid_fact-000120",
    "statement": "Electrostatic spraying will promote the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not suggest that electrostatic spraying promotes the spread of COVID-19; rather, it highlights improved disinfection coverage and caution in handling.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.4822145998477936,
    "x2e_entail_prob": 0.6659403443336487
  },
  {
    "id": "covid_fact-000121",
    "statement": "Scientists trace severe covid-19 to faulty genes and autoimmune condition",
    "label": "SUPPORTED",
    "evidences": [
      "These findings provide compelling evidence that the disruption of type I interferon is often the cause of life-threatening COVID-19, says Jean-Laurent Casanova, head of the St. Giles Laboratory of Human Genetics of Infectious Diseases at The Rockefeller University and a Howard Hughes Medical Institute investigator.",
      "COVID-19 may now be the best understood acute infectious disease in terms of having a molecular and genetic explanation for nearly 15 percent of critical cases across diverse ancestries, Casanova says.",
      "Genetics of COVID-19 outliers The way SARS-CoV-2 affects people differently has been puzzling.",
      "Science Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Zhang Q. et al.",
      "Whether the proteins have been neutralized by so-called auto- antibodies, or were not produced in sufficient amounts in the first place due to a faulty gene, their missing-in-action appears to be a common theme among a subgroup of COVID-19 sufferers whose disease has thus far been a mystery."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly links severe COVID-19 cases to both faulty genes and autoimmune conditions. The mention of inborn errors in type I IFN immunity, whether due to faulty genes or auto-antibodies, strongly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8345436453819275,
    "x2e_entail_prob": 0.02577671967446804
  },
  {
    "id": "covid_fact-000122",
    "statement": "Mice trace severe covid-19 to faulty genes and autoimmune condition",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These findings provide compelling evidence that the disruption of type I interferon is often the cause of life-threatening COVID-19, says Jean-Laurent Casanova, head of the St. Giles Laboratory of Human Genetics of Infectious Diseases at The Rockefeller University and a Howard Hughes Medical Institute investigator.",
      "COVID-19 may now be the best understood acute infectious disease in terms of having a molecular and genetic explanation for nearly 15 percent of critical cases across diverse ancestries, Casanova says.",
      "Genetics of COVID-19 outliers The way SARS-CoV-2 affects people differently has been puzzling.",
      "Science Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Zhang Q. et al.",
      "Whether the proteins have been neutralized by so-called auto- antibodies, or were not produced in sufficient amounts in the first place due to a faulty gene, their missing-in-action appears to be a common theme among a subgroup of COVID-19 sufferers whose disease has thus far been a mystery."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses human genetics and autoimmune conditions contributing to severe COVID-19 cases but does not mention any studies involving mice or animal tracing. Therefore, the claim about mice is unsupported.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.005132653284817934,
    "x2e_entail_prob": 0.005672402214258909
  },
  {
    "id": "covid_fact-000123",
    "statement": "Uv-emitting led lights found to kill coronavirus efficiently and cheaply.",
    "label": "SUPPORTED",
    "evidences": [
      "In a recent study, researchers found that UV light-emitting diodes (LEDs) can quickly and effectively kill the human coronavirus HCoV-OC43.",
      "A new study suggests the novel coronavirus can be killed cheaply and efficiently by ultraviolet light-emitting diodes (UV-LEDs).",
      "LED lights found to kill coronavirus efficiently, quickly, and cheaply ",
      "\"We discovered that it is quite simple to kill the coronavirus using LED bulbs that radiate ultraviolet light.",
      "In the study, the researchers found a range of wavelengths at which UV-LEDs effectively kill coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that UV-LEDs can kill coronaviruses efficiently and cheaply, supporting all aspects of the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.18021142482757568,
    "x2e_entail_prob": 0.9093918800354004
  },
  {
    "id": "covid_fact-000124",
    "statement": "Uv-emitting bat lights found to kill coronavirus efficiently and cheaply.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a recent study, researchers found that UV light-emitting diodes (LEDs) can quickly and effectively kill the human coronavirus HCoV-OC43.",
      "A new study suggests the novel coronavirus can be killed cheaply and efficiently by ultraviolet light-emitting diodes (UV-LEDs).",
      "LED lights found to kill coronavirus efficiently, quickly, and cheaply ",
      "\"We discovered that it is quite simple to kill the coronavirus using LED bulbs that radiate ultraviolet light.",
      "In the study, the researchers found a range of wavelengths at which UV-LEDs effectively kill coronaviruses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms UV LEDs can kill coronaviruses efficiently and cheaply but does not mention 'bat lights.'",
    "confidence": 0.7,
    "e2x_entail_prob": 0.006753453519195318,
    "x2e_entail_prob": 0.8706458210945129
  },
  {
    "id": "covid_fact-000125",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol for covid-19 outpatients in saudi arabia",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that hydroxychloroquine is safe for COVID-19 outpatients in mild to moderate cases but does not specify that this applies to Saudi Arabia, making the claim's regional context unsupported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0010267895413562655,
    "x2e_entail_prob": 0.07724540680646896
  },
  {
    "id": "covid_fact-000126",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol of covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim by stating that hydroxychloroquine is safe, highly tolerable, and has minimal side effects when used within protocol recommendations for mild to moderate COVID-19 outpatients. The alignment between the study's findings and the claim's specifics on safety and protocol use confirms the support.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9382607936859131,
    "x2e_entail_prob": 0.879716694355011
  },
  {
    "id": "covid_fact-000127",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol included covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms hydroxychloroquine's safety for COVID-19 outpatients within protocols but doesn't specify Saudi Arabia. However, the general finding supports the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0010146971326321363,
    "x2e_entail_prob": 0.2529698312282562
  },
  {
    "id": "covid_fact-000128",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol is covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports the safety of hydroxychloroquine for COVID-19 outpatients within an approved protocol but does not mention Saudi Arabia.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0010440716287121177,
    "x2e_entail_prob": 0.1124107763171196
  },
  {
    "id": "covid_fact-000129",
    "statement": "Covid-19 coronavirus spike holds infectivity details",
    "label": "SUPPORTED",
    "evidences": [
      "As a whole, details contained in the results reported in this weeks paper may help to explain the efficiency of the new coronavirus in delivering its viral code into human cells, and its rapid transmission among people.",
      "This finding might help account for the efficient spread of the new coronavirus between people.",
      "The spikes crowning the new coronavirus that causes COVID-19 atypical pneumonia are divulging how they attach, fuse and gain entry to cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explains that the spike proteins of the coronavirus are responsible for attaching, fusing, and entering cells, which are key aspects of infectivity.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6836003661155701,
    "x2e_entail_prob": 0.011623595841228962
  },
  {
    "id": "covid_fact-000130",
    "statement": "Covid-19 coronavirus genomes holds infectivity details",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "As a whole, details contained in the results reported in this weeks paper may help to explain the efficiency of the new coronavirus in delivering its viral code into human cells, and its rapid transmission among people.",
      "This finding might help account for the efficient spread of the new coronavirus between people.",
      "The spikes crowning the new coronavirus that causes COVID-19 atypical pneumonia are divulging how they attach, fuse and gain entry to cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explains that the Covid-19 genome contains features related to infectivity, such as efficient delivery into human cells and rapid transmission. The spikes on the virus are described as crucial for cell attachment and entry, supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.8546515107154846,
    "x2e_entail_prob": 0.03329600766301155
  },
  {
    "id": "covid_fact-000131",
    "statement": "We had the covid-19 vaccine the whole time",
    "label": "SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While there was preparation and existing technology enabling quick vaccine development once COVID-19 emerged, the evidence doesn't support that a specific COVID-19 vaccine existed before the pandemic.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.026836588978767395,
    "x2e_entail_prob": 0.001236960757523775
  },
  {
    "id": "covid_fact-000132",
    "statement": "We had the covid-19 vaccine the next time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that vaccines were developed using established platforms, allowing for rapid production. The mention of pre-developed vaccines ready before new viruses emerged supports the claim of having a vaccine available quickly the next time.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8641464114189148,
    "x2e_entail_prob": 0.001493919757194817
  },
  {
    "id": "covid_fact-000133",
    "statement": "We had the covid-19 vaccine the following time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence shows that vaccines were developed quickly using known platforms, it does not explicitly confirm having the vaccine ready at a specific 'following time.'",
    "confidence": 0.7,
    "e2x_entail_prob": 0.05129030719399452,
    "x2e_entail_prob": 0.003039413597434759
  },
  {
    "id": "covid_fact-000134",
    "statement": "We had the covid-19 vaccine the second time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses plans to develop vaccines quickly using existing platforms and pre-pandemic preparedness but does not confirm that a COVID-19 vaccine was already available during the second wave.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.020350858569145203,
    "x2e_entail_prob": 0.001464711269363761
  },
  {
    "id": "covid_fact-000135",
    "statement": "Quantitative assays reveal cell fusion at minimal levels of sars-cov-2 spike protein and fusion-from-without",
    "label": "SUPPORTED",
    "evidences": [
      "Cell-cell fusion, in contrast, was only moderately inhibited despite requiring much lower levels of S protein, which were below the detection limit of flow cytometry and Western blot."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that cell-cell fusion requires much lower levels of S protein than detection limits of flow cytometry and Western blot, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.319428026676178,
    "x2e_entail_prob": 0.017956145107746124
  },
  {
    "id": "covid_fact-000136",
    "statement": "Quantitative assays reveal no fusion at minimal levels of sars-cov-2 spike protein and fusion-from-without",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cell-cell fusion, in contrast, was only moderately inhibited despite requiring much lower levels of S protein, which were below the detection limit of flow cytometry and Western blot."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that cell-cell fusion occurred at low S protein levels below detection limits, contradicting the claim of no fusion at minimal spike protein levels.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.2885144054889679,
    "x2e_entail_prob": 0.0060670580714941025
  },
  {
    "id": "covid_fact-000137",
    "statement": "Weekly national flu and covid-19 surveillance reports published",
    "label": "SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses COVID-19 hospital admissions by NHS regions but does not mention flu surveillance or weekly national reports, failing to support the claim.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.0016622105613350868,
    "x2e_entail_prob": 0.0009111180552281439
  },
  {
    "id": "covid_fact-000138",
    "statement": "Weekly national flu and covid-19 pandemic reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses COVID-19 hospital admission rates but does not mention any weekly national flu or COVID-19 pandemic reports being published. Without evidence supporting the existence of such reports, the claim cannot be confirmed.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.004907011054456234,
    "x2e_entail_prob": 0.0009488430223427713
  },
  {
    "id": "covid_fact-000139",
    "statement": "Weekly national flu and covid-19 epidemic reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses COVID-19 hospital admissions but does not mention flu or weekly reports. Without information on flu or report publication, the claim is unsupported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.015182935632765293,
    "x2e_entail_prob": 0.001800753059796989
  },
  {
    "id": "covid_fact-000140",
    "statement": "Weekly national flu and covid-19 infection reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention weekly flu reports or confirm that both flu and COVID-19 are included in national reports.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0025902357883751392,
    "x2e_entail_prob": 0.005297925788909197
  },
  {
    "id": "covid_fact-000141",
    "statement": "Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors",
    "label": "SUPPORTED",
    "evidences": [
      "Furthermore, the HCV replication complexes may hide the viral RNA from recognition by host sensors (43)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses HCV replication complexes hiding viral RNA from host sensors but does not mention coronaviruses, endoribonuclease, or polyuridine sequences. Therefore, the claim about coronaviruses is not supported by this evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.007506437599658966,
    "x2e_entail_prob": 0.02064298838376999
  },
  {
    "id": "covid_fact-000142",
    "statement": "Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host defense",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Furthermore, the HCV replication complexes may hide the viral RNA from recognition by host sensors (43)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses HCV replication complexes hiding viral RNA from host sensors, not coronaviruses specifically using endoribonucleases on polyuridine sequences.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.014055420644581318,
    "x2e_entail_prob": 0.07861302047967911
  },
  {
    "id": "covid_fact-000143",
    "statement": "The spike glycoprotein of the new coronavirus 2019-ncov contains a furin-like cleavage site absent in cov of the same clade .",
    "label": "SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that 2019-nCoV has a furin-like cleavage site absent in other SARS-like CoVs and lineage B betaCoVs.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1302366405725479,
    "x2e_entail_prob": 0.3258264660835266
  },
  {
    "id": "covid_fact-000144",
    "statement": "The spike glycoprotein of the new coronavirus a-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the spike glycoprotein of 2019-nCoV contains a furin-like cleavage site absent in other coronaviruses of the same clade, such as SARS-CoV.",
    "confidence": 1,
    "e2x_entail_prob": 0.7590110301971436,
    "x2e_entail_prob": 0.46555086970329285
  },
  {
    "id": "covid_fact-000145",
    "statement": "The spike glycoprotein of the new coronavirus s-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that SARS-CoV-2 has a furin-like cleavage site in its spike protein, which is absent in other coronaviruses of the same clade. This matches the claim exactly.",
    "confidence": 1,
    "e2x_entail_prob": 0.14779655635356903,
    "x2e_entail_prob": 0.6033996343612671
  },
  {
    "id": "covid_fact-000146",
    "statement": "The spike glycoprotein of the new coronavirus e-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the spike glycoprotein of 2019-nCoV (likely referring to e-ncov) contains a furin-like cleavage site, RRAR, which is absent in other coronaviruses within the same clade, such as SARS-CoV.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7389745712280273,
    "x2e_entail_prob": 0.41883647441864014
  },
  {
    "id": "covid_fact-000147",
    "statement": "Breakthrough covid-19 antibody test with nearly 100 % accuracy can help reopen economy",
    "label": "SUPPORTED",
    "evidences": [
      "Scientists said Friday they found the test can determine if someone had COVID-19 with nearly 100% accuracy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports the existence of a highly accurate COVID-19 antibody test but does not provide information on how this test would help reopen the economy.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0010583744151517749,
    "x2e_entail_prob": 0.001585058867931366
  },
  {
    "id": "covid_fact-000148",
    "statement": "Breakthrough covid-19 antibody test with nearly 100 % accuracy cannot help reopen economy",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Scientists said Friday they found the test can determine if someone had COVID-19 with nearly 100% accuracy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only supports that the COVID-19 antibody test has nearly 100% accuracy but does not provide any information about whether it can or cannot help reopen the economy.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0010258499532938004,
    "x2e_entail_prob": 0.00614746892824769
  },
  {
    "id": "covid_fact-000149",
    "statement": "Pyridoxal 5'-phosphate to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that pharmacological doses of pyridoxal 5'-phosphate (PLP) can alleviate both immune dysregulation by reducing inflammatory cytokines and coagulopathy through improved endothelial integrity and reduced clotting markers like D-dimer. These effects directly address the issues mentioned in the claim related to COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.6830702424049377,
    "x2e_entail_prob": 0.9175461530685425
  },
  {
    "id": "covid_fact-000150",
    "statement": "Pyridoxal 5'- inability to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that pyridoxal 5'-phosphate (PLP) cannot mitigate immune dysregulation and coagulopathy in COVID-19, but the evidence provided contradicts this by showing that PLP supplementation can alleviate these conditions.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.16583006083965302,
    "x2e_entail_prob": 0.029516229405999184
  },
  {
    "id": "covid_fact-000151",
    "statement": "Pyridoxal 5'-phosphate to mitigate cardiac dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that PLP supplementation can mitigate coagulopathy in COVID-19 by reducing inflammatory cytokines and improving endothelial integrity. While there's strong support for the coagulopathy aspect, the link to cardiac dysregulation is plausible but not explicitly demonstrated.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.8286507725715637,
    "x2e_entail_prob": 0.6464575529098511
  },
  {
    "id": "covid_fact-000152",
    "statement": "Pyridoxal 5'-c to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim by showing that PLP supplementation decreases inflammatory cytokines and improves endothelial integrity, addressing both immune dysregulation and coagulopathy in COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9604827165603638,
    "x2e_entail_prob": 0.9119870066642761
  },
  {
    "id": "covid_fact-000153",
    "statement": "Antibodies in infants born to mothers with covid-19 pneumonia",
    "label": "SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence, though only a study title, focuses on transplacental antibody transfer from mothers with COVID-19. General knowledge supports that antibodies are transferred to infants, providing some protection.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.003788749687373638,
    "x2e_entail_prob": 0.4510878920555115
  },
  {
    "id": "covid_fact-000154",
    "statement": "Antibodies in women born to mothers with covid-19 pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about antibody transfer in women born to mothers with COVID-19 pneumonia, likely referring to neonates. The evidence discusses transplacental antibody transfer from infected mothers, suggesting that antibodies are passed to the child. General knowledge supports this as part of passive immunity.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.07154953479766846,
    "x2e_entail_prob": 0.4852257966995239
  },
  {
    "id": "covid_fact-000155",
    "statement": "Mortality in infants born to mothers with covid-19 pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses maternal and neonatal aspects of SARS-CoV-2 during pregnancy but does not address infant mortality rates among mothers with COVID-19 pneumonia.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.00261005200445652,
    "x2e_entail_prob": 0.25560423731803894
  },
  {
    "id": "covid_fact-000156",
    "statement": "Aggregated mobility data could help fight covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explains that aggregated mobility data provides real-time insights into human movement patterns, which can be used to refine public health interventions during the COVID-19 pandemic.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0015814058715477586,
    "x2e_entail_prob": 0.9592669010162354
  },
  {
    "id": "covid_fact-000157",
    "statement": "Aggregated mobility data could not fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that aggregated mobility data can help refine interventions by providing real-time information about human movement patterns, which is directly related to fighting COVID-19. Therefore, the claim that aggregated mobility data could not fight COVID-19 is contradicted by the evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.3301824927330017,
    "x2e_entail_prob": 0.8335626721382141
  },
  {
    "id": "covid_fact-000158",
    "statement": "Aggregated mobility data could help generate covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim incorrectly states that mobility data could help generate COVID-19, which is misleading as it implies creating the virus. The evidence shows aggregated data aids in refining interventions by tracking movement patterns, not generating the virus.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.014769472181797028,
    "x2e_entail_prob": 0.02895030751824379
  },
  {
    "id": "covid_fact-000159",
    "statement": "Aggregated mobility data could help study covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by showing that aggregated mobility data provides near real-time information on movement changes, which helps refine COVID-19 interventions.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.06689849495887756,
    "x2e_entail_prob": 0.9709983468055725
  },
  {
    "id": "covid_fact-000160",
    "statement": "Preliminary evidence that higher temperatures are associated with lower incidence of covid-19 , for cases reported globally up to 29th february 2020",
    "label": "SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1\u00b0C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a strong association between higher temperatures and lower COVID-19 incidence for temperatures above 1\u00b0C, which supports the claim that higher temperatures are associated with lower incidence of COVID-19. However, temperature explains only a modest amount of the variation, indicating that other factors also play significant roles.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9036975502967834,
    "x2e_entail_prob": 0.005894171539694071
  },
  {
    "id": "covid_fact-000161",
    "statement": "Preliminary evidence that lower temperatures are associated with lower incidence of covid-19, for cases reported globally up to 29th february 2020",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1\u00b0C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates higher temperatures are associated with lower COVID-19 incidence, contradicting the claim about lower temperatures.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.2803293466567993,
    "x2e_entail_prob": 0.00129313999786973
  },
  {
    "id": "covid_fact-000162",
    "statement": "Preliminary evidence that low temperatures are associated with lower incidence of covid-19, for cases reported globally up to 29th february 2020",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1\u00b0C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that higher average temperatures are associated with lower COVID-19 incidence, which contradicts the claim that low temperatures are linked to lower incidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0033733558375388384,
    "x2e_entail_prob": 0.0012273790780454874
  },
  {
    "id": "covid_fact-000163",
    "statement": "The fda weighs its first coronavirus vaccine",
    "label": "SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the FDA is reviewing Moderna's vaccine, which was one of the first to be considered for emergency use authorization, supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0036529614590108395,
    "x2e_entail_prob": 0.01160056795924902
  },
  {
    "id": "covid_fact-000164",
    "statement": "The fda weighs its new coronavirus vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the FDA is expected to grant authorization for Moderna's vaccine, which suggests they are evaluating it. While the term 'weighs' isn't explicitly used, the context implies evaluation.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.12981221079826355,
    "x2e_entail_prob": 0.033251773566007614
  },
  {
    "id": "covid_fact-000165",
    "statement": "The fda weighs its sars coronavirus vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from NBC News discusses the FDA's expected action on the Moderna COVID-19 vaccine, confirming that the FDA is evaluating a SARS-CoV-2 vaccine.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.06804045289754868,
    "x2e_entail_prob": 0.031038524582982063
  },
  {
    "id": "covid_fact-000166",
    "statement": "High incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses high rates of VTE in hospitalized and ICU COVID-19 patients but does not specifically address anticoagulated patients, making the claim about this subset unsupported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0031365707982331514,
    "x2e_entail_prob": 0.40276190638542175
  },
  {
    "id": "covid_fact-000167",
    "statement": "Low incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided consists only of study titles without specific data or findings regarding anticoagulated severe COVID-19 patients and their VTE incidence. Without concrete results, it's impossible to confirm the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.014401942491531372,
    "x2e_entail_prob": 0.24201703071594238
  },
  {
    "id": "covid_fact-000168",
    "statement": "Median incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly mention whether the severe COVID-19 patients were anticoagulated, which is a crucial component of the claim. Additionally, there's no indication that the studies measured the median incidence specifically for this group.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.00223940028809011,
    "x2e_entail_prob": 0.2854003608226776
  },
  {
    "id": "covid_fact-000169",
    "statement": "Average incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses VTE rates and thrombotic complications in hospitalized or ICU COVID-19 patients but does not specifically address whether these patients were anticoagulated, making the claim unsupported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.001933411811478436,
    "x2e_entail_prob": 0.4606325328350067
  },
  {
    "id": "covid_fact-000170",
    "statement": "Epa proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that the EPA is proposing broad science restrictions, affecting multiple areas and being criticized by its Science Advisory Board. However, it does not explicitly mention these proposals occurring during the coronavirus pandemic.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0025164082180708647,
    "x2e_entail_prob": 0.0020300184842199087
  },
  {
    "id": "covid_fact-000171",
    "statement": "Epa proposes broad science support in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses EPA's changes to scientific processes but does not mention COVID-19 or pandemic-related support.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0029730501119047403,
    "x2e_entail_prob": 0.0016552320448681712
  },
  {
    "id": "covid_fact-000172",
    "statement": "Cdc proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses restrictions proposed by the EPA, not the CDC, and does not mention any actions related to the coronavirus pandemic.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0021506324410438538,
    "x2e_entail_prob": 0.00146492978092283
  },
  {
    "id": "covid_fact-000173",
    "statement": "Who proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes EPA's proposed science restrictions but does not link these actions to the coronavirus pandemic.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0036446780432015657,
    "x2e_entail_prob": 0.0017538456013426185
  },
  {
    "id": "covid_fact-000174",
    "statement": "Moderna provides covid-19 vaccine supply update.",
    "label": "SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions forward-looking statements regarding manufacturing and distribution timelines but does not explicitly provide an update on the current supply status of the Moderna COVID-19 vaccine.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.012887812219560146,
    "x2e_entail_prob": 0.46736598014831543
  },
  {
    "id": "covid_fact-000175",
    "statement": "Cdca provides covid-19 vaccine supply update.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses Moderna's vaccine development and manufacturing plans but does not provide any information about the CDC or another entity providing COVID-19 vaccine supply updates.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0028827872592955828,
    "x2e_entail_prob": 0.42170724272727966
  },
  {
    "id": "covid_fact-000176",
    "statement": "Wa provides covid-19 vaccine supply update.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions 'Wa providing COVID-19 vaccine supply updates,' but the evidence discusses Moderna's vaccine development and future manufacturing/distribution plans without any specific updates or mention of 'Wa.'",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0039955670945346355,
    "x2e_entail_prob": 0.03927001357078552
  },
  {
    "id": "covid_fact-000177",
    "statement": "Engineered ace2 receptor traps potently neutralize sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that engineered ACE2 receptor traps effectively neutralize SARS-CoV-2 infections, comparable to antibodies from convalescent patients and capable of binding viral spike proteins from other coronaviruses.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8976758718490601,
    "x2e_entail_prob": 0.0218103788793087
  },
  {
    "id": "covid_fact-000178",
    "statement": "Engineered ace2 receptor cannot potently neutralize sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that engineered ACE2 receptors can potently neutralize SARS-CoV-2, contradicting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1436956375837326,
    "x2e_entail_prob": 0.021408746019005775
  },
  {
    "id": "covid_fact-000179",
    "statement": "Recombinant ace2 receptor traps potently neutralize sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that optimized ACE2 receptor traps effectively neutralize SARS-CoV-2 and bind viral spike proteins, similar to high-affinity antibodies, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6167357563972473,
    "x2e_entail_prob": 0.010088097304105759
  },
  {
    "id": "covid_fact-000180",
    "statement": "Professional and home-made face masks reduce exposure to respiratory infections among the general population",
    "label": "SUPPORTED",
    "evidences": [
      "Face- masks worn by the general population could be an accessible and affordable intervention, if effective when worn under routine circumstances.",
      "Conclusions/significance: Any type of general mask use is likely to decrease viral exposure and infection risk on a population level, in spite of imperfect fit and imperfect adherence, personal respirators providing most protection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports both professional and homemade face masks reducing respiratory infection risk by decreasing viral exposure, even with imperfect use.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.2563592791557312,
    "x2e_entail_prob": 0.021513693034648895
  },
  {
    "id": "covid_fact-000181",
    "statement": "Genomic epidemiology of a densely sampled covid19 outbreak in china",
    "label": "SUPPORTED",
    "evidences": [
      "With few exceptions, genomic epidemiological analysis has focused on geographically distributed data sets with few isolates in any given location.",
      "Here we report an analysis of 20 whole SARS-CoV 2 genomes from a single relatively small and geographically constrained outbreak in Weifang, People's Republic of China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim refers to a genomic epidemiology study involving a densely sampled COVID-19 outbreak in China. The evidence describes an analysis of 20 whole SARS-CoV-2 genomes from a single, geographically constrained outbreak in Weifang, which aligns with the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.5803147554397583,
    "x2e_entail_prob": 0.02119784615933895
  },
  {
    "id": "covid_fact-000182",
    "statement": "Genomic epidemiology of a randomly sampled covid19 outbreak in china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With few exceptions, genomic epidemiological analysis has focused on geographically distributed data sets with few isolates in any given location.",
      "Here we report an analysis of 20 whole SARS-CoV 2 genomes from a single relatively small and geographically constrained outbreak in Weifang, People's Republic of China."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.00853690691292286,
    "x2e_entail_prob": 0.05969119444489479
  },
  {
    "id": "covid_fact-000183",
    "statement": "Large sars-cov-2 outbreak caused by asymptomatic traveler , china",
    "label": "SUPPORTED",
    "evidences": [
      "Timeline of exposure and connections between cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among persons in Heilongjiang Province, China."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides a timeline of exposure and connections between SARS-CoV-2 cases in Heilongjiang Province, China, but it does not specifically mention an asymptomatic traveler causing a large outbreak. Without explicit information linking the outbreak to an asymptomatic individual, the claim cannot be supported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.007699841633439064,
    "x2e_entail_prob": 0.9672915935516357
  },
  {
    "id": "covid_fact-000184",
    "statement": "One sars-cov-2 outbreak caused by asymptomatic traveler, china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Timeline of exposure and connections between cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among persons in Heilongjiang Province, China."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses exposure and connections between cases in Heilongjiang Province but does not specifically mention an outbreak caused by an asymptomatic traveler from China.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.002589022507891059,
    "x2e_entail_prob": 0.5156798362731934
  },
  {
    "id": "covid_fact-000185",
    "statement": "More than 80 clinical trials launch to test coronavirus treatments",
    "label": "SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions 'dozens' of clinical trials but does not specify that there are more than 80.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.003447030670940876,
    "x2e_entail_prob": 0.001230652560479939
  },
  {
    "id": "covid_fact-000186",
    "statement": "less than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions 'dozens of other controlled trials' but does not provide an exact number, making it unclear if the total is less than 80.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.001649716985411942,
    "x2e_entail_prob": 0.001296622329391539
  },
  {
    "id": "covid_fact-000187",
    "statement": "fewer than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions 'dozens' of clinical trials but doesn't provide a specific number. Without exact figures or additional context, it's impossible to confirm if the total is fewer than 80.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.009768565185368061,
    "x2e_entail_prob": 0.0011139493435621262
  },
  {
    "id": "covid_fact-000188",
    "statement": "younger than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions 'dozens' of trials but doesn't specify if they're all for COVID-19 or total less than 80.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0012751827016472816,
    "x2e_entail_prob": 0.0017938183154910803
  },
  {
    "id": "covid_fact-000189",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in mice.",
    "label": "SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response lasting at least seven months and enhances memory B cell responses in mice, directly supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7152796983718872,
    "x2e_entail_prob": 0.027179714292287827
  },
  {
    "id": "covid_fact-000190",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in humans.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the effects of a ferritin nanoparticle-based SARS-CoV-2 RBD vaccine in mice, showing long-term antibody persistence and memory response. However, it does not provide any data or information about human studies. Therefore, the claim that this vaccine induces persistent antibody responses and long-term memory in humans is not supported by the given evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.18161971867084503,
    "x2e_entail_prob": 0.007847818545997143
  },
  {
    "id": "covid_fact-000191",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in rabbits.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses results from a study on mice, not rabbits, thus not supporting the claim regarding rabbits.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.027821151539683342,
    "x2e_entail_prob": 0.02349082939326763
  },
  {
    "id": "covid_fact-000192",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine cans persistent antibody response and long-term memory in mice.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports that the ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces persistent antibody responses lasting at least seven months and enhances memory B cell activity in mice, which aligns with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6088811755180359,
    "x2e_entail_prob": 0.01158760953694582
  },
  {
    "id": "covid_fact-000193",
    "statement": "Hydroxychloroquine fails to prevent covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from a randomized, controlled trial indicates that hydroxychloroquine offers no benefit in preventing COVID-19 after exposure, showing similar infection rates to placebo.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.928099513053894,
    "x2e_entail_prob": 0.04962196946144104
  },
  {
    "id": "covid_fact-000194",
    "statement": "Hydroxychloroquine remains to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that hydroxychloroquine does not prevent COVID-19, contradicting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.5996977090835571,
    "x2e_entail_prob": 0.02757463976740837
  },
  {
    "id": "covid_fact-000195",
    "statement": "Hydroxychloroquine appears to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that hydroxychloroquine does not prevent COVID-19, as shown by the randomized controlled trial where it was ineffective compared to a placebo.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.950183093547821,
    "x2e_entail_prob": 0.04719622805714607
  },
  {
    "id": "covid_fact-000196",
    "statement": "Hydroxychloroquine is to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that hydroxychloroquine does not prevent COVID-19, showing it is ineffective in a randomized trial.",
    "confidence": 1,
    "e2x_entail_prob": 0.9458386301994324,
    "x2e_entail_prob": 0.05427391082048416
  },
  {
    "id": "covid_fact-000197",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a narrow bottleneck.",
    "label": "SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates that SARS-CoV-2 transmission in domestic cats involves a narrow bottleneck with new infections founded by fewer than ten viruses, specifically mentioning estimates of 2-5 viruses.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8073365688323975,
    "x2e_entail_prob": 0.9790639281272888
  },
  {
    "id": "covid_fact-000198",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a global bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that SARS-CoV-2 transmission in domestic cats involves a narrow bottleneck with only 2-5 viruses, which directly supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.13528408110141754,
    "x2e_entail_prob": 0.8680070042610168
  },
  {
    "id": "covid_fact-000199",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a major bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 transmission in cats involves a narrow bottleneck with only 2-5 viruses transmitted, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7077652812004089,
    "x2e_entail_prob": 0.8955853581428528
  },
  {
    "id": "covid_fact-000200",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a common bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that SARS-CoV-2 transmission in cats involves a narrow bottleneck, with infections founded by fewer than ten viruses and even as few as 2-5.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5736809968948364,
    "x2e_entail_prob": 0.9766792058944702
  },
  {
    "id": "covid_fact-000201",
    "statement": "California state epidemiologist statement recommending providers pause administration of single lot of moderna covid-19 vaccine.",
    "label": "SUPPORTED",
    "evidences": [
      "California state epidemiologist Dr. Erica Pan issued a statement Sunday recommending providers pause the administration of lot 041L20A of the Moderna COVID-19 vaccine due to possible allergic reactions that are being investigated.",
      "Updated: 10:06 PM PST Jan 18, 2021 KCRA Staff UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials sayORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions.",
      "SACRAMENTO, Calif. -- UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials say Advertisement ORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly confirms that California state epidemiologist Dr. Erica Pan recommended pausing administration of a single lot of Moderna's COVID-19 vaccine, specifically lot 041L20A, due to investigations into possible allergic reactions.",
    "confidence": 1,
    "e2x_entail_prob": 0.1567658632993698,
    "x2e_entail_prob": 0.03351390361785889
  },
  {
    "id": "covid_fact-000202",
    "statement": "California state epidemiologist statement recommending providers include administration of single lot of moderna covid-19 vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "California state epidemiologist Dr. Erica Pan issued a statement Sunday recommending providers pause the administration of lot 041L20A of the Moderna COVID-19 vaccine due to possible allergic reactions that are being investigated.",
      "Updated: 10:06 PM PST Jan 18, 2021 KCRA Staff UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials sayORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions.",
      "SACRAMENTO, Calif. -- UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials say Advertisement ORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests the epidemiologist recommended including administration of a specific Moderna lot, but evidence shows she advised pausing it due to allergic reactions, though the pause was later lifted.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.058437131345272064,
    "x2e_entail_prob": 0.03469587862491608
  },
  {
    "id": "covid_fact-000203",
    "statement": "Baricitinib restrains the immune dysregulation in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that baricitinib corrects immune abnormalities in hospitalized COVID-19 patients, which supports the claim that it restrains immune dysregulation.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0027335449121892452,
    "x2e_entail_prob": 0.29430732131004333
  },
  {
    "id": "covid_fact-000204",
    "statement": "Uncitinib restrains the immune dysregulation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to 'Uncitinib,' which may be a misspelling of 'baricitinib.' The evidence supports baricitinib's efficacy in COVID-19 but does not mention Uncitinib.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.001410484779626131,
    "x2e_entail_prob": 0.531176745891571
  },
  {
    "id": "covid_fact-000205",
    "statement": "Excitinib restrains the immune dysregulation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions 'Excitinib,' but the evidence discusses 'baricitinib.' These are different drugs; thus, the evidence does not support the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0064662154763937,
    "x2e_entail_prob": 0.01893722079694271
  },
  {
    "id": "covid_fact-000206",
    "statement": "Us covid-19 deaths poorly predicted by ihme model",
    "label": "SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that 70% of U.S. states had death rates outside the IHME model's prediction interval and that the model underestimated uncertainty, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.31493252515792847,
    "x2e_entail_prob": 0.03785460442304611
  },
  {
    "id": "covid_fact-000207",
    "statement": "Us covid-19 deaths as predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the IHME model was used to predict COVID-19 deaths in the US. While it highlights inaccuracies and underestimation of uncertainty, the claim is supported as the model's predictions were indeed made.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0054063922725617886,
    "x2e_entail_prob": 0.002214203355833888
  },
  {
    "id": "covid_fact-000208",
    "statement": "Us covid-19 deaths previously predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that IHME modeled predictions for COVID-19 deaths in the US.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.015338815748691559,
    "x2e_entail_prob": 0.003244206076487899
  },
  {
    "id": "covid_fact-000209",
    "statement": "Us covid-19 deaths were predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the IHME model did attempt to predict COVID-19 deaths in the US, the evidence indicates significant inaccuracies and underestimation of uncertainty, with 70% of states' death rates outside the prediction interval.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9674638509750366,
    "x2e_entail_prob": 0.015325583517551422
  },
  {
    "id": "covid_fact-000210",
    "statement": "China 's changing coronavirus case count is not unusual in an outbreak , health official says",
    "label": "SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Sylvie Briand, a health official at WHO, explicitly states that it's not unusual for counting methods to change as the epidemic evolves, which directly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1269208788871765,
    "x2e_entail_prob": 0.03143298625946045
  },
  {
    "id": "covid_fact-000211",
    "statement": "China's changing coronavirus case count is not available in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses confusion over how China is counting coronavirus cases and mentions that Sylvie Briand noted changing counting methods as the epidemic evolves. However, it does not state that the case counts are unavailable during an outbreak, which is the specific claim made.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.011532860808074474,
    "x2e_entail_prob": 0.07987260818481445
  },
  {
    "id": "covid_fact-000212",
    "statement": "China's changing coronavirus case count is very unusual in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "Sylvie Briand from WHO mentioned it's common for counting methods to evolve during an outbreak, so changing case counts aren't unusual.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9602062702178955,
    "x2e_entail_prob": 0.013767139986157417
  },
  {
    "id": "covid_fact-000213",
    "statement": "China's changing coronavirus case count is particularly unusual in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that changing case counts are a normal aspect of an epidemic's evolution, as stated by WHO official Sylvie Briand. This contradicts the claim that such changes are particularly unusual.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.4847262501716614,
    "x2e_entail_prob": 0.03482542932033539
  },
  {
    "id": "covid_fact-000214",
    "statement": "Results released for antibody and covid-19 testing of boston residents",
    "label": "SUPPORTED",
    "evidences": [
      "Mayor Martin J. Walsh, together with Massachusetts General Hospital (MGH), and the Boston Public Health Commission (BPHC), today announced the study to evaluate community exposure to COVID-19 through a representative sampling of asymptomatic Boston residents resulted in 9.9% testing positive for antibodies and 2.6% of currently asymptomatic individuals testing positive for COVID-19.",
      "In conclusion, approximately 1 in 10 residents in this study have developed antibodies and approximately 1 in 40 currently asymptomatic individuals are positive for COVID-19 and potentially infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Mayor Walsh, along with MGH and BPHC, released results of a study involving antibody and COVID-19 testing of asymptomatic Boston residents. The findings showed specific percentages for antibodies and current infections.",
    "confidence": 1,
    "e2x_entail_prob": 0.7991888523101807,
    "x2e_entail_prob": 0.593026340007782
  },
  {
    "id": "covid_fact-000215",
    "statement": "Results released for antibody and covid-19 production of boston residents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mayor Martin J. Walsh, together with Massachusetts General Hospital (MGH), and the Boston Public Health Commission (BPHC), today announced the study to evaluate community exposure to COVID-19 through a representative sampling of asymptomatic Boston residents resulted in 9.9% testing positive for antibodies and 2.6% of currently asymptomatic individuals testing positive for COVID-19.",
      "In conclusion, approximately 1 in 10 residents in this study have developed antibodies and approximately 1 in 40 currently asymptomatic individuals are positive for COVID-19 and potentially infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that results were released regarding antibody levels and COVID-19 cases among Boston residents, aligning with the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.3853425085544586,
    "x2e_entail_prob": 0.011259285733103752
  },
  {
    "id": "covid_fact-000216",
    "statement": "Vulnerable populations , such as older adults and those with underlying medical conditions , should wear face masks if available .",
    "label": "SUPPORTED",
    "evidences": [
      "Wearing a face covering can help to reduce the chance that those who may not know they are sick will spread the infection to others.",
      "Perhaps it would also be rational to recommend that people in quarantine wear face masks if they need to leave home for any reason, to prevent potential asymptomatic or presymptomatic transmission."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "While the evidence doesn't explicitly mention vulnerable populations, it supports the idea that face masks prevent asymptomatic or presymptomatic transmission, which would protect high-risk groups by reducing exposure.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.006385477259755135,
    "x2e_entail_prob": 0.011546275578439236
  },
  {
    "id": "covid_fact-000217",
    "statement": "Vulnerable populations, such as older adults and those with underlying medical conditions, not wear face masks if available.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wearing a face covering can help to reduce the chance that those who may not know they are sick will spread the infection to others.",
      "Perhaps it would also be rational to recommend that people in quarantine wear face masks if they need to leave home for any reason, to prevent potential asymptomatic or presymptomatic transmission."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports mask use to prevent infection spread, particularly relevant for vulnerable groups.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.3067759573459625,
    "x2e_entail_prob": 0.002025785157456994
  },
  {
    "id": "covid_fact-000218",
    "statement": "The differing immune system responses of patients with covid-19 can help predict who will experience moderate and severe consequences of disease , according to a new study",
    "label": "SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that a new study suggests differing immune system responses in Covid-19 patients can predict who will experience moderate and severe consequences of disease, which aligns with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.4357905387878418,
    "x2e_entail_prob": 0.038631144911050797
  },
  {
    "id": "covid_fact-000219",
    "statement": "The differing immune system responses of patients with covid-19 cannot help predict who will experience moderate and severe consequences of disease, according to a new study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim asserts that differing immune responses cannot predict disease severity, but the evidence directly contradicts this by stating they can help predict moderate and severe outcomes.",
    "confidence": 1,
    "e2x_entail_prob": 0.003176242345944047,
    "x2e_entail_prob": 0.059255748987197876
  },
  {
    "id": "covid_fact-000220",
    "statement": "The differing immune system responses of patients with covid-19 can help predict who will experience moderate and severe consequences of disease, according to a previous study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim by showing that differing immune parameters between mild and severe COVID-19 cases can predict disease severity, aligning with the study mentioned in the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5893275737762451,
    "x2e_entail_prob": 0.08349915593862534
  },
  {
    "id": "covid_fact-000221",
    "statement": "Father with motor neurone disease dies from coronavirus in uk",
    "label": "SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions Craig Ruston had motor neurone disease but does not confirm his death from coronavirus or that he was a father.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.003628740319982171,
    "x2e_entail_prob": 0.6394779682159424
  },
  {
    "id": "covid_fact-000222",
    "statement": "Father with motor neurone disease originated from coronavirus in uk",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that Craig Ruston was battling motor neurone disease but does not provide any information connecting his condition to coronavirus or its origin in the UK.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.009289013221859932,
    "x2e_entail_prob": 0.0972491204738617
  },
  {
    "id": "covid_fact-000223",
    "statement": "Father with motor neurone disease differs from coronavirus in uk",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only mentions a father with motor neurone disease without providing any comparison to COVID-19, thus not supporting the claim that they differ.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.005738165229558945,
    "x2e_entail_prob": 0.03938031941652298
  },
  {
    "id": "covid_fact-000224",
    "statement": "Yale 's rapid covid-19 saliva test receives fda emergency use authorization",
    "label": "SUPPORTED",
    "evidences": [
      "Stat: FDA Clears Saliva Test For Covid-19, Opening Door To Wider Testing The Food and Drug Administration on Saturday authorized emergency use of a new and inexpensive saliva test for Covid-19 that could greatly expand testing capacity.",
      "A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.",
      "NEW HAVEN, Conn. \\- A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that Yale developed a saliva-based COVID-19 test and received FDA emergency use authorization but does not mention it being a 'rapid' test.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.009488005191087723,
    "x2e_entail_prob": 0.1307242214679718
  },
  {
    "id": "covid_fact-000225",
    "statement": "Yale's rapid covid-19 saliva test without fda emergency use authorization",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Stat: FDA Clears Saliva Test For Covid-19, Opening Door To Wider Testing The Food and Drug Administration on Saturday authorized emergency use of a new and inexpensive saliva test for Covid-19 that could greatly expand testing capacity.",
      "A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.",
      "NEW HAVEN, Conn. \\- A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that Yale's saliva test received FDA emergency use authorization, contradicting the claim that it was without such authorization.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.06253023445606232,
    "x2e_entail_prob": 0.1465427130460739
  },
  {
    "id": "covid_fact-000226",
    "statement": "The antiviral compound remdesivir potently inhibits rna-dependent rna polymerase from middle east respiratory syndrome coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.",
      "Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that remdesivir inhibits MERS-CoV, including its RNA polymerase activity as inferred from deltacoronavirus data. However, it does not explicitly confirm the potency of this inhibition.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.005450129508972168,
    "x2e_entail_prob": 0.11054855585098267
  },
  {
    "id": "covid_fact-000227",
    "statement": "The antiviral compound remdesivir potently binds rna-dependent rna polymerase from middle east respiratory syndrome coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.",
      "Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows remdesivir inhibits MERS-CoV and targets RNA-dependent RNA polymerase, supporting its potent interaction.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.01032683439552784,
    "x2e_entail_prob": 0.2841746211051941
  },
  {
    "id": "covid_fact-000228",
    "statement": "Trials of oxford coronavirus vaccine begin in kenya",
    "label": "SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the Oxford coronavirus vaccine trial has begun in Kenya, with volunteers already receiving vaccinations and official confirmation from Professor Andy Pollard.",
    "confidence": 1,
    "e2x_entail_prob": 0.7175763249397278,
    "x2e_entail_prob": 0.0015915629919618368
  },
  {
    "id": "covid_fact-000229",
    "statement": "Lack of oxford coronavirus vaccine begin in kenya",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Kenya is actively participating in the Oxford coronavirus vaccine trials with necessary approvals, but it does not mention any lack of the vaccine beginning in Kenya.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.009193658828735352,
    "x2e_entail_prob": 0.0009290542220696807
  },
  {
    "id": "covid_fact-000230",
    "statement": "Trials of oxford coronavirus vaccine begin in great",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the Oxford coronavirus vaccine trials have begun in several countries, including Great Britain (UK). The phrase 'begin in great' is assumed to refer to Great Britain, and the evidence supports that the UK is conducting trials as part of the effort.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.47661054134368896,
    "x2e_entail_prob": 0.0010888795368373394
  },
  {
    "id": "covid_fact-000231",
    "statement": "Pandemic infection rates are deterministic but can not be modeled",
    "label": "SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence shows that pandemic infection rates cannot be modeled effectively, it does not confirm that these rates are deterministic. The failure of models to predict accurately may stem from complexity rather than a deterministic nature.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.032620448619127274,
    "x2e_entail_prob": 0.10884270817041397
  },
  {
    "id": "covid_fact-000232",
    "statement": "Pandemic infection rates are deterministic but can then be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that pandemic infection rates cannot be accurately modeled due to their variability and inability to be predicted from fixed initial conditions. This contradicts the claim that they are deterministic and can be modeled.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.41322001814842224,
    "x2e_entail_prob": 0.40498632192611694
  },
  {
    "id": "covid_fact-000233",
    "statement": "Pandemic infection rates are deterministic but can therefore be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that pandemic infection rates are too variable and cannot be accurately modeled or predicted beyond a few days, indicating they are not deterministic as the claim suggests.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.2803761065006256,
    "x2e_entail_prob": 0.4487231969833374
  },
  {
    "id": "covid_fact-000234",
    "statement": "Pandemic infection rates are deterministic but can also be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that infection rates cannot be accurately modeled due to their complexity and variability, making them unpredictable beyond a few days despite being calculated daily.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8568532466888428,
    "x2e_entail_prob": 0.36124032735824585
  },
  {
    "id": "covid_fact-000235",
    "statement": "New coronavirus variant is identified in uk.",
    "label": "SUPPORTED",
    "evidences": [
      "England's Chief Medical Officer Prof Chris Whitty said current coronavirus swab tests would detect the new variant that has been found predominantly in Kent and neighbouring areas in recent weeks.",
      "The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.",
      "It is thought the variant either emerged in a patient in the UK or has been imported from a country with a lower ability to monitor coronavirus mutations.",
      "A number of variants have already been detected in the UK.",
      "Matt Hancock said the new variant of coronavirus \"may be associated\" with the faster spread in the south-east of England."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that a new coronavirus variant has been detected in the UK, particularly in Kent and surrounding regions.",
    "confidence": 1,
    "e2x_entail_prob": 0.8892475366592407,
    "x2e_entail_prob": 0.009098684415221214
  },
  {
    "id": "covid_fact-000236",
    "statement": "No coronavirus variant is identified in uk.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "England's Chief Medical Officer Prof Chris Whitty said current coronavirus swab tests would detect the new variant that has been found predominantly in Kent and neighbouring areas in recent weeks.",
      "The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.",
      "It is thought the variant either emerged in a patient in the UK or has been imported from a country with a lower ability to monitor coronavirus mutations.",
      "A number of variants have already been detected in the UK.",
      "Matt Hancock said the new variant of coronavirus \"may be associated\" with the faster spread in the south-east of England."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that several coronavirus variants have been detected in the UK, contradicting the claim that no variant has been identified.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.23290929198265076,
    "x2e_entail_prob": 0.005674834828823805
  },
  {
    "id": "covid_fact-000237",
    "statement": "The coronavirus has mutated and appears to be more contagious now , new study finds",
    "label": "SUPPORTED",
    "evidences": [
      "The coronavirus has mutated and May52020 COVID19 KEY POINTS: The coronavirus that emerged in Wuhan, China, has mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study.",
      "If the coronavirus doesnt subside in the summer like the seasonal flu, it could mutate further and potentially limit the effectiveness of the coronavirus vaccines being developed by scientists around the world, the researchers warned.",
      "The coronavirus that emerged in Wuhan, China, over four months ago has since mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that the coronavirus has mutated and the new dominant strain in the U.S. is more contagious.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.17680427432060242,
    "x2e_entail_prob": 0.15274161100387573
  },
  {
    "id": "covid_fact-000238",
    "statement": "The coronavirus has mutated and appears to be more contagious before, new study finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The coronavirus has mutated and May52020 COVID19 KEY POINTS: The coronavirus that emerged in Wuhan, China, has mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study.",
      "If the coronavirus doesnt subside in the summer like the seasonal flu, it could mutate further and potentially limit the effectiveness of the coronavirus vaccines being developed by scientists around the world, the researchers warned.",
      "The coronavirus that emerged in Wuhan, China, over four months ago has since mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly confirms that the coronavirus has mutated and the new strain in the U.S. appears more contagious, aligning with the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.3001748323440552,
    "x2e_entail_prob": 0.16815879940986633
  },
  {
    "id": "covid_fact-000239",
    "statement": "Two known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence endorses the idea of using two therapies as adjuvants, highlighting their potential benefits and recommending their inclusion in treatment strategies despite acknowledging the need for clinical trials.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.9143107533454895,
    "x2e_entail_prob": 0.8524621725082397
  },
  {
    "id": "covid_fact-000240",
    "statement": "Many known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the potential benefit of two specific therapies and recommends adding them to the therapeutic arsenal, but it does not support the claim that 'many known therapies' are useful as adjuvants in critical COVID-19 patients.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0026473726611584425,
    "x2e_entail_prob": 0.050006113946437836
  },
  {
    "id": "covid_fact-000241",
    "statement": "Several known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions two therapies with potential benefits and recommends adding them to treatment plans, supporting the claim of several known therapies being useful as adjuvant therapy.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.572918176651001,
    "x2e_entail_prob": 0.006420394405722618
  },
  {
    "id": "covid_fact-000242",
    "statement": "All known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only supports the recommendation of two specific therapies, not all known therapies.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.08824741095304489,
    "x2e_entail_prob": 0.0035325263161212206
  },
  {
    "id": "covid_fact-000243",
    "statement": "Protein structure and sequence reanalysis of 2019-ncov genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and hiv-1",
    "label": "SUPPORTED",
    "evidences": [
      "In this Communication, we first analyzed two recent studies that concluded that snakes are the intermediate hosts of 2019-nCoV and that the 2019-nCoV spike protein insertions share a unique similarity to HIV-1."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not confirm that the reanalysis refutes snakes as intermediate hosts or the unique similarity to HIV-1; it only mentions analyzing prior studies making these claims.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.002612103009596467,
    "x2e_entail_prob": 0.013914437033236027
  },
  {
    "id": "covid_fact-000244",
    "statement": "Protein structure and sequence reanalysis of 2019-ncov genome refutes bats as its intermediate host and the unique similarity between its spike protein insertions and hiv-1",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this Communication, we first analyzed two recent studies that concluded that snakes are the intermediate hosts of 2019-nCoV and that the 2019-nCoV spike protein insertions share a unique similarity to HIV-1."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that two studies concluded snakes as intermediate hosts for 2019-nCoV, refuting bats, and found a unique similarity between the spike protein insertions of 2019-nCoV and HIV-1.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.04121933877468109,
    "x2e_entail_prob": 0.20991238951683044
  },
  {
    "id": "covid_fact-000245",
    "statement": "Mhra suspends recruitment to covid-19 hydroxychloroquine trials",
    "label": "SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that the MHRA considered the results of trials, including the RECOVERY trial and a NEJM study, which found no benefit from hydroxychloroquine in treating or preventing COVID-19. However, it does not explicitly state that the MHRA suspended recruitment for these trials.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0012521665776148438,
    "x2e_entail_prob": 0.14914464950561523
  },
  {
    "id": "covid_fact-000246",
    "statement": "Mhra acts recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the MHRA considering trial results but doesn't mention their role in recruitment for hydroxychloroquine trials.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0018209780100733042,
    "x2e_entail_prob": 0.039308104664087296
  },
  {
    "id": "covid_fact-000247",
    "statement": "Mhra 1990s recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses MHRA's consideration of recent hydroxychloroquine trials during the COVID-19 pandemic, not any recruitment in the 1990s.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.011647469364106655,
    "x2e_entail_prob": 0.06473506987094879
  },
  {
    "id": "covid_fact-000248",
    "statement": "Mhra 1980s recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to MHRA recruitment in the 1980s for COVID-19 hydroxychloroquine trials, but the evidence discusses MHRA's consideration of recent studies during the COVID-19 pandemic, not the 1980s.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.005449566524475813,
    "x2e_entail_prob": 0.08431343734264374
  },
  {
    "id": "covid_fact-000249",
    "statement": "Transcriptional profiling reveals trpm5-expressing cells involved in viral infection in the olfactory epithelium",
    "label": "SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that TRPM5-expressing cells are involved in responses to viral infections and specifically mentions their role in the olfactory epithelium, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.32867351174354553,
    "x2e_entail_prob": 0.22492347657680511
  },
  {
    "id": "covid_fact-000250",
    "statement": "Transcriptional profiling reveals trpm5-deficient cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses TRPM5-expressing cells involved in viral infection but does not mention trpm5-deficient cells.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.009986178949475288,
    "x2e_entail_prob": 0.30704623460769653
  },
  {
    "id": "covid_fact-000251",
    "statement": "Transcriptional profiling reveals trpm5-depleted cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports the involvement of TRPM5-expressing cells in viral infection responses but does not address trpm5-depleted cells.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.007817857898771763,
    "x2e_entail_prob": 0.3052893877029419
  },
  {
    "id": "covid_fact-000252",
    "statement": "Immunal profiling reveals trpm5-expressing cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by showing TRPM5-expressing cells are involved in viral responses in the olfactory epithelium.",
    "confidence": 1,
    "e2x_entail_prob": 0.17925529181957245,
    "x2e_entail_prob": 0.19004452228546143
  },
  {
    "id": "covid_fact-000253",
    "statement": "Aprotinin inhibits sars-cov-2 replication",
    "label": "SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates that aprotinin inhibits SARS-CoV-2 replication in multiple cell types and virus isolates at therapeutically achievable concentrations.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8684520125389099,
    "x2e_entail_prob": 0.6912015676498413
  },
  {
    "id": "covid_fact-000254",
    "statement": "Aprotinin 1980s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not connect Aprotinin's use in the 1980s with SARS-CoV-2 replication. It discusses recent findings about aprotinin's anti-SARS-CoV-2 activity but lacks historical data from the 1980s regarding this effect.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.021069256588816643,
    "x2e_entail_prob": 0.4958455562591553
  },
  {
    "id": "covid_fact-000255",
    "statement": "Aprotinin (s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that aprotinin inhibits SARS-CoV-2 replication in therapeutic concentrations, across different cell types, and against multiple virus isolates, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7678715586662292,
    "x2e_entail_prob": 0.7167073488235474
  },
  {
    "id": "covid_fact-000256",
    "statement": "Aprotinin 1970s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention any studies or uses of aprotinin in the 1970s related to SARS-CoV-2 replication, focusing instead on recent findings.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0018409850308671594,
    "x2e_entail_prob": 0.3096786141395569
  },
  {
    "id": "covid_fact-000257",
    "statement": "Homozygous l-sign plays a protective role in sars coronavirus infection",
    "label": "SUPPORTED",
    "evidences": [
      "Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection.",
      "Thus, homozygosity for L-SIGN plays a protective role during SARS infection.",
      "Homozygous L-SIGN ( CLEC4M ) plays a protective role in SARS coronavirus infection.",
      "This observation confirms that homozygous L-SIGN does have a protective role in SARS-CoV infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly confirms that homozygous L-SIGN plays a protective role in SARS-CoV infection.",
    "confidence": 1,
    "e2x_entail_prob": 0.9049493670463562,
    "x2e_entail_prob": 0.9702507853507996
  },
  {
    "id": "covid_fact-000258",
    "statement": "Homozygous l-atpase plays a protective role in sars coronavirus infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection.",
      "Thus, homozygosity for L-SIGN plays a protective role during SARS infection.",
      "Homozygous L-SIGN ( CLEC4M ) plays a protective role in SARS coronavirus infection.",
      "This observation confirms that homozygous L-SIGN does have a protective role in SARS-CoV infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses homozygous L-SIGN (CLEC4M) playing a protective role in SARS-CoV infection, not homozygous l-ATPase. The claim incorrectly substitutes 'l-atpase' for 'L-SIGN'.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.30876070261001587,
    "x2e_entail_prob": 0.9220268726348877
  },
  {
    "id": "covid_fact-000259",
    "statement": "The us doesnt have enough hospital beds for a bad coronavirus outbreak.",
    "label": "SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence includes statements from Cuomo and Dillinger warning about insufficient hospital beds during an expected larger coronavirus outbreak in the U.S., supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.02281167358160019,
    "x2e_entail_prob": 0.09682761132717133
  },
  {
    "id": "covid_fact-000260",
    "statement": "The usset have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that both Cuomo and Dillinger warned about insufficient hospital beds for a bad coronavirus outbreak, directly contradicting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.02141663059592247,
    "x2e_entail_prob": 0.22488929331302643
  },
  {
    "id": "covid_fact-000261",
    "statement": "The uswt have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim as it highlights Cuomo's warning about the U.S. lacking enough hospital beds during a severe coronavirus outbreak.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.010085565969347954,
    "x2e_entail_prob": 0.25734081864356995
  },
  {
    "id": "covid_fact-000262",
    "statement": "The usert have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided includes warnings from New York Governor Cuomo and others indicating a shortage of hospital beds in the US during the COVID-19 pandemic, supporting the claim that the US does not have enough hospital beds for a severe outbreak.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.20933601260185242,
    "x2e_entail_prob": 0.009031142108142376
  },
  {
    "id": "covid_fact-000263",
    "statement": "La doctor seeing 100 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not explicitly state a 100% success rate with hydroxychloroquine and zinc alone, as it mentions a three-drug regimen including azithromycin and only refers to 'very promising results.'",
    "confidence": 0.85,
    "e2x_entail_prob": 0.06502934545278549,
    "x2e_entail_prob": 0.20640461146831512
  },
  {
    "id": "covid_fact-000264",
    "statement": "La doctor seeing 80 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence supports that Dr. Anthony Cardillo saw success with hydroxychloroquine and zinc, it does not mention an 80% success rate.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0024719981011003256,
    "x2e_entail_prob": 0.2639983892440796
  },
  {
    "id": "covid_fact-000265",
    "statement": "La doctor seeing 60 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions promising results with hydroxychloroquine and zinc but does not specify a 60% success rate.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.011259575374424458,
    "x2e_entail_prob": 0.3511078655719757
  },
  {
    "id": "covid_fact-000266",
    "statement": "La doctor seeing 70 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention a 70% success rate for hydroxychloroquine and zinc in treating COVID-19. While Dr. Cardillo reports promising results, the specific percentage is unsupported by the provided information.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.017552465200424194,
    "x2e_entail_prob": 0.21119439601898193
  },
  {
    "id": "covid_fact-000267",
    "statement": "Repurposing existing drugs for covid-19 a more rapid alternative to a vaccine , say researchers",
    "label": "SUPPORTED",
    "evidences": [
      "Although clinical trials found it to be insufficiently effective at treating Ebola, clinical trials in the USA have suggested the drug may be beneficial for treating patients hospitalised with COVID-19, and the FDA has now approved it for emergency use.",
      "> \"[Repurposed drugs] will have already been shown to be safe and so, if they > can now be shown to be effective in COVID-19, they could be brought to > clinical use relatively quickly\" > > Anthony Davenport Since the emergence of the SARS-CoV-2 virus in late 2019, more than 3.5 million people are known to have been infected, leading to over 240,000 deaths worldwide from COVID-19, the disease caused by the novel coronavirus.",
      "While we're waiting for a vaccine, drugs currently being used to treat other illnesses can be investigated as treatments for COVID-19  in other words repurposed, said Dr Steve Alexander from the University of Nottingham.",
      "These treatments will have already been shown to be safe and so, if they can now be shown to be effective in COVID-19, they could be brought to clinical use relatively quickly. One promising candidate is remdesivir, a drug originally developed for Ebola."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim by highlighting that repurposed drugs have already been shown to be safe and can potentially be brought into clinical use quickly for COVID-19, as exemplified by remdesivir.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.668256938457489,
    "x2e_entail_prob": 0.001808613771572709
  },
  {
    "id": "covid_fact-000268",
    "statement": "Repurposing existing drugs for covid-19 a less rapid alternative to a vaccine, say researchers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although clinical trials found it to be insufficiently effective at treating Ebola, clinical trials in the USA have suggested the drug may be beneficial for treating patients hospitalised with COVID-19, and the FDA has now approved it for emergency use.",
      "> \"[Repurposed drugs] will have already been shown to be safe and so, if they > can now be shown to be effective in COVID-19, they could be brought to > clinical use relatively quickly\" > > Anthony Davenport Since the emergence of the SARS-CoV-2 virus in late 2019, more than 3.5 million people are known to have been infected, leading to over 240,000 deaths worldwide from COVID-19, the disease caused by the novel coronavirus.",
      "While we're waiting for a vaccine, drugs currently being used to treat other illnesses can be investigated as treatments for COVID-19  in other words repurposed, said Dr Steve Alexander from the University of Nottingham.",
      "These treatments will have already been shown to be safe and so, if they can now be shown to be effective in COVID-19, they could be brought to clinical use relatively quickly. One promising candidate is remdesivir, a drug originally developed for Ebola."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explains that repurposing drugs can be quicker due to existing safety data but doesn't provide a comparison with vaccine development timelines, thus not confirming the claim about being less rapid.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.009785468690097332,
    "x2e_entail_prob": 0.0022575254552066326
  },
  {
    "id": "covid_fact-000269",
    "statement": "68 per cent of patients hospitalized for severe covid-19 , who were treated with compassionate-use remdesivir , showed clinical improvement",
    "label": "SUPPORTED",
    "evidences": [
      "Although data from several ongoing randomized, controlled trials will soon provide more informative evidence regarding the safety and efficacy of remdesivir for Covid-19, the outcomes observed in this compassionate-use program are the best currently available data."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not provide specific statistics or percentages regarding clinical improvement rates in patients treated with compassionate-use remdesivir, thus it cannot confirm the claim of a 68% improvement.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0018038222333416343,
    "x2e_entail_prob": 0.0007198643870651722
  },
  {
    "id": "covid_fact-000270",
    "statement": "68 per cent of patients hospitalized for severe covid-19, who were treated with compassionate-use remdesivir, without clinical improvement",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although data from several ongoing randomized, controlled trials will soon provide more informative evidence regarding the safety and efficacy of remdesivir for Covid-19, the outcomes observed in this compassionate-use program are the best currently available data."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.0054168906062841415,
    "x2e_entail_prob": 0.004659561440348625
  },
  {
    "id": "covid_fact-000271",
    "statement": "Years of life lost due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that the study used YLL as a measure for Switzerland and found 0.205 YLL per person due to psychosocial consequences of COVID-19 mitigation strategies, aligning with the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.41930633783340454,
    "x2e_entail_prob": 0.879541277885437
  },
  {
    "id": "covid_fact-000272",
    "statement": "Years of life increases due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that psychosocial consequences of COVID-19 mitigation strategies in Switzerland led to an increase in years of life lost, supporting the claim when interpreted correctly regarding YLL.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.31482014060020447,
    "x2e_entail_prob": 0.187329962849617
  },
  {
    "id": "covid_fact-000273",
    "statement": "Years of life remains due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by providing Swiss data showing years of life lost (YLL) due to psychosocial consequences from COVID-19 mitigation strategies, with a specific average YLL of 0.205 per person.",
    "confidence": 1,
    "e2x_entail_prob": 0.23148177564144135,
    "x2e_entail_prob": 0.9197849631309509
  },
  {
    "id": "covid_fact-000274",
    "statement": "Years of life occurred due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by providing Swiss data showing years of life lost due to psychosocial consequences from COVID-19 mitigation strategies.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.03918329253792763,
    "x2e_entail_prob": 0.05451207980513573
  },
  {
    "id": "covid_fact-000275",
    "statement": "Astrazeneca covid-19 vaccine study is put on hold",
    "label": "SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that AstraZeneca put its Covid-19 vaccine trial on hold for a safety review, directly supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.013804248534142971,
    "x2e_entail_prob": 0.003161280881613493
  },
  {
    "id": "covid_fact-000276",
    "statement": "Astrazeneca covid-19 vaccine study is put on!",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that AstraZeneca's COVID-19 vaccine trial was put on hold due to a standard review process and safety data evaluation, aligning with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.03247321769595146,
    "x2e_entail_prob": 0.004629418253898621
  },
  {
    "id": "covid_fact-000277",
    "statement": "Astrazeneca covid-19 vaccine study is put on.\"",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that AstraZeneca's COVID-19 vaccine study was paused to review safety data, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.007604649756103754,
    "x2e_entail_prob": 0.0022318176925182343
  },
  {
    "id": "covid_fact-000278",
    "statement": "Astrazeneca covid-19 vaccine study is put on.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that AstraZeneca's Covid-19 vaccine trial was put on hold, aligning with the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.012300236150622368,
    "x2e_entail_prob": 0.0015916803386062384
  },
  {
    "id": "covid_fact-000279",
    "statement": "Giuliani-promoted covid-19 therapy from celularity nabs fda speedy trial start",
    "label": "SUPPORTED",
    "evidences": [
      "Trials need to be EXPEDITED. It seems he got his wish: Today, New Jersey-based Celularity said it has been given the all-clear from the FDA to start its clinical trial of CYNK-001, its allogeneic, off-the-shelf, cryopreserved natural killer cell therapy to be used in a phase 1/2 study in up to 86 patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that Celularity received FDA approval to start their clinical trial, but it does not mention Giuliani promoting the therapy.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.01045704260468483,
    "x2e_entail_prob": 0.03202120214700699
  },
  {
    "id": "covid_fact-000280",
    "statement": "Giuliani-free covid-19 therapy from celularity nabs fda speedy trial start",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Trials need to be EXPEDITED. It seems he got his wish: Today, New Jersey-based Celularity said it has been given the all-clear from the FDA to start its clinical trial of CYNK-001, its allogeneic, off-the-shelf, cryopreserved natural killer cell therapy to be used in a phase 1/2 study in up to 86 patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that Celularity received FDA approval for a clinical trial but does not mention Giuliani's involvement or absence.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.07252690941095352,
    "x2e_entail_prob": 0.03883517161011696
  },
  {
    "id": "covid_fact-000281",
    "statement": "Mucus production stimulated by ifn-ahr signaling triggers hypoxia of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that mucus production via AhR signaling is associated with hypoxia in COVID-19 patients, but it does not explicitly establish a causal link where mucus production triggers hypoxia. Additionally, there's no mention of IFN specifically being involved in this process.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.023355776444077492,
    "x2e_entail_prob": 0.13692206144332886
  },
  {
    "id": "covid_fact-000282",
    "statement": "Mucus production stimulated by ifn-ahr signaling prevents hypoxia of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates mucus production in COVID-19 patients and AhR involvement but does not directly link IFN-AHR signaling or show that mucus prevents hypoxia.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.00671619176864624,
    "x2e_entail_prob": 0.6448701024055481
  },
  {
    "id": "covid_fact-000283",
    "statement": "Mucus damage stimulated by ifn-ahr signaling triggers hypoxia of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates mucus production in COVID-19 patients and AhR-upregulated mucins contributing to hypoxia, but it doesn't mention IFN signaling or how it leads to mucus damage causing hypoxia.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0016340840375050902,
    "x2e_entail_prob": 0.6570119261741638
  },
  {
    "id": "covid_fact-000284",
    "statement": "Gilead has suspended access to remdesivir",
    "label": "SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that Gilead has shifted their approach to providing remdesivir from compassionate-use requests to expanded access programs but does not indicate a complete suspension of access.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.05032602697610855,
    "x2e_entail_prob": 0.02477719448506832
  },
  {
    "id": "covid_fact-000285",
    "statement": "Gilead has allowed access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Gilead provided access to remdesivir under compassionate use before a suspension and later switched to expanded access programs, confirming they allowed access.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.69841068983078,
    "x2e_entail_prob": 0.020519381389021873
  },
  {
    "id": "covid_fact-000286",
    "statement": "Gilead has received access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Gilead was distributing remdesivir through expanded access programs and compassionate use before a suspension, which implies they had access to the drug.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.17906947433948517,
    "x2e_entail_prob": 0.002729191677644849
  },
  {
    "id": "covid_fact-000287",
    "statement": "Gilead has provided access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Gilead provided remdesivir under compassionate-use requests and emergency use before transitioning to expanded access programs, confirming the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.14444302022457123,
    "x2e_entail_prob": 0.009014436043798923
  },
  {
    "id": "covid_fact-000288",
    "statement": "Immune cell activation in severe covid-19 resembles lupus .",
    "label": "SUPPORTED",
    "evidences": [
      "The scientists found that patients with severe COVID-19 displayed many of these hallmarks of extrafollicular B cell responses associated with lupus.",
      "The critically-ill COVID-19 patients who survived and recovered from the infection also showed lingering symptoms similar to those experienced by lupus patients during acute flare-ups."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that severe COVID-19 patients exhibit hallmarks of extrafollicular B cell responses and lingering symptoms similar to lupus, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6090542078018188,
    "x2e_entail_prob": 0.005629272200167179
  },
  {
    "id": "covid_fact-000289",
    "statement": "Immune cell death in severe covid-19 resembles lupus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The scientists found that patients with severe COVID-19 displayed many of these hallmarks of extrafollicular B cell responses associated with lupus.",
      "The critically-ill COVID-19 patients who survived and recovered from the infection also showed lingering symptoms similar to those experienced by lupus patients during acute flare-ups."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that severe COVID-19 patients exhibit hallmarks and lingering symptoms similar to those in lupus, suggesting a resemblance in immunological processes. While the claim about immune cell death isn't directly addressed, the similarities in immune responses support the overall claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.441800057888031,
    "x2e_entail_prob": 0.006225479766726494
  },
  {
    "id": "covid_fact-000290",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few weeks.",
    "label": "SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that the CDC forecasts up to 100,000 more COVID-19 deaths in less than a month. The timeframe and figures align with the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.0664527416229248,
    "x2e_entail_prob": 0.028890185058116913
  },
  {
    "id": "covid_fact-000291",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few decades.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a forecast of up to 100,000 more COVID-19 deaths in less than a month, while the claim refers to 'the next few decades.' The timeframes do not match.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0367112010717392,
    "x2e_entail_prob": 0.03641454502940178
  },
  {
    "id": "covid_fact-000292",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few years.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The CDC's forecast of up to 100,000 more COVID-19 deaths was for less than a month, not 'the next few years,' as claimed.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.002309896517544985,
    "x2e_entail_prob": 0.14197340607643127
  },
  {
    "id": "covid_fact-000293",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few century.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim incorrectly states that CDC forecasts up to 100,000 more COVID-19 deaths in the next few centuries. The evidence shows the forecast was for less than a month, not a century.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.007195633836090565,
    "x2e_entail_prob": 0.07946617156267166
  },
  {
    "id": "covid_fact-000294",
    "statement": "Gaps in early surveillance of coronavirus led to record-breaking us trajectory",
    "label": "SUPPORTED",
    "evidences": [
      "As illustrated in the COVID-19 study, while public health officials must work quickly to understand how a new virus functions, without appropriate testing or coordinated response strategies the risk grows for infections to go unreported.",
      "The study provides insight into how limited testing and gaps in surveillance during the initial phase of the epidemic resulted in so many cases going undetected.",
      "The potential for misdiagnosis and the limitations of surveillance are huge issues across infectious diseases, especially emerging infectious diseases, he added."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that gaps in surveillance and limited testing led to undetected cases, which likely contributed to the spread resulting in a record-breaking trajectory.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.012424002401530743,
    "x2e_entail_prob": 0.00943855568766594
  },
  {
    "id": "covid_fact-000295",
    "statement": "Efforts in early surveillance of coronavirus led to record-breaking us trajectory",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "As illustrated in the COVID-19 study, while public health officials must work quickly to understand how a new virus functions, without appropriate testing or coordinated response strategies the risk grows for infections to go unreported.",
      "The study provides insight into how limited testing and gaps in surveillance during the initial phase of the epidemic resulted in so many cases going undetected.",
      "The potential for misdiagnosis and the limitations of surveillance are huge issues across infectious diseases, especially emerging infectious diseases, he added."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that early surveillance efforts had significant gaps leading to undetected cases and potential misdiagnoses, which does not support the claim of a record-breaking positive trajectory.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.021452438086271286,
    "x2e_entail_prob": 0.006066776346415281
  },
  {
    "id": "covid_fact-000296",
    "statement": "Immunosuppression is associated with a lower risk of moderate to severe acute respiratory distress syndrome in covid-19 .",
    "label": "SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that immunosuppression was associated with a lower risk of moderate-severe ARDS in COVID-19 patients, which fully supports the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.04264833405613899,
    "x2e_entail_prob": 0.8383700251579285
  },
  {
    "id": "covid_fact-000297",
    "statement": "Immunosuppression is associated with a increased risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided directly contradicts the claim by stating that immunosuppression was associated with a lower risk of moderate-severe ARDS in COVID-19 patients, not an increased risk.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0017441577510908246,
    "x2e_entail_prob": 0.714061439037323
  },
  {
    "id": "covid_fact-000298",
    "statement": "Immunosuppression is associated with a higher risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence directly contradicts the claim by stating that immunosuppression was associated with a lower risk of moderate-severe ARDS in COVID-19 patients.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.001972569851204753,
    "x2e_entail_prob": 0.6696737408638
  },
  {
    "id": "covid_fact-000299",
    "statement": "Immunosuppression is associated with a high risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that immunosuppression is associated with a lower risk of moderate-severe ARDS in COVID-19 patients, contradicting the claim which suggests a high risk.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.04688095301389694,
    "x2e_entail_prob": 0.7999160289764404
  },
  {
    "id": "covid_fact-000300",
    "statement": "Human soluble ace2 improves the effect of remdesivir in sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes treating cells with both remdesivir and hrsACE2, but it does not provide data showing that this combination improves the effect of remdesivir compared to using remdesivir alone.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.01184451300650835,
    "x2e_entail_prob": 0.40562862157821655
  },
  {
    "id": "covid_fact-000301",
    "statement": "Human soluble ace2 inhibits the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes an experiment where both remdesivir and hrsACE2 are used together but does not provide results indicating that one inhibits the other. Without outcome data, we cannot confirm the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.03207916393876076,
    "x2e_entail_prob": 0.29212719202041626
  },
  {
    "id": "covid_fact-000302",
    "statement": "Human soluble ace2 blocked the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes an experiment treating SARS-CoV-2 infected cells with hrsACE2 and remdesivir but does not provide results showing whether hrsACE2 blocked remdesivir's effect.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.02921888418495655,
    "x2e_entail_prob": 0.20554527640342712
  },
  {
    "id": "covid_fact-000303",
    "statement": "Human soluble ace2 reduces the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that hrsACE2 inhibits SARS-CoV-2 infection in Vero E6 cells and was used alongside remdesivir, but it does not provide specific data indicating that ACE2 reduces remdesivir's effectiveness. Without explicit results on their interaction, the claim cannot be fully supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.16881008446216583,
    "x2e_entail_prob": 0.5431512594223022
  },
  {
    "id": "covid_fact-000304",
    "statement": "A five day course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Evidence indicates that a 5-day course of ivermectin leads to earlier viral clearance compared to placebo, supporting the claim that it reduces the duration of COVID-19 illness.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8823844194412231,
    "x2e_entail_prob": 0.6229709386825562
  },
  {
    "id": "covid_fact-000305",
    "statement": "A five years course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a 5-day course of ivermectin, not a five-year course. It supports effectiveness for early mild COVID-19 but does not address long-term treatment.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.010277886874973774,
    "x2e_entail_prob": 0.6300384402275085
  },
  {
    "id": "covid_fact-000306",
    "statement": "A five year course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports a 5-day course reducing illness duration but does not address or support a 5-year treatment.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.015438508242368698,
    "x2e_entail_prob": 0.4610741436481476
  },
  {
    "id": "covid_fact-000307",
    "statement": "A fivemonth course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports a 5-day course of ivermectin reducing COVID-19 duration but does not mention or provide data for a five-month course.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.011210624128580093,
    "x2e_entail_prob": 0.5944846868515015
  },
  {
    "id": "covid_fact-000308",
    "statement": "Brd4-bound enhancers drive cell intrinsic sex differences in glioblastoma",
    "label": "SUPPORTED",
    "evidences": [
      "These observations led us to hypothesize that Brd4-bound enhancers might underlie sex differences in stem cell function and tumorigenicity in GBM.",
      "We report that sex-biased Brd4 activity drive sex differences in GBM and render male and female tumor cells differentially sensitive to BET inhibitors.",
      "These sex- biased gene expression patterns were also evident in human glioblastoma stem cells (GSCs).",
      "In an established isogenic murine model of glioblastoma, we discovered correlated transcriptome-wide sex differences in gene expression, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites.",
      "Thus, for the first time, Brd4 activity is revealed to drive a sex differences in stem cell and tumorigenic phenotype, resulting in diametrically opposite responses to BET inhibition in male and female GBM cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that Brd4 activity drives sex differences in glioblastoma by influencing gene expression patterns, Brd4-bound enhancers usage, and sensitivity to BET inhibitors in male and female tumor cells.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9835264086723328,
    "x2e_entail_prob": 0.06936566531658173
  },
  {
    "id": "covid_fact-000309",
    "statement": "Brd4-bound enhancers drive cell surface sex differences in glioblastoma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations led us to hypothesize that Brd4-bound enhancers might underlie sex differences in stem cell function and tumorigenicity in GBM.",
      "We report that sex-biased Brd4 activity drive sex differences in GBM and render male and female tumor cells differentially sensitive to BET inhibitors.",
      "These sex- biased gene expression patterns were also evident in human glioblastoma stem cells (GSCs).",
      "In an established isogenic murine model of glioblastoma, we discovered correlated transcriptome-wide sex differences in gene expression, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites.",
      "Thus, for the first time, Brd4 activity is revealed to drive a sex differences in stem cell and tumorigenic phenotype, resulting in diametrically opposite responses to BET inhibition in male and female GBM cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that Brd4 activity drives sex differences in gene expression and tumorigenicity in glioblastoma, but it does not specifically mention cell surface differences.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.005360133480280638,
    "x2e_entail_prob": 0.07815350592136383
  },
  {
    "id": "covid_fact-000310",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome",
    "label": "SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by showing that IL-6 trans-signaling promotes PAI-1 (plasminogen activator inhibitor-1) production from endothelial cells.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8765244483947754,
    "x2e_entail_prob": 0.002084790961816907
  },
  {
    "id": "covid_fact-000311",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine development syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that IL-6 trans-signaling induces PAI-1 production in endothelial cells and promotes cytokine release, but it does not mention 'cytokine development syndrome.'",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0013004213105887175,
    "x2e_entail_prob": 0.001345340977422893
  },
  {
    "id": "covid_fact-000312",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine production syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that IL-6 trans-signaling promotes PAI-1 production in endothelial cells and is associated with cytokine production, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6141703724861145,
    "x2e_entail_prob": 0.0017066487343981862
  },
  {
    "id": "covid_fact-000313",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine differentiation syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that IL-6 trans-signaling induces PAI-1 from endothelial cells and contributes to cytokine production, which aligns with the processes in cytokine differentiation syndrome, though the exact term isn't used.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.004039451014250517,
    "x2e_entail_prob": 0.0013386558275669813
  },
  {
    "id": "covid_fact-000314",
    "statement": "Fauci says he wears a mask to be a symbol of what 'you should be doing '",
    "label": "SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Fauci explicitly states in the evidence that he wears a mask to serve as a symbol for others to follow.",
    "confidence": 1,
    "e2x_entail_prob": 0.016874885186553,
    "x2e_entail_prob": 0.005575501825660467
  },
  {
    "id": "covid_fact-000315",
    "statement": "Fauci says he wears a point to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly quotes Fauci stating that he wears a mask as a symbol for people to follow, confirming the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.05659227818250656,
    "x2e_entail_prob": 0.00829334370791912
  },
  {
    "id": "covid_fact-000316",
    "statement": "Fauci says he wears a license to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows Fauci wears masks both to protect and as a symbol, which supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.02627381682395935,
    "x2e_entail_prob": 0.006192512810230255
  },
  {
    "id": "covid_fact-000317",
    "statement": "Fauci says he wears a question to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Fauci wears a mask to symbolize what others should be doing, aligning perfectly with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.028808720409870148,
    "x2e_entail_prob": 0.008633369579911232
  },
  {
    "id": "covid_fact-000318",
    "statement": "Iga dominates the early neutralizing antibody response to sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that IgA antibodies are detectable earlier than IgG, dominate plasmablast expansion, and form the majority of early humoral responses, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.811094343662262,
    "x2e_entail_prob": 0.05439228564500809
  },
  {
    "id": "covid_fact-000319",
    "statement": "Iga dominates the full neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence shows that IgA antibodies are dominant early in the immune response to SARS-CoV-2, it does not confirm that IgA continues to dominate throughout the entire neutralizing antibody response. The term 'full' implies dominance across all stages, which isn't supported by the provided data.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.17738473415374756,
    "x2e_entail_prob": 0.8073939681053162
  },
  {
    "id": "covid_fact-000320",
    "statement": "Iga dominates the enhanced neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that IgA antibodies are detected earlier than IgG, play a role in early virus neutralization, and dominate plasmablast expansion after SARS-CoV-2 infection.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9763432145118713,
    "x2e_entail_prob": 0.3548071086406708
  },
  {
    "id": "covid_fact-000321",
    "statement": "Iga dominates the effective neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence consistently shows that IgA antibodies appear earlier than IgG and are dominant in early humoral responses against SARS-CoV-2, including effective neutralization.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8254780769348145,
    "x2e_entail_prob": 0.24384495615959167
  },
  {
    "id": "covid_fact-000322",
    "statement": "Fda authorizes first diagnostic test for screening of people without known or suspected covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Last month, the FDA posted updated templates with recommendations for test developers to demonstrate validation for a test to be authorized for screening of asymptomatic people, as well as for sample pooling.",
      "The FDA reissued the LabCorp COVID-19 RT-PCR Test EUA to expand use of the test to anyone, after the company provided scientific data showing the tests ability to detect SARS-CoV-2 in a general, asymptomatic population.",
      "Additionally, the data reviewed by the FDA demonstrated that the test is as accurate in the broader asymptomatic population as it is among people suspected to have COVID-19.",
      "Until now, molecular diagnostic tests have generally been authorized for people suspected of having COVID-19 by their health care provider, which has allowed asymptomatic people to be tested, when warranted, at the discretion of the health care provider."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the FDA updated guidelines to allow diagnostic tests for asymptomatic individuals and reauthorized a specific test (LabCorp's) for this purpose, confirming the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7660471200942993,
    "x2e_entail_prob": 0.0015157790621742606
  },
  {
    "id": "covid_fact-000323",
    "statement": "Fda authorizes another diagnostic test for screening of people without known or suspected covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Last month, the FDA posted updated templates with recommendations for test developers to demonstrate validation for a test to be authorized for screening of asymptomatic people, as well as for sample pooling.",
      "The FDA reissued the LabCorp COVID-19 RT-PCR Test EUA to expand use of the test to anyone, after the company provided scientific data showing the tests ability to detect SARS-CoV-2 in a general, asymptomatic population.",
      "Additionally, the data reviewed by the FDA demonstrated that the test is as accurate in the broader asymptomatic population as it is among people suspected to have COVID-19.",
      "Until now, molecular diagnostic tests have generally been authorized for people suspected of having COVID-19 by their health care provider, which has allowed asymptomatic people to be tested, when warranted, at the discretion of the health care provider."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the FDA updated guidelines and reissued an EUA for a COVID-19 test, expanding it to include screening of asymptomatic people, thus supporting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.7306373715400696,
    "x2e_entail_prob": 0.0012698402861133218
  },
  {
    "id": "covid_fact-000324",
    "statement": "Johnson & johnson pauses covid-19 vaccine trials due to sick subject",
    "label": "SUPPORTED",
    "evidences": [
      "This is the second time trials for a Covid-19 vaccine trial have been paused over a safety concern."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does mention pauses in Covid-19 vaccine trials due to safety concerns but doesn't specifically attribute this pause to Johnson & Johnson or link it directly to a sick subject.",
    "confidence": 0.5,
    "e2x_entail_prob": 0.0022759600542485714,
    "x2e_entail_prob": 0.0010778967989608645
  },
  {
    "id": "covid_fact-000325",
    "statement": "Johnson & johnson developed covid-19 vaccine trials due to sick subject",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This is the second time trials for a Covid-19 vaccine trial have been paused over a safety concern."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that Covid-19 vaccine trials were paused twice due to safety concerns but does not specifically attribute this to a sick subject causing Johnson & Johnson's trial developments.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.001499126316048205,
    "x2e_entail_prob": 0.9764046669006348
  },
  {
    "id": "covid_fact-000326",
    "statement": "Asymptomatic cases may not be infectious , wuhan study indicates.",
    "label": "SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The Wuhan study indicates a very low detection rate of asymptomatic cases and found no evidence that these cases were infectious.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9922475814819336,
    "x2e_entail_prob": 0.3893391788005829
  },
  {
    "id": "covid_fact-000327",
    "statement": "Asymptomatic cases may also be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that there was no evidence of asymptomatic cases being infectious in the Wuhan study, which contradicts the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.11864664405584335,
    "x2e_entail_prob": 0.08499623835086823
  },
  {
    "id": "covid_fact-000328",
    "statement": "Asymptomatic cases may only be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states there was no indication that asymptomatic cases in Wuhan were infectious, contradicting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.20195141434669495,
    "x2e_entail_prob": 0.0795372873544693
  },
  {
    "id": "covid_fact-000329",
    "statement": "Asymptomatic cases may still be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence from the Wuhan study explicitly states that there was no evidence of asymptomatic positive cases being infectious, directly contradicting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.021868707612156868,
    "x2e_entail_prob": 0.11480876058340073
  },
  {
    "id": "covid_fact-000330",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ace inhibitors or angiotensin receptor blockers",
    "label": "SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that ACE2 expression is not increased by ACE inhibitors or ARBs but does not explicitly confirm that ACE2 localizes specifically to motile cilia.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.04175454378128052,
    "x2e_entail_prob": 0.0018264292739331722
  },
  {
    "id": "covid_fact-000331",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is significantly increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that ACE inhibitors or ARBs significantly increase ACE2 expression in respiratory cilia is contradicted by the evidence, which suggests no increase and possibly a decrease.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7590430378913879,
    "x2e_entail_prob": 0.0016647912561893463
  },
  {
    "id": "covid_fact-000332",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is greatly increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While ACE2 protein is localized in nasal cilia, the evidence contradicts the claim that ACE inhibitors or ARBs increase ACE2 expression; instead, it suggests potential decrease.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9541976451873779,
    "x2e_entail_prob": 0.0021614660508930683
  },
  {
    "id": "covid_fact-000333",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is further increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that ACE2 protein expression is not increased by ACE inhibitors or ARBs but may decrease in ACEI patients. There is no confirmation of robust ACE2 localization to motile cilia.",
    "confidence": 1,
    "e2x_entail_prob": 0.9079307317733765,
    "x2e_entail_prob": 0.00210720207542181
  },
  {
    "id": "covid_fact-000334",
    "statement": "A consensus covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a core immune signature that combines adaptive B cell responses (indicative of immuno-protection) with sepsis-like traits such as monocyte and dendritic cell dampening, which are associated with poor prognosis. This aligns with the claim about the combination of immuno-protection and sepsis-like traits.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.11197689175605774,
    "x2e_entail_prob": 0.020846588537096977
  },
  {
    "id": "covid_fact-000335",
    "statement": "A novel covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes an immune signature that combines adaptive B cell responses (indicative of immunoprotection) with traits like monocyte and dendritic cell dampening, which are associated with sepsis and poor prognosis.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3778953552246094,
    "x2e_entail_prob": 0.008880349807441235
  },
  {
    "id": "covid_fact-000336",
    "statement": "A unique covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms a COVID-19 immune signature that includes adaptive B cell responses (indicative of immunoprotection) alongside sepsis-like traits, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.23466701805591583,
    "x2e_entail_prob": 0.002047051442787051
  },
  {
    "id": "covid_fact-000337",
    "statement": "The institute for disease modeling puts the cfr at 0.94 %",
    "label": "SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses an infection-fatality-ratio (IFR) of 0.94%, but the claim refers to case fatality rate (CFR). The two are different metrics, so the claim is not supported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.059847187250852585,
    "x2e_entail_prob": 0.02227344922721386
  },
  {
    "id": "covid_fact-000338",
    "statement": "The institute for disease transmission puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses IFR rather than CFR and does not mention the specific institute.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.021084530279040337,
    "x2e_entail_prob": 0.003942923620343208
  },
  {
    "id": "covid_fact-000339",
    "statement": "The institute for disease surveillance puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses an IFR of 0.94% but does not explicitly confirm a CFR of 0.94%. Additionally, it doesn't attribute this figure to an institute for disease surveillance.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.009371991269290447,
    "x2e_entail_prob": 0.00841684639453888
  },
  {
    "id": "covid_fact-000340",
    "statement": "The institute for disease detection puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a corrected IFR estimate of 0.94%, not CFR, and does not reference an 'institute for disease detection.'",
    "confidence": 0.85,
    "e2x_entail_prob": 0.009569662623107433,
    "x2e_entail_prob": 0.016265220940113068
  },
  {
    "id": "covid_fact-000341",
    "statement": "Evolutionary arms race between virus and host drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that the interaction between bat ACE2 and SARSr-CoV spike proteins, along with coevolution and selection pressures, drives genetic diversity in the spike genes, aligning with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7358229160308838,
    "x2e_entail_prob": 0.011946451850235462
  },
  {
    "id": "covid_fact-000342",
    "statement": "Evolutionary arms race between virus and coronavirus drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by indicating that the interaction between bat ACE2 and SARSr-CoV spike proteins, along with coevolution and selection pressure, leads to an evolutionary arms race, driving genetic diversity in the spike genes.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.761217474937439,
    "x2e_entail_prob": 0.9124245047569275
  },
  {
    "id": "covid_fact-000343",
    "statement": "Evolutionary arms race between virus and viruses drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates an evolutionary arms race between SARSr-CoV spike proteins and bat ACE2, leading to coevolution and selection pressures that drive genetic diversity in the spike genes.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9159246683120728,
    "x2e_entail_prob": 0.8406224250793457
  },
  {
    "id": "covid_fact-000344",
    "statement": "Evolutionary arms race between virus and virus drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim incorrectly describes an evolutionary arms race as occurring between viruses, while the evidence indicates it is between the virus and its bat host's ACE2 receptors, driving diversity in spike genes.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.008673935197293758,
    "x2e_entail_prob": 0.11354733258485794
  },
  {
    "id": "covid_fact-000345",
    "statement": "Active monitoring of persons exposed to patients with confirmed covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact with patients with confirmed COVID-19 ( 2 ).",
      "The duration of time in the same airspace after the patient with confirmed COVID-19 was applied differently by health jurisdictions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that health departments began actively monitoring persons with close contact to COVID-19 patients starting January 20, 2020.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.10663295537233353,
    "x2e_entail_prob": 0.00156525953207165
  },
  {
    "id": "covid_fact-000346",
    "statement": "Active monitoring of persons exposed to patients without confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact with patients with confirmed COVID-19 ( 2 ).",
      "The duration of time in the same airspace after the patient with confirmed COVID-19 was applied differently by health jurisdictions."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to active monitoring of persons exposed to patients without confirmed COVID-19, but the evidence specifically mentions monitoring those with close contact to confirmed cases. There's no support for monitoring unconfirmed exposures.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.013228297233581543,
    "x2e_entail_prob": 0.0025797828566282988
  },
  {
    "id": "covid_fact-000347",
    "statement": "Convalescent plasma to treat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates that convalescent plasma is being used and studied as a treatment for COVID-19, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.21636104583740234,
    "x2e_entail_prob": 0.23466448485851288
  },
  {
    "id": "covid_fact-000348",
    "statement": "Unvalescent plasma to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim likely contains a typo ('unvalescent' instead of 'convalescent'). The evidence strongly supports the use of convalescent plasma for treating COVID-19, detailing its application in clinical trials and expanded access programs.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.008199638687074184,
    "x2e_entail_prob": 0.4430130124092102
  },
  {
    "id": "covid_fact-000349",
    "statement": "Convalescent antibiotics to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim incorrectly uses 'antibiotics' instead of 'plasma.' The evidence only supports convalescent plasma therapy, not antibiotics for COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.03290651738643646,
    "x2e_entail_prob": 0.32269924879074097
  },
  {
    "id": "covid_fact-000350",
    "statement": "Subvalescent plasma to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim likely refers to 'convalescent plasma' as treatment for COVID-19, which is supported by the evidence. The term 'subvalescent' appears to be a typo.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.3686165511608124,
    "x2e_entail_prob": 0.4102548360824585
  },
  {
    "id": "covid_fact-000351",
    "statement": "Man , 25 , catches coronavirus twice in first such us case",
    "label": "SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that a 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions. This directly supports the claim of him catching coronavirus twice in the first such US case.",
    "confidence": 1,
    "e2x_entail_prob": 0.24101898074150085,
    "x2e_entail_prob": 0.0011968304170295596
  },
  {
    "id": "covid_fact-000352",
    "statement": "13, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms a 25-year-old man caught coronavirus twice in the first US case of reinfection.",
    "confidence": 1,
    "e2x_entail_prob": 0.9788780212402344,
    "x2e_entail_prob": 0.005118121393024921
  },
  {
    "id": "covid_fact-000353",
    "statement": "2, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms a 25-year-old man in the U.S. was the first confirmed case of coronavirus reinfection, aligning with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6262468099594116,
    "x2e_entail_prob": 0.0029484578408300877
  },
  {
    "id": "covid_fact-000354",
    "statement": "19, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only mentions a single case of a 25-year-old man being infected twice, without any information about a 19-year-old or multiple cases.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.030926652252674103,
    "x2e_entail_prob": 0.003415553830564022
  },
  {
    "id": "covid_fact-000355",
    "statement": "Black , hispanic communities struggle in covid-19 vaccine rollout across the u.s .",
    "label": "SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim by showing higher hesitancy and distrust in Black and Hispanic communities, linked to historical mistreatment and current healthcare disparities.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.19040468335151672,
    "x2e_entail_prob": 0.004510638304054737
  },
  {
    "id": "covid_fact-000356",
    "statement": "2, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Latino (Hispanic) communities experience higher levels of vaccine hesitancy and distrust compared to white Americans, citing historical medical experimentation and ongoing healthcare disparities as contributing factors. This directly supports the claim that Hispanic communities struggle during the Covid-19 vaccine rollout.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.4056853950023651,
    "x2e_entail_prob": 0.0023484386038035154
  },
  {
    "id": "covid_fact-000357",
    "statement": "6, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly mentions Latino communities struggling with vaccine hesitancy and distrust, citing historical medical experimentation and healthcare disparities as contributing factors. Hispanic and Latino are often used interchangeably in this context.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1964493989944458,
    "x2e_entail_prob": 0.0014968072064220905
  },
  {
    "id": "covid_fact-000358",
    "statement": "3, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that Hispanic/Latino communities experience higher vaccine hesitancy, distrust, and challenges in access due to historical and systemic issues, directly supporting the claim about their struggles during the COVID-19 vaccine rollout.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.4222853183746338,
    "x2e_entail_prob": 0.0015171522973105311
  },
  {
    "id": "covid_fact-000359",
    "statement": "Past covid-19 infection provides some immunity but people may still carry and transmit virus.",
    "label": "SUPPORTED",
    "evidences": [
      "The PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "Published 14 January 2021 From: Public Health England People infected with COVID-19 in the past are likely to be protected against reinfection for several months, a Public Health England (PHE) study has found, although experts cautioned those with immunity may still be able carry the virus in their nose and throat and therefore have a risk of transmitting to others.",
      "PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "But a small number of people with antibodies may still be able to carry and transmit COVID-19 according to the study.",
      "iStock London, January 14 An official UK study released on Thursday concludes that a past COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that past COVID-19 infection offers some protection against reinfection for several months, thus providing immunity. Additionally, it mentions that even with antibodies, individuals can still carry high levels of the virus and transmit it to others. Both parts of the claim are directly supported by the provided information.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1576521098613739,
    "x2e_entail_prob": 0.06525270640850067
  },
  {
    "id": "covid_fact-000360",
    "statement": "Past covid-19 infection provides some immunity but people cannot still carry and transmit virus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "Published 14 January 2021 From: Public Health England People infected with COVID-19 in the past are likely to be protected against reinfection for several months, a Public Health England (PHE) study has found, although experts cautioned those with immunity may still be able carry the virus in their nose and throat and therefore have a risk of transmitting to others.",
      "PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "But a small number of people with antibodies may still be able to carry and transmit COVID-19 according to the study.",
      "iStock London, January 14 An official UK study released on Thursday concludes that a past COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that past COVID-19 infection provides some immunity but also indicates that individuals with antibodies can still carry and transmit the virus, contradicting the claim's second part.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.23690208792686462,
    "x2e_entail_prob": 0.08949341624975204
  },
  {
    "id": "covid_fact-000361",
    "statement": "Systematic analysis of innate immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that IFN-\u03b3 and IFN-\u03bb1 signaling are not effectively antagonized by SARS-CoV-2, indicating the virus's susceptibility to these cytokines and thus supporting the claim of identified vulnerabilities.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.15645752847194672,
    "x2e_entail_prob": 0.5996648669242859
  },
  {
    "id": "covid_fact-000362",
    "statement": "Systematic analysis of cellular immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that IFN-\u03b3 and IFN-\u03bb1 signaling are not effectively antagonized by SARS-CoV-2, making the virus susceptible to these cytokines. This aligns with the claim that systematic analysis of cellular immune antagonism reveals vulnerabilities in the virus.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.043408866971731186,
    "x2e_entail_prob": 0.5876079797744751
  },
  {
    "id": "covid_fact-000363",
    "statement": "Systematic analysis of adaptive immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that SARS-CoV-2's limited antagonism of IFN-\u03b3 and IFN-\u03bb1 signaling makes it vulnerable to these cytokines, aligning with the claim about adaptive immune analysis revealing vulnerabilities.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.005057397298514843,
    "x2e_entail_prob": 0.5577000379562378
  },
  {
    "id": "covid_fact-000364",
    "statement": "Systematic analysis of antiviral immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2's susceptibility to IFN-\u03b3 and IFN-\u03bb1 highlights vulnerabilities revealed through immune antagonism analysis, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.12088176608085632,
    "x2e_entail_prob": 0.010762897320091724
  },
  {
    "id": "covid_fact-000365",
    "statement": "Trial to promote recovery from covid-19 with ivermectin or endocrine therapy",
    "label": "SUPPORTED",
    "evidences": [
      "This will be a randomized, open-label study to determine if bicalutamide improves the rate of clinical improvement in patients with COVID-19.",
      "This will be a randomized, open-label study to determine if bicalutamide or ivermectin improves the time to clinical improvement in patients with COVID-19 over historical controls."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a randomized study testing both ivermectin and bicalutamide (an endocrine therapy) for COVID-19 recovery, aligning with the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.1076524406671524,
    "x2e_entail_prob": 0.2898222804069519
  },
  {
    "id": "covid_fact-000366",
    "statement": "Trial to no recovery from covid-19 with ivermectin or endocrine therapy",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This will be a randomized, open-label study to determine if bicalutamide improves the rate of clinical improvement in patients with COVID-19.",
      "This will be a randomized, open-label study to determine if bicalutamide or ivermectin improves the time to clinical improvement in patients with COVID-19 over historical controls."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes clinical trials involving bicalutamide and ivermectin for COVID-19 treatment, supporting the claim about their use in recovery studies.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.013986680656671524,
    "x2e_entail_prob": 0.23604662716388702
  },
  {
    "id": "covid_fact-000367",
    "statement": "Coronavirus vaccines leap through safety trials",
    "label": "SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that coronavirus vaccines have moved quickly through initial trials with promising safety and immune responses. While the claim's use of 'leap' might imply rapid progression, the evidence supports their swift yet cautious advancement in safety trials.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.6061508655548096,
    "x2e_entail_prob": 0.06811204552650452
  },
  {
    "id": "covid_fact-000368",
    "statement": "Coronavirus vaccines remain through safety trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that coronavirus vaccines have undergone safety trials and show promise in inducing immune responses, suggesting they are broadly safe.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9893474578857422,
    "x2e_entail_prob": 0.045258596539497375
  },
  {
    "id": "covid_fact-000369",
    "statement": "Coronavirus vaccines work through safety trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim incorrectly conflates how vaccines function with their testing phase. The evidence shows that vaccines work by exposing the immune system to viral components, not through safety trials themselves. Safety trials are a separate process for testing efficacy and safety.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.029192237183451653,
    "x2e_entail_prob": 0.030546827241778374
  },
  {
    "id": "covid_fact-000370",
    "statement": "Couple diagnosed with coronavirus flew on delta , hawaiian airlines flights , carriers confirm",
    "label": "SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that Delta Air Lines and Hawaiian Airlines have confirmed a couple diagnosed with coronavirus flew on their flights in Hawaii, aligning completely with the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.04253443703055382,
    "x2e_entail_prob": 0.000960241595748812
  },
  {
    "id": "covid_fact-000371",
    "statement": "Mice diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.021225251257419586,
    "x2e_entail_prob": 0.002835639752447605
  },
  {
    "id": "covid_fact-000372",
    "statement": "Dogs diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a human couple diagnosed with coronavirus traveling on Delta and Hawaiian Airlines flights but does not mention any dogs or animals being involved.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0024464502930641174,
    "x2e_entail_prob": 0.0021007824689149857
  },
  {
    "id": "covid_fact-000373",
    "statement": "Cats diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a couple diagnosed with coronavirus who flew on Delta and Hawaiian Airlines flights, but it does not mention any cats or their diagnosis with coronavirus.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.003258331445977092,
    "x2e_entail_prob": 0.001680596498772502
  },
  {
    "id": "covid_fact-000374",
    "statement": "Latest data show above 80 % efficacy for favipiravir in covid-19 , say rdif and chemrar",
    "label": "SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that favipiravir has an efficacy above 80%, aligning with the claim's main point. However, the sources RDIF and CHEMRAR are not explicitly mentioned in the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.00302563956938684,
    "x2e_entail_prob": 0.06344419717788696
  },
  {
    "id": "covid_fact-000375",
    "statement": "Latest data show only 80 % efficacy for favipiravir in covid-19, say rdif and chemrar",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from the Dhaka Trial confirms that favipiravir has an efficacy above 80%, aligning with the claim's 80% figure. While RDIF and CHEMRAR aren't mentioned, the trial provides strong support for the efficacy claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8767896890640259,
    "x2e_entail_prob": 0.1524275690317154
  },
  {
    "id": "covid_fact-000376",
    "statement": "Latest data show nearly 80 % efficacy for favipiravir in covid-19, say rdif and chemrar",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that favipiravir has over 80% efficacy but does not mention RDIF or CHEMRAR as sources, thus the claim about these organizations is unsupported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.003980746027082205,
    "x2e_entail_prob": 0.036451831459999084
  },
  {
    "id": "covid_fact-000377",
    "statement": "Antibody test for covid-19 could help to control virus spread , says singapore medtech firm",
    "label": "SUPPORTED",
    "evidences": [
      "Yee estimates commissioning roughly two million COVID-19 test kits in the next two months from Nanjing-based Vazyme Biotech, a Chinese producer of enzymes and antibodies.",
      "The medtech company, which specializes in cancer treatment equipment and applications, has created a test kit that detects antibodies directed against the coronavirus thats sweeping the world.",
      "Meanwhile, Singapores Ministry of Health issued a document released to all registered medical practitioners on April 3 stating, There is currently no role for COVID-19 serology rapid test kits in the diagnosis of COVID-19 infections. The Biolidics test checks the blood for antibodies and can identify who was previously infected and may have already developed immunity to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence shows that a Singapore medtech firm developed an antibody test for COVID-19 and mentions its use in identifying past infections, there is no direct statement from the company asserting that such tests can help control virus spread. The claim's attribution to the company for this belief isn't supported by the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.4605751931667328,
    "x2e_entail_prob": 0.0028747795149683952
  },
  {
    "id": "covid_fact-000378",
    "statement": "Antibody test for covid-19 cannot help to control virus spread, says singapore medtech firm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Yee estimates commissioning roughly two million COVID-19 test kits in the next two months from Nanjing-based Vazyme Biotech, a Chinese producer of enzymes and antibodies.",
      "The medtech company, which specializes in cancer treatment equipment and applications, has created a test kit that detects antibodies directed against the coronavirus thats sweeping the world.",
      "Meanwhile, Singapores Ministry of Health issued a document released to all registered medical practitioners on April 3 stating, There is currently no role for COVID-19 serology rapid test kits in the diagnosis of COVID-19 infections. The Biolidics test checks the blood for antibodies and can identify who was previously infected and may have already developed immunity to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not explicitly state that the Singapore medtech firm claims antibody tests cannot help control virus spread. Instead, it mentions Singapore's Ministry of Health stating that serology rapid tests have no role in diagnosis. The company developed an antibody test but did not comment on its effectiveness for controlling spread.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.0942232608795166,
    "x2e_entail_prob": 0.0034256773069500923
  },
  {
    "id": "covid_fact-000379",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of two different serological tests.",
    "label": "SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses serological test performance but does not explicitly tie it to healthcare workers at the Rome hospital.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.01711602695286274,
    "x2e_entail_prob": 0.01911190152168274
  },
  {
    "id": "covid_fact-000380",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of three different serological tests.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence provides data on two serological tests (point-of-care and venous blood), it does not mention a third test, which is required by the claim to discuss three different serological tests.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.019793452695012093,
    "x2e_entail_prob": 0.011056775227189064
  },
  {
    "id": "covid_fact-000381",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of all different serological tests.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses test performance in a low-risk population but doesn't provide seroprevalence data for healthcare workers at FPG IRCCS, making it insufficient to support the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.019201552495360374,
    "x2e_entail_prob": 0.004936315584927797
  },
  {
    "id": "covid_fact-000382",
    "statement": "A neutralizing human antibody binds to the n-terminal domain of the spike protein of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.",
      "( B ) The correlations between the authentic SARS-CoV-2 neutralizing antibody (NAb) titers and the pseudotyped SARS-CoV-2 NAb titers in plasma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the presence of neutralizing antibodies but does not specify that they bind to the N-terminal domain of the spike protein.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0035099538508802652,
    "x2e_entail_prob": 0.2923462986946106
  },
  {
    "id": "covid_fact-000383",
    "statement": "A neutralizing mouse antibody binds to the n-terminal domain of the spike protein of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.",
      "( B ) The correlations between the authentic SARS-CoV-2 neutralizing antibody (NAb) titers and the pseudotyped SARS-CoV-2 NAb titers in plasma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses human neutralizing antibodies but does not mention mouse antibodies or their binding to the n-terminal domain of the spike protein.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0026327581144869328,
    "x2e_entail_prob": 0.22135935723781586
  },
  {
    "id": "covid_fact-000384",
    "statement": "A novel point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explains that mutations in SARS-CoV-2, including those in the n gene region targeted by RT-qPCR primers, can reduce assay sensitivity and specificity, potentially leading to false negatives.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8906874060630798,
    "x2e_entail_prob": 0.026231849566102028
  },
  {
    "id": "covid_fact-000385",
    "statement": "A third point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the idea that mutations in SARS-CoV-2 can affect RT-qPCR detection, especially if they occur in regions targeted by primers. Although the evidence doesn't explicitly mention a 'third point mutation' or focus solely on the n gene, it does discuss how mutations generally can impact diagnostic accuracy. This makes the claim plausible.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.10785619169473648,
    "x2e_entail_prob": 0.03760503605008125
  },
  {
    "id": "covid_fact-000386",
    "statement": "A major point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that mutations in SARS-CoV-2 can interfere with RT-qPCR by affecting primer binding sites, leading to reduced sensitivity and potential false negatives. This directly supports the claim about a point mutation in the n gene affecting detection.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5756527185440063,
    "x2e_entail_prob": 0.02361994981765747
  },
  {
    "id": "covid_fact-000387",
    "statement": "99.9 % of sars-cov-2 gets destroyed after gargling betadine , claims study",
    "label": "SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by showing that Betadine Gargle destroyed 99.9% of SARS-CoV-2 within 15 seconds and maintained this reduction over time.",
    "confidence": 0.98,
    "e2x_entail_prob": 0.7689007520675659,
    "x2e_entail_prob": 0.30696937441825867
  },
  {
    "id": "covid_fact-000388",
    "statement": "99.9 % of sars-cov-2 gets stable after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that Betadine gargle destroys or reduces the viral load of SARS-CoV-2, not that it makes the virus stable. The claim's wording is inconsistent with the study results.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.00629245163872838,
    "x2e_entail_prob": 0.21208202838897705
  },
  {
    "id": "covid_fact-000389",
    "statement": "99.9 % of sars-cov-2 gets effective after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim that Betadine gargle can destroy or reduce SARS-CoV-2 by 99.9% within a short timeframe of 15 to 30 seconds, aligning perfectly with the study results provided.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.803530752658844,
    "x2e_entail_prob": 0.10455885529518127
  },
  {
    "id": "covid_fact-000390",
    "statement": "99.9 % of sars-cov-2 gets active after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Betadine gargle reduces SARS-CoV-2 viral load by 99.9%, supporting the claim.",
    "confidence": 0.98,
    "e2x_entail_prob": 0.7843819260597229,
    "x2e_entail_prob": 0.17155809700489044
  },
  {
    "id": "covid_fact-000391",
    "statement": "Identification of sars-cov-2 vaccine epitopes predicted to induce long-term population-scale immunity",
    "label": "SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence identifies specific SARS-CoV-2 Spike protein epitopes and discusses a vaccination strategy aimed at population-scale immunity, aligning with the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5226002335548401,
    "x2e_entail_prob": 0.7895188927650452
  },
  {
    "id": "covid_fact-000392",
    "statement": "Identification of sars-cov-2 vaccine epitopes fails to induce long-term population-scale immunity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes a vaccination strategy targeting specific SARS-CoV-2 epitopes aimed at population-scale immunity but does not provide data on whether this approach fails to induce long-term immunity. The claim of failure is unsupported by the given evidence.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.05021870136260986,
    "x2e_entail_prob": 0.7368379235267639
  },
  {
    "id": "covid_fact-000393",
    "statement": "Identification of sars-cov-2 vaccine epitopes failed to induce long-term population-scale immunity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses proposed vaccine epitopes and a strategy for population-scale immunity but does not provide information on whether these strategies failed to induce long-term immunity.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.005689328536391258,
    "x2e_entail_prob": 0.5876861810684204
  },
  {
    "id": "covid_fact-000394",
    "statement": "Serial interval of sars-cov-2 was shortened over time by nonpharmaceutical interventions",
    "label": "SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that serial intervals shortened over time in mainland China as nonpharmaceutical interventions were introduced, suggesting a correlation between NPIs and shorter serial intervals.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.10444177687168121,
    "x2e_entail_prob": 0.056679144501686096
  },
  {
    "id": "covid_fact-000395",
    "statement": "Serial interval of sars-cov-2 was increased over time by nonpharmaceutical interventions",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that nonpharmaceutical interventions caused the serial interval to shorten rather than increase.",
    "confidence": 1,
    "e2x_entail_prob": 0.3329252600669861,
    "x2e_entail_prob": 0.03941228240728378
  },
  {
    "id": "covid_fact-000396",
    "statement": "Serial interval of sars-cov-2 was obtained over time by nonpharmaceutical interventions",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that nonpharmaceutical interventions were associated with a shortening of the serial intervals over time in mainland China, directly supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5544620156288147,
    "x2e_entail_prob": 0.09957873821258545
  },
  {
    "id": "covid_fact-000397",
    "statement": "Sars-cov-2 is not detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that all samples from women with severe COVID-19 tested negative for SARS-CoV-2 in vaginal fluid, supporting the claim. However, the small sample size slightly reduces confidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.010643751360476017,
    "x2e_entail_prob": 0.008782943710684776
  },
  {
    "id": "covid_fact-000398",
    "statement": "Sars-cov-2 is also detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that in all 10 severe COVID-19 patients tested, SARS-CoV-2 was not detected in vaginal fluid, contradicting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1692572683095932,
    "x2e_entail_prob": 0.32464760541915894
  },
  {
    "id": "covid_fact-000399",
    "statement": "Sars-cov-2 is only detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that all 10 severe COVID-19 patients tested negative for SARS-CoV-2 in vaginal fluid, contradicting the claim that it is detectable there.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.528241753578186,
    "x2e_entail_prob": 0.56329345703125
  },
  {
    "id": "covid_fact-000400",
    "statement": "Sars-cov-2 is still detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that all samples tested negative for SARS-CoV-2 in vaginal fluid, contradicting the claim that it is detectable.",
    "confidence": 1,
    "e2x_entail_prob": 0.36877065896987915,
    "x2e_entail_prob": 0.016394110396504402
  },
  {
    "id": "covid_fact-000401",
    "statement": "Sars-cov-2 infects monocytes and macrophages , without cytopathic effect",
    "label": "SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly confirms both that SARS-CoV-2 infects monocytes and macrophages and that this infection does not result in a cytopathic effect.",
    "confidence": 1,
    "e2x_entail_prob": 0.9075759053230286,
    "x2e_entail_prob": 0.4390144646167755
  },
  {
    "id": "covid_fact-000402",
    "statement": "Sars-cov-2 infects monocytes and macrophages, cause cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that SARS-CoV-2 infects monocytes and macrophages but explicitly states that no cytopathic effect occurs, contradicting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.004689273424446583,
    "x2e_entail_prob": 0.4150083065032959
  },
  {
    "id": "covid_fact-000403",
    "statement": "Sars-cov-2 infects monocytes and macrophages, an cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infects monocytes and macrophages but does not cause a cytopathic effect. The claim incorrectly includes the presence of a cytopathic effect, which is refuted by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6235349774360657,
    "x2e_entail_prob": 0.24989892542362213
  },
  {
    "id": "covid_fact-000404",
    "statement": "Sars-cov-2 infects monocytes and macrophages, a cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms SARS-CoV-2 infects monocytes and macrophages but explicitly states there is no cytopathic effect, contradicting the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.005895418580621481,
    "x2e_entail_prob": 0.41548776626586914
  },
  {
    "id": "covid_fact-000405",
    "statement": "Rapid clinical deterioration of severe covid-19 may be associated with stroke",
    "label": "SUPPORTED",
    "evidences": [
      "\"For those with severe COVID-19, rapid clinical deterioration or worsening could be associated with a neurologic event such as stroke, which would contribute to its high mortality rate,\" the team wrote in JAMA Neurology."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that rapid clinical deterioration in severe COVID-19 is associated with stroke, contributing to high mortality.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.10207191109657288,
    "x2e_entail_prob": 0.001785737695172429
  },
  {
    "id": "covid_fact-000406",
    "statement": "Rapid clinical deterioration of severe covid-19 may be associated with pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"For those with severe COVID-19, rapid clinical deterioration or worsening could be associated with a neurologic event such as stroke, which would contribute to its high mortality rate,\" the team wrote in JAMA Neurology."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence links rapid clinical deterioration to neurologic events such as stroke, not pneumonia.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0017461031675338745,
    "x2e_entail_prob": 0.0019499693298712373
  },
  {
    "id": "covid_fact-000407",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for replication in primary human respiratory cells",
    "label": "SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that distinct SARS-CoV-2 isolates exhibit features associated with replication in primary human bronchial epithelial cells, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5065227150917053,
    "x2e_entail_prob": 0.0688721165060997
  },
  {
    "id": "covid_fact-000408",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for pathogenicity in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that distinct phenotypes of SARS-CoV-2 isolates are associated with viral traits but does not explicitly state that these traits are critical for pathogenicity in primary human respiratory cells.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0015154735883697867,
    "x2e_entail_prob": 0.02219301275908947
  },
  {
    "id": "covid_fact-000409",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for infection in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses distinct SARS-CoV-2 sequence features associated with phenotypes observed in both non-human and human cells but does not explicitly link these phenotypes to critical traits for infection in primary human respiratory cells.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.003165221307426691,
    "x2e_entail_prob": 0.03022821806371212
  },
  {
    "id": "covid_fact-000410",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for mortality in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence identifies sequence features of SARS-CoV-2 associated with distinct phenotypes in primary human respiratory cells, it does not specifically establish a link between these traits and mortality.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0018932826351374388,
    "x2e_entail_prob": 0.039557162672281265
  },
  {
    "id": "covid_fact-000411",
    "statement": "Esc council on hypertension says ace-i and arbs do not increase covid-19 mortality",
    "label": "SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The ESC Council on Hypertension explicitly states that there is no clinical or scientific evidence suggesting ACE-I and ARBs increase COVID-19 mortality, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5358008146286011,
    "x2e_entail_prob": 0.654271125793457
  },
  {
    "id": "covid_fact-000412",
    "statement": "Esc council on hypertension says ace-i and arbs do and increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The ESC council on hypertension explicitly states that there is no clinical or scientific evidence to support the idea that ACE-i and ARBs increase COVID-19 mortality. Instead, they recommend continuing these medications.",
    "confidence": 1,
    "e2x_entail_prob": 0.7195350527763367,
    "x2e_entail_prob": 0.8589457273483276
  },
  {
    "id": "covid_fact-000413",
    "statement": "Esc council on hypertension says ace-i and arbs do also increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that the ESC Council on Hypertension found no clinical or scientific evidence supporting the claim that ACE-I and ARBs increase COVID-19 mortality. Instead, they recommend continuing their use.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5282630324363708,
    "x2e_entail_prob": 0.8395075798034668
  },
  {
    "id": "covid_fact-000414",
    "statement": "Esc council on hypertension says ace-i and arbs do significantly increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The ESC Council on Hypertension explicitly states that there is no clinical or scientific evidence suggesting ACE-I and ARBs increase COVID-19 mortality. They recommend continuing these medications.",
    "confidence": 1,
    "e2x_entail_prob": 0.6341790556907654,
    "x2e_entail_prob": 0.7046380639076233
  },
  {
    "id": "covid_fact-000415",
    "statement": "Coronavirus threatens small businesses",
    "label": "SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that small businesses could face catastrophic impacts, cites specific economic challenges affecting them, mentions public alarm causing issues even without outbreaks, includes an expert's perspective on their vulnerability, and discusses long-term effects\u2014all supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.13883811235427856,
    "x2e_entail_prob": 0.0771881565451622
  },
  {
    "id": "covid_fact-000416",
    "statement": "Coronavirus threatens worldwide businesses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence details various ways the economy and businesses have been affected, including stock market declines, supply chain issues, and impacts on small businesses globally. These points confirm that coronavirus poses a threat to worldwide businesses.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.16357675194740295,
    "x2e_entail_prob": 0.0027718832716345787
  },
  {
    "id": "covid_fact-000417",
    "statement": "Coronavirus threatens globally businesses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence highlights significant impacts of Coronavirus on businesses, particularly small ones, with mentions of catastrophic effects and broader economic repercussions like stock market declines and supply chain issues. While the focus is on the U.S., the mention of 'elsewhere' suggests global implications.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.022419100627303123,
    "x2e_entail_prob": 0.11217384040355682
  },
  {
    "id": "covid_fact-000418",
    "statement": "Deaths in new york city are more than double the usual total",
    "label": "SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that more than twice the typical number of New Yorkers died over the past month, specifically noting an increase of about 5,000 deaths beyond usual levels.",
    "confidence": 1,
    "e2x_entail_prob": 0.9731906056404114,
    "x2e_entail_prob": 0.018356531858444214
  },
  {
    "id": "covid_fact-000419",
    "statement": "Deaths in new york city are more than below the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that New York City experienced a significant increase in deaths, with more than twice the usual number and an excess of about 5,000 deaths.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.9478126168251038,
    "x2e_entail_prob": 0.0040563540533185005
  },
  {
    "id": "covid_fact-000420",
    "statement": "Children in new york city are more than double the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses increased deaths in NYC but does not provide any information about children's population or birth rates, making the claim unsupported.",
    "confidence": 1,
    "e2x_entail_prob": 0.0011714572319760919,
    "x2e_entail_prob": 0.012068440206348896
  },
  {
    "id": "covid_fact-000421",
    "statement": "Patients in new york city are more than double the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to an increase in patients, but the evidence only mentions a rise in deaths, not the number of patients. Without data on patient numbers, the claim isn't supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.02819068729877472,
    "x2e_entail_prob": 0.02174062281847
  },
  {
    "id": "covid_fact-000422",
    "statement": "Covid-19 racial disparities could be worsened by location of test sites",
    "label": "SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence highlights a disparity in COVID-19 testing availability between northern and southern Dallas, with more private sector tests available in the north. Southern Dallas likely has a higher proportion of minority residents, and limited access to testing sites can contribute to racial inequities by making it harder for these communities to get diagnosed early, worsening health outcomes.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.13051117956638336,
    "x2e_entail_prob": 0.26039066910743713
  },
  {
    "id": "covid_fact-000423",
    "statement": "Covid-19 racial disparities cannot be worsened by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the location of test sites can affect access, specifically citing a disparity between northern and southern Dallas which may impact racial inequities.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.954122006893158,
    "x2e_entail_prob": 0.0028589493595063686
  },
  {
    "id": "covid_fact-000424",
    "statement": "Covid-19 racial disparities could be assessed by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence connects the location of test sites to COVID-19 disparities, specifically noting differences between northern and southern Dallas, which are likely related to racial and resource access issues.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.748496949672699,
    "x2e_entail_prob": 0.016002200543880463
  },
  {
    "id": "covid_fact-000425",
    "statement": "Covid-19 racial disparities could be defined by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence highlights unequal testing site availability between different areas of Dallas, suggesting that location affects access. This can contribute to racial disparities if minority groups in less-served areas have reduced access to Covid-19 tests.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.7057912349700928,
    "x2e_entail_prob": 0.008096348494291306
  },
  {
    "id": "covid_fact-000426",
    "statement": "Overweight and obesity are risks factors of severe illness in patients with covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Having obesity may triple the risk of hospitalization due to a COVID-19 infection.",
      "Conclusions: Overweight and obesity were independent risk factors of severe illness in COVID-19 patients.",
      "Overweight, Obesity and Severe Obesity Having obesity, defined as a body mass index (BMI) between 30 kg/m2 and <40 kg/m2 or severe obesity (BMI of 40 kg/m2 or above), increases your risk of severe illness from COVID-19.",
      "Having obesity puts people at risk for many other serious chronic diseases and increases the risk of severe illness from COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that obesity increases the risk of severe COVID-19 illness and hospitalization, with a tripling of hospitalization risk. While it mentions overweight in a supporting context, the focus is on obesity as a significant factor. The claim is therefore supported.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0628446415066719,
    "x2e_entail_prob": 0.2173633724451065
  },
  {
    "id": "covid_fact-000427",
    "statement": "Overweight and obesity are risks factors of severe illness in patients without covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Having obesity may triple the risk of hospitalization due to a COVID-19 infection.",
      "Conclusions: Overweight and obesity were independent risk factors of severe illness in COVID-19 patients.",
      "Overweight, Obesity and Severe Obesity Having obesity, defined as a body mass index (BMI) between 30 kg/m2 and <40 kg/m2 or severe obesity (BMI of 40 kg/m2 or above), increases your risk of severe illness from COVID-19.",
      "Having obesity puts people at risk for many other serious chronic diseases and increases the risk of severe illness from COVID-19."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.09300683438777924,
    "x2e_entail_prob": 0.6883141994476318
  },
  {
    "id": "covid_fact-000428",
    "statement": "Intestinal inflammation modulates the expression of ace2 and tmprss2 and potentially overlaps with the pathogenesis of sars-cov-2 related disease",
    "label": "SUPPORTED",
    "evidences": [
      "These considerations led us to systematically examine the intersections between COVID-19 and the GI tract during health and intestinal inflammation."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses examining intersections between COVID-19 and intestinal inflammation in the GI tract but does not provide specific information about ACE2 or TMPRSS2 modulation, making the claim unsubstantiated.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0024678842164576054,
    "x2e_entail_prob": 0.0022439206950366497
  },
  {
    "id": "covid_fact-000429",
    "statement": "Intestinal inflammation modulates the production of ace2 and tmprss2 and potentially overlaps with the pathogenesis of sars-cov-2 related disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These considerations led us to systematically examine the intersections between COVID-19 and the GI tract during health and intestinal inflammation."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that there is an interest in examining the intersection between COVID-19 and intestinal inflammation, including the role of ACE2 and TMPRSS2. However, it does not provide specific findings or data to confirm that intestinal inflammation modulates the production of these proteins or overlaps with SARS-CoV-2 pathogenesis.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.003170470939949155,
    "x2e_entail_prob": 0.004141642712056637
  },
  {
    "id": "covid_fact-000430",
    "statement": "Sars-cov-2 simulations go exascale to capture spike opening and reveal cryptic pockets across the proteome",
    "label": "SUPPORTED",
    "evidences": [
      "We also observe dramatic conformational changes across the proteome, which reveal over 50 cryptic pockets that expand targeting options for the design of antivirals.",
      "To address this challenge, over a million citizen scientists banded together through the Folding@home distributed computing project to create the first exascale computer and simulate an unprecedented 0.1 seconds of the viral proteome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim by showing that Folding@home achieved exascale computing to simulate the viral proteome, revealing cryptic pockets and conformational changes, which includes spike dynamics.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.2533687651157379,
    "x2e_entail_prob": 0.0010327125201001763
  },
  {
    "id": "covid_fact-000431",
    "statement": "Sars-cov-2 simulations go exascale to avoid spike opening and reveal cryptic pockets across the proteome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We also observe dramatic conformational changes across the proteome, which reveal over 50 cryptic pockets that expand targeting options for the design of antivirals.",
      "To address this challenge, over a million citizen scientists banded together through the Folding@home distributed computing project to create the first exascale computer and simulate an unprecedented 0.1 seconds of the viral proteome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that simulations went exascale and revealed cryptic pockets across the proteome, but it doesn't mention anything about avoiding spike opening.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0030515161342918873,
    "x2e_entail_prob": 0.0007446882664225996
  },
  {
    "id": "covid_fact-000432",
    "statement": "Experts divide into two camps of actionshielding versus blanket policies",
    "label": "SUPPORTED",
    "evidences": [
      "One group of doctors and academics is calling for segmentation and shielding of the most vulnerable groups of people rather than local or national lockdown measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a division where one group supports shielding vulnerable groups (action-shielding) while another supports blanket lockdown policies, confirming the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.008003924041986465,
    "x2e_entail_prob": 0.001321609946899116
  },
  {
    "id": "covid_fact-000433",
    "statement": "Poolkeh finds the optimal pooling strategy for a population-wide covid-19 testing",
    "label": "SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a framework that finds the optimal pooling strategy for COVID-19 testing, which aligns with the claim about Poolkeh finding such strategies. While Poolkeh isn't explicitly named, the described method fits the claim's context.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6966960430145264,
    "x2e_entail_prob": 0.006160713266581297
  },
  {
    "id": "covid_fact-000434",
    "statement": "Poolkeh finds the initial pooling strategy for a population-wide covid-19 testing",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a framework for finding optimal COVID-19 test pooling strategies based on SIR-D status but does not mention 'Poolkeh.' Without specific reference to Poolkeh, the claim cannot be supported.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.03449822589755058,
    "x2e_entail_prob": 0.01573987677693367
  },
  {
    "id": "covid_fact-000435",
    "statement": "Poolkeh finds the first pooling strategy for a population-wide covid-19 testing",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention 'Poolkeh' or credit them with developing a pooling strategy for COVID-19 testing.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.00248708832077682,
    "x2e_entail_prob": 0.012260559014976025
  },
  {
    "id": "covid_fact-000436",
    "statement": "Global coronavirus death toll could be 60 % higher than reported",
    "label": "SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates significant underreporting in certain regions, with specific figures showing a 58% and 76% increase in excess deaths compared to reported Covid-deaths, supporting the claim that global death toll could be higher than reported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.6251510381698608,
    "x2e_entail_prob": 0.001029485953040421
  },
  {
    "id": "covid_fact-000437",
    "statement": "Global coronavirus death toll could be 60 % less than reported",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.08598854392766953,
    "x2e_entail_prob": 0.018400371074676514
  },
  {
    "id": "covid_fact-000438",
    "statement": "Global coronavirus death toll could be 60 % lower than reported",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that in certain regions, excess mortality was significantly higher than reported COVID-19 fatalities, suggesting that actual deaths are undercounted rather than overcounted.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.09454872459173203,
    "x2e_entail_prob": 0.001053140964359045
  },
  {
    "id": "covid_fact-000439",
    "statement": "In a phylogenetic network analysis of 160 complete human severe acute respiratory syndrome coronavirus 2 genomes , we find three central variants distinguished by amino acid changes , which we have named a , b , and c ...",
    "label": "SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms a phylogenetic network analysis of 160 SARS-CoV-2 genomes but does not mention three central variants named a, b, and c distinguished by amino acid changes.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0034633318427950144,
    "x2e_entail_prob": 0.006352412048727274
  },
  {
    "id": "covid_fact-000440",
    "statement": "In a phylogenetic network analysis of five complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a phylogenetic network of 160 genomes but does not mention analyzing only five or identifying three specific variants named a, b, and c.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0027712511364370584,
    "x2e_entail_prob": 0.0027761056553572416
  },
  {
    "id": "covid_fact-000441",
    "statement": "In a phylogenetic network analysis of four complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses 160 genomes without mentioning four genomes, variants a, b, c, or amino acid changes.",
    "confidence": 1,
    "e2x_entail_prob": 0.0034010375384241343,
    "x2e_entail_prob": 0.01062215305864811
  },
  {
    "id": "covid_fact-000442",
    "statement": "In a phylogenetic network analysis of six complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention analyzing six genomes or identifying three central variants named a, b, and c. Instead, it discusses 160 genomes.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.02454034984111786,
    "x2e_entail_prob": 0.0068495688028633595
  },
  {
    "id": "covid_fact-000443",
    "statement": "The cellular immune response to covid-19 deciphered by single cell multi-omics across three uk centres.",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these data detail the cellular processes present in peripheral blood during an acute immune response to COVID-19, and serve as a template for multi-omic single cell data integration across multiple centers to rapidly build powerful resources to help combat diseases such as COVID-19.",
      "Full single cell transcriptomes coupled with quantification of 188 cell surface proteins, and T and B lymphocyte antigen receptor repertoires have provided several insights into COVID-19: 1. a new non-classical monocyte state that sequesters platelets and replenishes the alveolar macrophage pool; 2. platelet activation accompanied by early priming towards megakaryopoiesis in immature haematopoietic stem/progenitor cells and expansion of megakaryocyte-primed progenitors; 3. increased clonally expanded CD8+ effector:effector memory T cells, and proliferating CD4+ and CD8+ T cells in patients with more severe disease; and 4. relative increase of IgA plasmablasts in asymptomatic stages that switches to expansion of IgG plasmablasts and plasma cells, accompanied with higher incidence of BCR sharing, as disease severity increases.",
      "To characterise the systemic host immune response to SARS-CoV-2, we performed single-cell RNA- sequencing coupled with analysis of cell surface proteins, providing molecular profiling of over 800,000 peripheral blood mononuclear cells from a cohort of 130 patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports the use of single-cell multi-omics to study the cellular immune response but does not specify that this was conducted across three UK centers.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0026949148159474134,
    "x2e_entail_prob": 0.006670093629509211
  },
  {
    "id": "covid_fact-000444",
    "statement": "The cellular immune response to covid-19 deciphered by single cell multi-omics across two uk centres.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these data detail the cellular processes present in peripheral blood during an acute immune response to COVID-19, and serve as a template for multi-omic single cell data integration across multiple centers to rapidly build powerful resources to help combat diseases such as COVID-19.",
      "Full single cell transcriptomes coupled with quantification of 188 cell surface proteins, and T and B lymphocyte antigen receptor repertoires have provided several insights into COVID-19: 1. a new non-classical monocyte state that sequesters platelets and replenishes the alveolar macrophage pool; 2. platelet activation accompanied by early priming towards megakaryopoiesis in immature haematopoietic stem/progenitor cells and expansion of megakaryocyte-primed progenitors; 3. increased clonally expanded CD8+ effector:effector memory T cells, and proliferating CD4+ and CD8+ T cells in patients with more severe disease; and 4. relative increase of IgA plasmablasts in asymptomatic stages that switches to expansion of IgG plasmablasts and plasma cells, accompanied with higher incidence of BCR sharing, as disease severity increases.",
      "To characterise the systemic host immune response to SARS-CoV-2, we performed single-cell RNA- sequencing coupled with analysis of cell surface proteins, providing molecular profiling of over 800,000 peripheral blood mononuclear cells from a cohort of 130 patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a study using single-cell multi-omics techniques across multiple centers but does not explicitly mention two UK centers specifically.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.007480252534151077,
    "x2e_entail_prob": 0.004969097673892975
  },
  {
    "id": "covid_fact-000445",
    "statement": "University of oxford resumes vaccine trial",
    "label": "SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the University of Oxford's vaccine trial was paused and then recommended to resume by the MHRA after a safety review. The tweet also confirms the trials are back up, fully supporting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.029417356476187706,
    "x2e_entail_prob": 0.007391633000224829
  },
  {
    "id": "covid_fact-000446",
    "statement": "Lack of oxford resumes vaccine trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that after a pause due to safety reviews, the Oxford vaccine trials resumed as recommended by MHRA.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.16499760746955872,
    "x2e_entail_prob": 0.002935393713414669
  },
  {
    "id": "covid_fact-000447",
    "statement": "Development of oxford resumes vaccine trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the University of Oxford, in partnership with AstraZeneca, received approval from the MHRA to resume their vaccine trials after a pause due to safety concerns. This directly supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.15767072141170502,
    "x2e_entail_prob": 0.0052038864232599735
  },
  {
    "id": "covid_fact-000448",
    "statement": "Slight reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that even a slight reduction in viral load from masking significantly reduces transmission when widely implemented, as shown by models linking mask efficacy to lower Re and transmission probability.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9835361242294312,
    "x2e_entail_prob": 0.0013841235777363181
  },
  {
    "id": "covid_fact-000449",
    "statement": "High reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that masking reduces sars-cov-2 exposure viral load, which in turn significantly reduces transmission when implemented widely.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1457756757736206,
    "x2e_entail_prob": 0.0017744289943948388
  },
  {
    "id": "covid_fact-000450",
    "statement": "Significant reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that masking reduces viral load exposure and thereby significantly reduces transmission when implemented widely.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9249888062477112,
    "x2e_entail_prob": 0.0021616467274725437
  },
  {
    "id": "covid_fact-000451",
    "statement": "National smoking rates correlate inversely with covid-19 mortality",
    "label": "SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows statistically significant inverse correlations between current daily smoking prevalence and COVID-19 mortality in hot, cold, and combined country groups.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9864233136177063,
    "x2e_entail_prob": 0.19709926843643188
  },
  {
    "id": "covid_fact-000452",
    "statement": "National smoking rates correlate closely with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows an inverse correlation between smoking rates and COVID-19 mortality but does not establish causation or account for confounding factors.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.002758609363809228,
    "x2e_entail_prob": 0.022274000570178032
  },
  {
    "id": "covid_fact-000453",
    "statement": "National smoking rates correlate closerly with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates a significant inverse correlation between smoking prevalence and COVID-19 mortality, which contradicts the claim of a positive correlation.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.4693354368209839,
    "x2e_entail_prob": 0.3944094479084015
  },
  {
    "id": "covid_fact-000454",
    "statement": "National smoking rates correlate greaterly with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a significant inverse correlation between smoking rates and COVID-19 mortality in both hot and cold countries, supporting the claim of a strong relationship.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9729737639427185,
    "x2e_entail_prob": 0.5669674277305603
  },
  {
    "id": "covid_fact-000455",
    "statement": "Cryptic transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that genomic epidemiology reveals cryptic transmission of novel coronavirus SARS-CoV-2 through genome sequencing, which reconstructs transmission history.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.511768639087677,
    "x2e_entail_prob": 0.3795127868652344
  },
  {
    "id": "covid_fact-000456",
    "statement": "Viral transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that genomic epidemiology uses genetic sequences to understand SARS-CoV-2 transmission, directly supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0998963862657547,
    "x2e_entail_prob": 0.20332252979278564
  },
  {
    "id": "covid_fact-000457",
    "statement": "Phylogenetic transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that genome sequencing of SARS-CoV-2 allows for reconstructing transmission history, which aligns with the claim about phylogenetic transmission revealed by genomic epidemiology.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.165448397397995,
    "x2e_entail_prob": 0.3665168583393097
  },
  {
    "id": "covid_fact-000458",
    "statement": "Initial transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that genome sequencing of SARS-CoV-2 aids in reconstructing transmission history, supporting the claim that initial transmissions were revealed via genomic epidemiology.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.37711459398269653,
    "x2e_entail_prob": 0.34348607063293457
  },
  {
    "id": "covid_fact-000459",
    "statement": "Nurses and other union workers authorize oct. 7 strike against east bay hospitals",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by confirming that nurses and union workers (via California Nurses Association) have authorized a strike on October 7 against East Bay hospitals, specifically the Alameda Health System.",
    "confidence": 1,
    "e2x_entail_prob": 0.3028257489204407,
    "x2e_entail_prob": 0.005994841922074556
  },
  {
    "id": "covid_fact-000460",
    "statement": "Nurses and other union workers authorize dr. 7 strike against east bay hospitals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that nurses and employees (likely union workers) in the Alameda Health System, part of the East Bay, plan a strike starting October 7, which aligns with 'Dr. 7.' While the term 'Dr. 7' isn't explicitly stated, it's reasonable to interpret it as referring to October 7.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5623772740364075,
    "x2e_entail_prob": 0.003467205446213484
  },
  {
    "id": "covid_fact-000461",
    "statement": "Nurses and other union workers authorize s. 7 strike against east bay hospitals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that nurses and other union workers in the east bay plan a strike, aligning with the claim's core elements despite the unspecified section reference.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.02416641265153885,
    "x2e_entail_prob": 0.0014953287318348885
  },
  {
    "id": "covid_fact-000462",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly vanishing in severe cases",
    "label": "SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows a significant decrease in IgG levels in severe cases, but it does not explicitly state that these antibodies are 'rapidly vanishing.' The term 'rapidly' is subjective and not clearly supported by the data provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.004625871777534485,
    "x2e_entail_prob": 0.0339825302362442
  },
  {
    "id": "covid_fact-000463",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly circulating in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that IgG levels decrease significantly in severe cases, contradicting the claim of rapidly circulating long-lived IgG antibodies.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.004862059839069843,
    "x2e_entail_prob": 0.04502841830253601
  },
  {
    "id": "covid_fact-000464",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly produced in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that while IgG antibodies are detected early in SARS-CoV-2 infection, their levels significantly decrease in severe cases, which contradicts the claim of rapid production and long-lived presence in such cases.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.004644779022783041,
    "x2e_entail_prob": 0.01669478416442871
  },
  {
    "id": "covid_fact-000465",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly transmitted in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that IgG antibodies were detected but their levels decreased significantly in severe cases, contradicting the claim of rapid transmission.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.021310703828930855,
    "x2e_entail_prob": 0.04358967766165733
  },
  {
    "id": "covid_fact-000466",
    "statement": "Moderna announces first participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses plans for a Phase 2/3 study in adolescents but does not confirm that dosing has occurred.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.013548403047025204,
    "x2e_entail_prob": 0.0011211273958906531
  },
  {
    "id": "covid_fact-000467",
    "statement": "Moderna announces all participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes the initiation of a Phase 2/3 study for adolescents but does not confirm that all participants have been dosed.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.02555641531944275,
    "x2e_entail_prob": 0.001580691896378994
  },
  {
    "id": "covid_fact-000468",
    "statement": "Moderna announces from participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes a planned Phase 2/3 study for adolescents but does not mention that participants have been dosed, so the claim is not confirmed.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.004919090773910284,
    "x2e_entail_prob": 0.0012805880978703499
  },
  {
    "id": "covid_fact-000469",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues",
    "label": "SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that ACE2 is an interferon-stimulated gene and is detected in specific cell subsets across tissues such as lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9379201531410217,
    "x2e_entail_prob": 0.7792444229125977
  },
  {
    "id": "covid_fact-000470",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in canine airway epithelial cells and is detected in specific cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim partially matches the evidence. ACE2 being an interferon-stimulated gene and its presence in specific cell subsets are supported, but there's no mention of canines.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0029888441786170006,
    "x2e_entail_prob": 0.03573102504014969
  },
  {
    "id": "covid_fact-000471",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in many cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that ACE2 is expressed in multiple cell subsets across tissues (lung, ileum, and nose) and suggests that its expression can be upregulated by interferons, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.931556224822998,
    "x2e_entail_prob": 0.1612977236509323
  },
  {
    "id": "covid_fact-000472",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in multiple cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that ACE2 is an interferon-stimulated gene, as it mentions interferon-driven upregulation and its presence in various tissues including airway cells.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.2772512137889862,
    "x2e_entail_prob": 0.058848097920417786
  },
  {
    "id": "covid_fact-000473",
    "statement": "Structure of sars-cov-2 orf8 , a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that ORF8 is implicated in immune evasion through unique assemblies but does not address whether it's rapidly evolving.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0012778774835169315,
    "x2e_entail_prob": 0.03221572935581207
  },
  {
    "id": "covid_fact-000474",
    "statement": "Loss of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses SARS-CoV-2 ORF8's role in immune evasion when present, not its loss. Losing ORF8 would likely reduce such activity.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.004750056192278862,
    "x2e_entail_prob": 0.03148339316248894
  },
  {
    "id": "covid_fact-000475",
    "statement": "Mutation of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that SARS-CoV-2 ORF8 is involved in immune evasion but does not mention its rapid evolution or mutation rate.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.001275382237508893,
    "x2e_entail_prob": 0.018178556114435196
  },
  {
    "id": "covid_fact-000476",
    "statement": "Activation of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that SARS-CoV-2 ORF8 forms unique assemblies mediating immune evasion, supporting its role in immune suppression.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6599861979484558,
    "x2e_entail_prob": 0.013703526929020882
  },
  {
    "id": "covid_fact-000477",
    "statement": "Israel is arresting palestine 's doctors fighting covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes Israel's efforts to assist in mitigating COVID-19, including providing medical resources and training for Palestinian health workers. There is no mention of arresting doctors.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.003952154889702797,
    "x2e_entail_prob": 0.0034719358664005995
  },
  {
    "id": "covid_fact-000478",
    "statement": "China is arresting palestine's doctors fighting covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only discusses Israel's efforts in mitigating COVID-19 impacts, including supporting Palestinian health workers. There is no information about China or the arrest of doctors.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.005797679536044598,
    "x2e_entail_prob": 0.0011462204856798053
  },
  {
    "id": "covid_fact-000479",
    "statement": "Israel is called palestine's doctors fighting covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows Israel provided medical support and training to Palestinian health workers during COVID-19, but it does not mention Israel being referred to as 'Palestine's doctors.'",
    "confidence": 0.7,
    "e2x_entail_prob": 0.004510936327278614,
    "x2e_entail_prob": 0.004656828474253416
  },
  {
    "id": "covid_fact-000480",
    "statement": "Identification of an existing japanese pancreatitis drug , nafamostat , which is expected to prevent the transmission of new coronavirus infection",
    "label": "SUPPORTED",
    "evidences": [
      "The University of Tokyo plans to launch clinical trials in April 2020 in order to evaluate the effectiveness of these two drugs for treating COVID-19.",
      "Both Nafamostat and Camostat were developed in Japan as treatments for pancreatitis and some other diseases.",
      "According to the new research, Nafamostat can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus SARS-CoV-2.",
      "Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that nafamostat is a Japanese drug for pancreatitis and highlights its potential effectiveness against COVID-19 through blocking viral entry, supported by planned clinical trials.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8741068840026855,
    "x2e_entail_prob": 0.001201727194711566
  },
  {
    "id": "covid_fact-000481",
    "statement": "Loss of an existing japanese pancreatitis drug, nafamostat, which is expected to prevent the transmission of new coronavirus infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Tokyo plans to launch clinical trials in April 2020 in order to evaluate the effectiveness of these two drugs for treating COVID-19.",
      "Both Nafamostat and Camostat were developed in Japan as treatments for pancreatitis and some other diseases.",
      "According to the new research, Nafamostat can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus SARS-CoV-2.",
      "Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that nafamostat can prevent the initial step of viral infection but does not explicitly support its ability to prevent transmission between individuals.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.006019533611834049,
    "x2e_entail_prob": 0.0011341237695887685
  },
  {
    "id": "covid_fact-000482",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice causes severe lung inflammation and impaired function",
    "label": "SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that SARS-CoV-2 infection in hACE2 transgenic mice results in severe lung inflammation and impaired function, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7110561728477478,
    "x2e_entail_prob": 0.7807997465133667
  },
  {
    "id": "covid_fact-000483",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice prevented severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infection in hACE2-transgenic mice leads to severe lung inflammation and impaired function, contradicting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.41805803775787354,
    "x2e_entail_prob": 0.7051463723182678
  },
  {
    "id": "covid_fact-000484",
    "statement": "Sars-cov-2 infection of human ace2-transgenic patients causes severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses severe lung inflammation and impaired function in K18-hACE2-transgenic mice but does not provide information on human patients with ACE2 transgenes, making the claim unsupported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0066233109682798386,
    "x2e_entail_prob": 0.6457999348640442
  },
  {
    "id": "covid_fact-000485",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice inhibited severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infection in human ACE2-transgenic mice led to severe inflammation and impaired lung function, contradicting the claim that it inhibited these effects.",
    "confidence": 1,
    "e2x_entail_prob": 0.3828445374965668,
    "x2e_entail_prob": 0.7836554646492004
  },
  {
    "id": "covid_fact-000486",
    "statement": "Thrombotic microvascular injury is not mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that while there was thrombotic microvascular injury (TMI), there were no signs of systemic thrombotic microangiopathy (TMA) such as hemolytic anemia or thrombocytopenia, despite complement activation.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9879868626594543,
    "x2e_entail_prob": 0.08970315754413605
  },
  {
    "id": "covid_fact-000487",
    "statement": "Thrombotic microvascular injury is mainly mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that thrombotic microvascular injury (TMI) was present in severe COVID-19 patients, but there was no systemic thrombotic microangiopathy (TMA). Instead, the study points to moderate complement and coagulation activation as factors contributing to TMI without systemic TMA involvement.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9786295294761658,
    "x2e_entail_prob": 0.007092566695064306
  },
  {
    "id": "covid_fact-000488",
    "statement": "Thrombotic microvascular injury is primarily mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows thrombotic microvascular injury without systemic TMA in COVID-19 patients, contradicting the claim that TMI is primarily mediated by TMA despite complement activation.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.10896186530590057,
    "x2e_entail_prob": 0.0038210642524063587
  },
  {
    "id": "covid_fact-000489",
    "statement": "Thrombotic microvascular injury is also mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates thrombotic microvascular injury in COVID-19 patients without systemic thrombotic microangiopathy, contradicting the claim that TMA mediates TMI despite complement activation.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.04153864085674286,
    "x2e_entail_prob": 0.0028384628240019083
  },
  {
    "id": "covid_fact-000490",
    "statement": "Serum amyloid p inhibits single stranded rna-induced lung inflammation , lung damage , and cytokine storm in mice",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these results suggest that aspiration of ORN06 is a simple model for both COVID-19 as well as cytokine storm in general, and that SAP is a potential therapeutic for diseases with COVID-19-like symptoms as well as diseases that generate a cytokine storm.",
      "A serum protein called serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports SAP's role in reducing cytokine storms and lung issues, but it doesn't explicitly confirm the inhibition of single-stranded RNA-induced effects.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0020095903892070055,
    "x2e_entail_prob": 0.2127298265695572
  },
  {
    "id": "covid_fact-000491",
    "statement": "Serum amyloid p inhibits single stranded rna-induced lung inflammation, lung damage, and cytokine storm in patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that aspiration of ORN06 is a simple model for both COVID-19 as well as cytokine storm in general, and that SAP is a potential therapeutic for diseases with COVID-19-like symptoms as well as diseases that generate a cytokine storm.",
      "A serum protein called serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that serum amyloid P (SAP) has potential therapeutic effects against cytokine storms and COVID-19-like symptoms, but it does not explicitly connect these effects to single-stranded RNA-induced conditions in patients. The mention of fibrosis suggests possible lung damage mitigation, yet the direct inhibition of ssRNA-induced issues isn't confirmed.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.11894464492797852,
    "x2e_entail_prob": 0.1209188774228096
  },
  {
    "id": "covid_fact-000492",
    "statement": "Fda approves the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports the emergency use authorization of hydroxychloroquine sulfate but does not mention chloroquine phosphate, making the claim about both substances partially unsupported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0013954064343124628,
    "x2e_entail_prob": 0.010658281855285168
  },
  {
    "id": "covid_fact-000493",
    "statement": "Fdaines the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only explicitly mentions hydroxychloroquine sulfate being authorized, not chloroquine phosphate.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.005832481198012829,
    "x2e_entail_prob": 0.007040692958980799
  },
  {
    "id": "covid_fact-000494",
    "statement": "Fdaards the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only mentions hydroxychloroquine sulfate and Resochin, not chloroquine phosphate. Therefore, while part of the claim is correct regarding hydroxychloroquine, it does not support the inclusion of chloroquine phosphate.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.03918469697237015,
    "x2e_entail_prob": 0.008209409192204475
  },
  {
    "id": "covid_fact-000495",
    "statement": "Fdaasts the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports the emergency use authorization for hydroxychloroquine sulfate but does not mention chloroquine phosphate.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0014517297968268394,
    "x2e_entail_prob": 0.019052650779485703
  },
  {
    "id": "covid_fact-000496",
    "statement": "Genomic epidemiology reveals transmission patterns and dynamics of sars-cov-2 in aotearoa new zealand",
    "label": "SUPPORTED",
    "evidences": [
      "d The sampling location and proportion of SARS-CoV-2 genomes sampled from each viral genomic lineage is shown on the map of New Zealand.",
      "Notably, the genomic diversity of SARS-CoV-2 sequences sampled in New Zealand represented nearly all of the genomic diversity present in the global viral population, with nine second-level A and B lineages from a proposed global SARS-CoV-2 genomic nomenclature17 identified.",
      "3: Genomic transmission lineages of SARS-CoV-2 in New Zealand.",
      "2: Genomic diversity of SARS-CoV-2 in New Zealand."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that genomic epidemiology techniques were applied by analyzing SARS-CoV-2 genomes in New Zealand, which revealed the genomic diversity and transmission patterns of the virus.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.20071746408939362,
    "x2e_entail_prob": 0.07672334462404251
  },
  {
    "id": "covid_fact-000497",
    "statement": "Genomic epidemiology reveals evolutionary patterns and dynamics of sars-cov-2 in aotearoa new zealand",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "d The sampling location and proportion of SARS-CoV-2 genomes sampled from each viral genomic lineage is shown on the map of New Zealand.",
      "Notably, the genomic diversity of SARS-CoV-2 sequences sampled in New Zealand represented nearly all of the genomic diversity present in the global viral population, with nine second-level A and B lineages from a proposed global SARS-CoV-2 genomic nomenclature17 identified.",
      "3: Genomic transmission lineages of SARS-CoV-2 in New Zealand.",
      "2: Genomic diversity of SARS-CoV-2 in New Zealand."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that genomic data from New Zealand revealed significant diversity in SARS-CoV-2 lineages and transmission patterns, supporting the claim about evolutionary dynamics.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.012704787775874138,
    "x2e_entail_prob": 0.1207018718123436
  },
  {
    "id": "covid_fact-000498",
    "statement": "Cross-species transmission of the newly identified coronavirus 2019-ncov",
    "label": "SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.008580435067415237,
    "x2e_entail_prob": 0.004454053472727537
  },
  {
    "id": "covid_fact-000499",
    "statement": "Cross-species transmission of the newly identified coronavirus e-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the virus may have originated from recombination between a bat coronavirus and another unknown coronavirus, supporting the idea of cross-species transmission in its origin.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.034392863512039185,
    "x2e_entail_prob": 0.6410163640975952
  },
  {
    "id": "covid_fact-000500",
    "statement": "Cross-species transmission of the previously identified coronavirus 2019-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that 2019-nCoV is a recombinant virus involving a bat coronavirus, supporting the claim of cross-species transmission.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.010133882984519005,
    "x2e_entail_prob": 0.3742070198059082
  },
  {
    "id": "covid_fact-000501",
    "statement": "Cross-species transmission of the newly identified coronavirus b-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that 2019-nCoV may be a recombinant virus involving bat coronaviruses and another unknown source, implying possible cross-species origins but not directly confirming transmission.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.02633662335574627,
    "x2e_entail_prob": 0.9321556687355042
  },
  {
    "id": "covid_fact-000502",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody escape.",
    "label": "SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by referencing a study that shows natural deletions in the spike glycoprotein drive antibody escape, aligning with the assertion made.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.19683215022087097,
    "x2e_entail_prob": 0.6550384163856506
  },
  {
    "id": "covid_fact-000503",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein prevent antibody escape.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that natural deletions in the spike glycoprotein drive antibody escape, which directly contradicts the claim that such deletions prevent it.",
    "confidence": 1,
    "e2x_entail_prob": 0.02897287905216217,
    "x2e_entail_prob": 0.29586488008499146
  },
  {
    "id": "covid_fact-000504",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody reactivity.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses how natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape, which implies reduced antibody reactivity. This contradicts the claim that such deletions drive antibody reactivity.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.04804610460996628,
    "x2e_entail_prob": 0.23734158277511597
  },
  {
    "id": "covid_fact-000505",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody production.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that deletions drive antibody production, while the evidence states that deletions cause antibody escape, indicating reduced effectiveness rather than increased production.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.06793123483657837,
    "x2e_entail_prob": 0.5685393214225769
  },
  {
    "id": "covid_fact-000506",
    "statement": "Sars-coronavirus-1 open reading frame-8b triggers intracellular stress pathways and activates nlrp3 inflammasomes",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we identify several mechanisms by which a SARS-CoV open reading frame (ORF) activates intracellular stress pathways and targets the innate immune response."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that a SARS-CoV open reading frame activates stress pathways but does not specifically identify ORF8b or mention NLRP3 inflammasome activation.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0023338173050433397,
    "x2e_entail_prob": 0.007679441943764687
  },
  {
    "id": "covid_fact-000507",
    "statement": "Sars-coronavirus-1 open reading frame-8b inhibits intracellular stress pathways and activates nlrp3 inflammasomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we identify several mechanisms by which a SARS-CoV open reading frame (ORF) activates intracellular stress pathways and targets the innate immune response."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not specify SARS-CoV-1 ORF-8b, only a general SARS-CoV ORF. Additionally, it states that the ORF activates stress pathways (contradicting inhibition) and doesn't mention NLRP3 inflammasomes.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.002738982904702425,
    "x2e_entail_prob": 0.024296049028635025
  },
  {
    "id": "covid_fact-000508",
    "statement": "A chest-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms the existence of a flowchart combining chest CT and clinical chemistry (lab-corona-score) for COVID-19 triage at EDs with high accuracy.",
    "confidence": 1,
    "e2x_entail_prob": 0.8982616066932678,
    "x2e_entail_prob": 0.12644149363040924
  },
  {
    "id": "covid_fact-000509",
    "statement": "A non-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests a non-CT based flowchart, but the evidence indicates it uses radiology (CO-RADS), which involves CT scans.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.049942925572395325,
    "x2e_entail_prob": 0.015809310600161552
  },
  {
    "id": "covid_fact-000510",
    "statement": "A meta-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that a flowchart combining radiology (CO-RADS) and clinical chemistry parameters was developed for rapid COVID-19 triage at emergency departments, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.785020649433136,
    "x2e_entail_prob": 0.09369594603776932
  },
  {
    "id": "covid_fact-000511",
    "statement": "A pre-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms a flowchart using radiology (CO-RADS) and clinical chemistry parameters for rapid COVID-19 triage, aligning with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8044975996017456,
    "x2e_entail_prob": 0.07262110710144043
  },
  {
    "id": "covid_fact-000512",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates that intravenous immunoglobulins produced from pre-pandemic plasma do not neutralize SARS-CoV-2, confirming the claim.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.005009674001485109,
    "x2e_entail_prob": 0.003021309617906809
  },
  {
    "id": "covid_fact-000513",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected after the 2020 pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses IVIG products made from pre-pandemic plasma, which do not neutralize SARS-CoV-2. However, the claim is about post-pandemic plasma. Since the evidence does not address post-pandemic plasma, it cannot confirm the lack of cross-neutralization in such cases.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.032963208854198456,
    "x2e_entail_prob": 0.04005863890051842
  },
  {
    "id": "covid_fact-000514",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses pre-pandemic IVIG products but does not provide information on IVIG from pandemic plasma.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.009335359558463097,
    "x2e_entail_prob": 0.009457098320126534
  },
  {
    "id": "covid_fact-000515",
    "statement": "Hospital readmissions of discharged patients with covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that hospital readmissions occur after discharge for COVID-19, with specific risk factors identified.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8408398032188416,
    "x2e_entail_prob": 0.005294878501445055
  },
  {
    "id": "covid_fact-000516",
    "statement": "Hospital readmissions of hospitalized patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that hospital readmissions of patients with COVID-19 occurred, although at a low rate.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9290392994880676,
    "x2e_entail_prob": 0.029078494757413864
  },
  {
    "id": "covid_fact-000517",
    "statement": "Hospital readmissions of sars patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses COVID-19 readmissions but does not mention SARS patients, so the claim is not supported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0027436325326561928,
    "x2e_entail_prob": 0.06589710712432861
  },
  {
    "id": "covid_fact-000518",
    "statement": "Hospital readmissions of icu patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not specifically mention ICU patients, only general readmissions of COVID-19 patients.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.004913631360977888,
    "x2e_entail_prob": 0.023193730041384697
  },
  {
    "id": "covid_fact-000519",
    "statement": "Hospitalization rates and characteristics of children aged < 18 years hospitalized with laboratory-confirmed covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020\u00a7,\u00b6 Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly addresses hospitalization rates and characteristics of children aged <18 years with COVID-19, providing data from a specific study period across multiple states.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8676019310951233,
    "x2e_entail_prob": 0.3720604479312897
  },
  {
    "id": "covid_fact-000520",
    "statement": "Hospitalization rates and characteristics of children aged < 18 months hospitalized with laboratory-confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020\u00a7,\u00b6 Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence discusses hospitalization rates and characteristics for children aged <18 years, which includes those under 18 months.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.11687662452459335,
    "x2e_entail_prob": 0.24068795144557953
  },
  {
    "id": "covid_fact-000521",
    "statement": "Hospitalization rates and characteristics of children aged < 18 days hospitalized with laboratory-confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020\u00a7,\u00b6 Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence focuses on children <18 years old, not specifically <18 days, so it doesn't support the claim about newborns.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0025465027429163456,
    "x2e_entail_prob": 0.40286874771118164
  },
  {
    "id": "covid_fact-000522",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim by discussing how the influenza vaccine's bystander effect can enhance immunity, leading to reduced severity of COVID-19 through cross-reactivity and general immune responses.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.685985267162323,
    "x2e_entail_prob": 0.03699171915650368
  },
  {
    "id": "covid_fact-000523",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to increase the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the influenza vaccine has a beneficial adjuvant effect to minimize the severity of COVID-19, which contradicts the claim that it increases the severity.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5296075940132141,
    "x2e_entail_prob": 0.06506612151861191
  },
  {
    "id": "covid_fact-000524",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to enhance the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided supports the idea that the influenza vaccine has a beneficial adjuvant effect in minimizing COVID-19 severity, not enhancing it. The claim incorrectly states 'enhance' instead of 'reduce,' which contradicts the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.014430036768317223,
    "x2e_entail_prob": 0.05464901402592659
  },
  {
    "id": "covid_fact-000525",
    "statement": "The possible negative adjuvant effect of influenza vaccine to minimize the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided supports a positive adjuvant effect of the influenza vaccine on minimizing COVID-19 severity through cross-reactivity and bystander immunity, contradicting the claim of a negative effect.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.311623215675354,
    "x2e_entail_prob": 0.04549765959382057
  },
  {
    "id": "covid_fact-000526",
    "statement": "Moderna 's covid-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 cove study",
    "label": "SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Moderna's vaccine met its primary efficacy endpoint in the first interim analysis of the Phase 3 study, as it prevented COVID-19 disease including severe cases.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.08630041033029556,
    "x2e_entail_prob": 0.9327247142791748
  },
  {
    "id": "covid_fact-000527",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the final interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Moderna's vaccine met its primary goal of preventing COVID-19 disease, including severe cases, based on the CEO's statement about a positive interim analysis from the Phase 3 study. However, the confidence is slightly reduced because the evidence does not explicitly mention 'primary efficacy endpoint' or provide detailed statistical results.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0182843916118145,
    "x2e_entail_prob": 0.5431174635887146
  },
  {
    "id": "covid_fact-000528",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the second interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Moderna's vaccine met its primary efficacy endpoint in a phase 3 interim analysis, though it doesn't specify if it was the second one.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.004945583641529083,
    "x2e_entail_prob": 0.9498898983001709
  },
  {
    "id": "covid_fact-000529",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the subsequent interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports that Moderna's vaccine met its primary efficacy endpoint by preventing COVID-19 disease, as stated in their interim analysis.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.08906880021095276,
    "x2e_entail_prob": 0.9452604651451111
  },
  {
    "id": "covid_fact-000530",
    "statement": "Landmark legal ruling finds that covid tests are not fit for purpose .",
    "label": "SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence includes a legal ruling that questions the reliability of Covid tests, indicating high false positive rates and suggesting that positive test results don't reliably indicate infection.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.964594304561615,
    "x2e_entail_prob": 0.0030329471919685602
  },
  {
    "id": "covid_fact-000531",
    "statement": "Landmark legal ruling finds that covid tests are good fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that a legal ruling found COVID tests, particularly PCR tests, to be unreliable with high false positive rates and questioned their correspondence to actual Covid cases, contradicting the claim that they are a good fit for purpose.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6919496655464172,
    "x2e_entail_prob": 0.004522508475929499
  },
  {
    "id": "covid_fact-000532",
    "statement": "Landmark legal ruling finds that covid tests are best fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that a legal ruling found issues with Covid tests, such as high false positive rates at certain Ct thresholds, and questioned their reliability. This contradicts the claim that the tests are best fit for purpose.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.44008275866508484,
    "x2e_entail_prob": 0.0032274748664349318
  },
  {
    "id": "covid_fact-000533",
    "statement": "Landmark legal ruling finds that covid tests are well fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that a legal ruling questioned the reliability of Covid tests, especially at higher cycle thresholds, suggesting high false positive rates and unreliable results, which contradicts the claim that the tests are well fit for purpose.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.4875827729701996,
    "x2e_entail_prob": 0.004101111553609371
  },
  {
    "id": "covid_fact-000534",
    "statement": "Trump just banned all travel from europe to stop coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Trump banned travel from Europe for 30 days to prevent coronavirus spread, although 'all' might be an overstatement.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.015935281291604042,
    "x2e_entail_prob": 0.05298033356666565
  },
  {
    "id": "covid_fact-000535",
    "statement": "Trump just allows all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that Trump imposed a travel ban, not allowed all travel.",
    "confidence": 1,
    "e2x_entail_prob": 0.1535569578409195,
    "x2e_entail_prob": 0.046005573123693466
  },
  {
    "id": "covid_fact-000536",
    "statement": "Trump just allowed all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that President Trump banned travel from Europe, not allowed it.",
    "confidence": 1,
    "e2x_entail_prob": 0.11351845413446426,
    "x2e_entail_prob": 0.03668084740638733
  },
  {
    "id": "covid_fact-000537",
    "statement": "Trump just requires all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While President Trump did impose a 30-day travel suspension affecting most foreign nationals who had been in Europe within the last 14 days, it was not a complete ban on all travel from Europe.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.648748517036438,
    "x2e_entail_prob": 0.04214835539460182
  },
  {
    "id": "covid_fact-000538",
    "statement": "Functional sars-cov-2-specific immune memory persists after mild covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral immunity: memory T cells secreted IFN-\u03b3 and expanded upon antigen re-encounter, while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies.",
      "These findings demonstrate that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.",
      "We found that recovered individuals developed SARS-CoV-2-specific IgG antibody and neutralizing plasma, as well as virus-specific memory B and T cells that not only persisted, but in some cases increased numerically over three months following symptom onset."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that individuals who had mild COVID-19 developed persistent SARS-CoV-2-specific immune memory, including B and T cells with functional antiviral capabilities. The findings indicate that these immune responses not only persisted but also showed signs of strengthening over time.",
    "confidence": 1,
    "e2x_entail_prob": 0.9726536870002747,
    "x2e_entail_prob": 0.0016128836432471871
  },
  {
    "id": "covid_fact-000539",
    "statement": "Functional sars-cov-2-independent immune memory persists after mild covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral immunity: memory T cells secreted IFN-\u03b3 and expanded upon antigen re-encounter, while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies.",
      "These findings demonstrate that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.",
      "We found that recovered individuals developed SARS-CoV-2-specific IgG antibody and neutralizing plasma, as well as virus-specific memory B and T cells that not only persisted, but in some cases increased numerically over three months following symptom onset."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that individuals who had mild COVID-19 developed persistent SARS-CoV-2-specific immune memory, including antibodies and T/B cells, which are indicative of functional antiviral immunity.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9837061166763306,
    "x2e_entail_prob": 0.002100349171087146
  },
  {
    "id": "covid_fact-000540",
    "statement": "Cdc says new covid strain in uk could already be circulating undetected in u.s .",
    "label": "SUPPORTED",
    "evidences": [
      "While the variant hasn't been found in the U.S. yet, the CDC noted that scientists haven't sequenced the genetic coding for many Covid-19 infections here.",
      "\"Given the small fraction of US infections that have been sequenced, the variant could already be in the United States without having been detected.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that the CDC acknowledges the possibility of the new COVID strain being in the U.S. undetected due to limited sequencing.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6183280348777771,
    "x2e_entail_prob": 0.13092152774333954
  },
  {
    "id": "covid_fact-000541",
    "statement": "Cdc says new covid strain in uk could not be circulating undetected in u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While the variant hasn't been found in the U.S. yet, the CDC noted that scientists haven't sequenced the genetic coding for many Covid-19 infections here.",
      "\"Given the small fraction of US infections that have been sequenced, the variant could already be in the United States without having been detected.\""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that due to limited sequencing in the U.S., the variant could already be present and undetected, contradicting the claim that it couldn't be circulating undetected.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3093518614768982,
    "x2e_entail_prob": 0.006843123119324446
  },
  {
    "id": "covid_fact-000542",
    "statement": "Sars-cov-2 infection protects against rechallenge in rhesus macaques",
    "label": "SUPPORTED",
    "evidences": [
      "2 Immune responses in SARS-CoV-2challenged rhesus macaques.",
      "SARS-CoV-2 infection in rhesus macaques led to humoral and cellular immune responses (Fig.",
      "In summary, SARS-CoV-2 infection in rhesus macaques induced humoral and cellular immune responses and provided protective efficacy against SARS-CoV-2 rechallenge.",
      "In this study, we have demonstrated that SARS-CoV-2 infection in rhesus macaques provides protective efficacy against SARS-CoV-2 rechallenge.",
      "To explore this question, we developed a rhesus macaque model of SARS-CoV-2 infection and assessed virologic, immunologic, and pathologic features of infection, as well as protective immunity against rechallenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that SARS-CoV-2 infection in rhesus macaques induced immune responses and provided protective efficacy against rechallenge, directly supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.010512905195355415,
    "x2e_entail_prob": 0.15665091574192047
  },
  {
    "id": "covid_fact-000543",
    "statement": "Sars-cov-2 infection failed against rechallenge in rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "2 Immune responses in SARS-CoV-2challenged rhesus macaques.",
      "SARS-CoV-2 infection in rhesus macaques led to humoral and cellular immune responses (Fig.",
      "In summary, SARS-CoV-2 infection in rhesus macaques induced humoral and cellular immune responses and provided protective efficacy against SARS-CoV-2 rechallenge.",
      "In this study, we have demonstrated that SARS-CoV-2 infection in rhesus macaques provides protective efficacy against SARS-CoV-2 rechallenge.",
      "To explore this question, we developed a rhesus macaque model of SARS-CoV-2 infection and assessed virologic, immunologic, and pathologic features of infection, as well as protective immunity against rechallenge."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infection in rhesus macaques provided protective efficacy against rechallenge, meaning they were protected from reinfection. This contradicts the claim that the infection failed against rechallenge.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0031489103566855192,
    "x2e_entail_prob": 0.16991682350635529
  },
  {
    "id": "covid_fact-000544",
    "statement": "Genetic epidemiology of variants associated with immune escape from global sars-cov-2 genomes.",
    "label": "SUPPORTED",
    "evidences": [
      "The researchers studied as many as 120 unique mutated variants of SARS-CoV-2, out of which 86 were found to possess the ability to dodge the human bodys immune response across 63 countries.",
      "The detailed investigation of 26,917 genomes pointed out that 86 out of the 120 genetic variants associated with immune escapes from 63 countries.",
      "Our analysis suggests that a number of genetic variants associated with immune escape have emerged in global populations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that researchers identified 86 SARS-CoV-2 variants associated with immune escape across 63 countries, supporting the claim about genetic epidemiology related to immune escape.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7378970384597778,
    "x2e_entail_prob": 0.011341845616698265
  },
  {
    "id": "covid_fact-000545",
    "statement": "Phylogenetic epidemiology of variants associated with immune escape from global sars-cov-2 genomes.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The researchers studied as many as 120 unique mutated variants of SARS-CoV-2, out of which 86 were found to possess the ability to dodge the human bodys immune response across 63 countries.",
      "The detailed investigation of 26,917 genomes pointed out that 86 out of the 120 genetic variants associated with immune escapes from 63 countries.",
      "Our analysis suggests that a number of genetic variants associated with immune escape have emerged in global populations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that researchers analyzed a large number of SARS-CoV-2 genomes and identified variants associated with immune escape across multiple countries, which directly supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8005714416503906,
    "x2e_entail_prob": 0.008217203430831432
  },
  {
    "id": "covid_fact-000546",
    "statement": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus in vitro",
    "label": "SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 \u03bcM; CC50 > 100 \u03bcM; SI > 129.87) and chloroquine (EC50 = 1.13 \u03bcM; CC50 > 100 \u03bcM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that both remdesivir and chloroquine effectively inhibit the novel coronavirus (2019-nCoV) in vitro. Additionally, experimental data supports this claim with details on EC50 values and mechanisms of action.",
    "confidence": 1,
    "e2x_entail_prob": 0.25085535645484924,
    "x2e_entail_prob": 0.2108650505542755
  },
  {
    "id": "covid_fact-000547",
    "statement": "Remdesivir and chloroquine effectively developed the recently emerged novel coronavirus in vitro",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 \u03bcM; CC50 > 100 \u03bcM; SI > 129.87) and chloroquine (EC50 = 1.13 \u03bcM; CC50 > 100 \u03bcM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates that remdesivir and chloroquine inhibit the novel coronavirus in vitro, as demonstrated by their EC50 values and mechanisms of action. Despite the claim using the term 'developed,' which is misleading, the substances effectively inhibit the virus.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.43820086121559143,
    "x2e_entail_prob": 0.19658510386943817
  },
  {
    "id": "covid_fact-000548",
    "statement": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus in humans",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 \u03bcM; CC50 > 100 \u03bcM; SI > 129.87) and chloroquine (EC50 = 1.13 \u03bcM; CC50 > 100 \u03bcM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While remdesivir and chloroquine demonstrate effectiveness against the novel coronavirus in vitro and preclinical models, there is no evidence provided regarding their efficacy in human trials. The claim requires support from human studies to be fully validated.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.04794320836663246,
    "x2e_entail_prob": 0.24056310951709747
  },
  {
    "id": "covid_fact-000549",
    "statement": "As covid-19 vaccines arrive , europe looks back at swine flu side effects.",
    "label": "SUPPORTED",
    "evidences": [
      "DW: We keep seeing vaccine skeptics referencing the swine flu pandemic in 2009 as the reason they won't be taking a COVID-19 vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While evidence shows vaccine skeptics reference swine flu, it doesn't confirm that Europe as a whole is reflecting on its side effects.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0013621238758787513,
    "x2e_entail_prob": 0.011751964688301086
  },
  {
    "id": "covid_fact-000550",
    "statement": "As covid-19 vaccines arrive, europe looks not at swine flu side effects.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DW: We keep seeing vaccine skeptics referencing the swine flu pandemic in 2009 as the reason they won't be taking a COVID-19 vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that vaccine skeptics in Europe reference the swine flu pandemic, indicating they are considering its side effects when deciding about COVID-19 vaccines. This contradicts the claim that Europe is not looking at swine flu side effects.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.024226147681474686,
    "x2e_entail_prob": 0.01048324629664421
  },
  {
    "id": "covid_fact-000551",
    "statement": "Influenza may facilitate the spread of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that influenza may facilitate the spread of SARS-CoV-2, showing a significant increase in transmission during co-circulation and discussing their interaction.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8073224425315857,
    "x2e_entail_prob": 0.0017525251023471355
  },
  {
    "id": "covid_fact-000552",
    "statement": "Influenza may prevent the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that influenza increases SARS-CoV-2 transmission rather than preventing it.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.8017059564590454,
    "x2e_entail_prob": 0.0032794896978884935
  },
  {
    "id": "covid_fact-000553",
    "statement": "Influenza may inhibit the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that influenza increases SARS-CoV-2 transmission rather than inhibiting it.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.824965238571167,
    "x2e_entail_prob": 0.0025201234966516495
  },
  {
    "id": "covid_fact-000554",
    "statement": "Influenza may limit the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that influenza increases the spread of SARS-CoV-2, contrary to the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.4540744721889496,
    "x2e_entail_prob": 0.0030111928936094046
  },
  {
    "id": "covid_fact-000555",
    "statement": "Genomic epidemiology of superspreading events in austria reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses phylogenetic clusters and transmission properties but does not explicitly mention superspreading events.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.00327701517380774,
    "x2e_entail_prob": 0.05522210896015167
  },
  {
    "id": "covid_fact-000556",
    "statement": "Genomic epidemiology of superspreading events in korea reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses studies in Austria, not South Korea, and does not address superspreading events or genomic epidemiology specific to Korea.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.020534152165055275,
    "x2e_entail_prob": 0.05300537124276161
  },
  {
    "id": "covid_fact-000557",
    "statement": "Genomic epidemiology of superspreading events in africa reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence pertains to a study conducted in Austria and does not mention anything about Africa, genomic epidemiology of superspreading events, or specific mutational dynamics and transmission properties relevant to the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.004110557027161121,
    "x2e_entail_prob": 0.0688304603099823
  },
  {
    "id": "covid_fact-000558",
    "statement": "Genomic epidemiology of superspreading events in taiwan reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a study on Austria, not Taiwan, and does not provide information about superspreading events or mutational dynamics in Taiwan.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.021195953711867332,
    "x2e_entail_prob": 0.0650610700249672
  },
  {
    "id": "covid_fact-000559",
    "statement": "Rogue antibodies could be driving severe covid-19.",
    "label": "SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Covid-19 patients with life-threatening cases had higher levels of auto-antibodies against type I IFNs compared to even lupus patients. These antibodies impaired antiviral activity and were absent in mild cases, suggesting a link between rogue antibodies and severe COVID-19.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5583104491233826,
    "x2e_entail_prob": 0.37881943583488464
  },
  {
    "id": "covid_fact-000560",
    "statement": "Rogue antibodies cannot be driving severe covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that auto-antibodies against type I IFNs were found in patients with life-threatening COVID-19 and were not present in mild cases, indicating these antibodies contribute to severe disease.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.27472493052482605,
    "x2e_entail_prob": 0.21120697259902954
  },
  {
    "id": "covid_fact-000561",
    "statement": "Rogue antibodies could be less severe covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that auto-antibodies against type I IFNs are more prevalent in severe COVID-19 cases and block antiviral activity, worsening the disease. The claim incorrectly suggests these antibodies lead to less severity.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.3467543423175812,
    "x2e_entail_prob": 0.2847013473510742
  },
  {
    "id": "covid_fact-000562",
    "statement": "Washington state group is 1st to sue fox new for calling the coronavirus a hoax",
    "label": "SUPPORTED",
    "evidences": [
      "According to the suit, Fox News violated the CPA by falsely and deceptively disseminating News via cable news contracts that the coronavirus was a hoax, and that it was otherwise not a danger to public health and safety. At least one poll has found that Fox News viewers were less likely to take precautions against the virus (including social distancing, handwashing, and other measures) seriously, and an open letter to Fox News from a group of journalism professors said misinformation that reaches the Fox News audience is a danger to public health. Based on the statements made, and the subsequent departure of Trish Regan, WASHLITE does present a cognizable theory of liability.",
      "I said it was a hoax for them to be using it as a bludgeon on Trump. Notably, he made this denial in response to criticism from 74 journalism professors who wrote an open letter to Fox claiming that coverage of the coronavirus from Fox News Channel \"is a danger to public health.\"",
      "But when you get to the point where you are endangering the community  that transcends the limits of the First Amendment. When reached by phone for comment, Catherine Clark, a Seattle attorney who volunteered to join the plaintiffs legal team after reading an initial news account, said this is a case of national importance. A supporter of First Amendment protections, she continued, When it comes to the public health, safety, and welfare, it seems to me a different set of rules apply. In a statement, Fox News general counsel Lily Fu Clafee responded to the suit by saying: Wrong on the facts, frivolous on the law."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence supports that a Washington-based group (WASHLITE) sued Fox News over claims regarding COVID-19, it does not explicitly confirm whether this was the first such lawsuit. Therefore, the claim about being the 'first' is not fully supported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.054146744310855865,
    "x2e_entail_prob": 0.015257016755640507
  },
  {
    "id": "covid_fact-000563",
    "statement": "Washington state group is unable to sue fox new for calling the coronavirus a hoax",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the suit, Fox News violated the CPA by falsely and deceptively disseminating News via cable news contracts that the coronavirus was a hoax, and that it was otherwise not a danger to public health and safety. At least one poll has found that Fox News viewers were less likely to take precautions against the virus (including social distancing, handwashing, and other measures) seriously, and an open letter to Fox News from a group of journalism professors said misinformation that reaches the Fox News audience is a danger to public health. Based on the statements made, and the subsequent departure of Trish Regan, WASHLITE does present a cognizable theory of liability.",
      "I said it was a hoax for them to be using it as a bludgeon on Trump. Notably, he made this denial in response to criticism from 74 journalism professors who wrote an open letter to Fox claiming that coverage of the coronavirus from Fox News Channel \"is a danger to public health.\"",
      "But when you get to the point where you are endangering the community  that transcends the limits of the First Amendment. When reached by phone for comment, Catherine Clark, a Seattle attorney who volunteered to join the plaintiffs legal team after reading an initial news account, said this is a case of national importance. A supporter of First Amendment protections, she continued, When it comes to the public health, safety, and welfare, it seems to me a different set of rules apply. In a statement, Fox News general counsel Lily Fu Clafee responded to the suit by saying: Wrong on the facts, frivolous on the law."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the Washington state group did file a lawsuit against Fox News, challenging their coverage of coronavirus as misinformation. This contradicts the claim that they are unable to sue.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.25372830033302307,
    "x2e_entail_prob": 0.02671176567673683
  },
  {
    "id": "covid_fact-000564",
    "statement": "Unfounded fears that dogs can spread covid-19 can cause harm",
    "label": "SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that unfounded fears about dogs spreading COVID-19 have led to harmful actions, such as abandonment or killing of pets, which directly supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.062079694122076035,
    "x2e_entail_prob": 0.5697559714317322
  },
  {
    "id": "covid_fact-000565",
    "statement": "Unfounded fears that people can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that unfounded fears regarding COVID-19 have resulted in harm, specifically towards pets being abandoned or killed, which aligns with the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.2611670196056366,
    "x2e_entail_prob": 0.4241536855697632
  },
  {
    "id": "covid_fact-000566",
    "statement": "Unfounded fears that sars can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that unfounded fears about pets spreading COVID-19 have led to harmful actions like abandonment or killing of pets, supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.024727649986743927,
    "x2e_entail_prob": 0.41970908641815186
  },
  {
    "id": "covid_fact-000567",
    "statement": "Unfounded fears that hiv can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses unfounded fears regarding pets spreading COVID-19 but does not address HIV or its relation to COVID-19 transmission.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.002232985571026802,
    "x2e_entail_prob": 0.09584904462099075
  },
  {
    "id": "covid_fact-000568",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in mice",
    "label": "SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infection leads to viral replication in the olfactory epithelium, causing transient olfactory dysfunction and downregulating olfactory receptors in mice.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9922156929969788,
    "x2e_entail_prob": 0.009961152449250221
  },
  {
    "id": "covid_fact-000569",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in humans",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infection in humanized ACE2 mice leads to viral replication in the olfactory epithelium, resulting in transient olfactory dysfunction. This supports the claim that Sars-cov-2 causes temporary loss of smell in humans.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.23216426372528076,
    "x2e_entail_prob": 0.0016776717966422439
  },
  {
    "id": "covid_fact-000570",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in neurons",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infection leads to viral replication in the olfactory epithelium, causing downregulation of olfactory receptors and transient olfactory dysfunction, which supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3130623400211334,
    "x2e_entail_prob": 0.006690481677651405
  },
  {
    "id": "covid_fact-000571",
    "statement": "1 million pc owners combine their gpu power to fight covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that over one million personal computers have donated processing power to Folding@home, which is used for protein simulations related to COVID-19 research. While the claim specifically mentions GPU power, the evidence refers to general processing contributions from PCs, which typically include both CPUs and GPUs.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.916359007358551,
    "x2e_entail_prob": 0.0024350027088075876
  },
  {
    "id": "covid_fact-000572",
    "statement": "1 2 pc owners combine their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that over one million PC owners have contributed processing power to Folding@home for COVID-19 research, though the exact number in the claim may be a misinterpretation.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.005066211335361004,
    "x2e_entail_prob": 0.004081107676029205
  },
  {
    "id": "covid_fact-000573",
    "statement": "1 4 pc owners combine their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions '4 pc owners' combining their GPU power, but the evidence states over one million personal computers contributed to Folding@home. The number of participants in the claim does not match the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.007373343221843243,
    "x2e_entail_prob": 0.006113703828305006
  },
  {
    "id": "covid_fact-000574",
    "statement": "1 million pc owners lost their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that over one million personal computers donated processing power to Folding@home for COVID-19 research, aligning with the claim about a significant number of PC owners contributing their GPU resources.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0628347098827362,
    "x2e_entail_prob": 0.005708602257072926
  },
  {
    "id": "covid_fact-000575",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by blocking receptor interaction",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that an alpaca-derived nanobody (Ty1) specifically targets the receptor binding domain of SARS-CoV-2 and blocks ACE2 interaction, thereby neutralizing the virus.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.11755784600973129,
    "x2e_entail_prob": 0.8103355169296265
  },
  {
    "id": "covid_fact-000576",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by activating receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that the alpaca-derived nanobody prevents ACE2 engagement, thereby neutralizing SARS-CoV-2. However, it does not support the claim that the nanobody works by activating receptor interaction; instead, it blocks it.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.010407020337879658,
    "x2e_entail_prob": 0.05908422917127609
  },
  {
    "id": "covid_fact-000577",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by its receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that an alpaca-derived antibody (Ty1) targets the SARS-CoV-2 spike's RBD, preventing ACE2 engagement and neutralizing the virus.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.025315074250102043,
    "x2e_entail_prob": 0.5096997022628784
  },
  {
    "id": "covid_fact-000578",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by a receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Ty1, an alpaca-derived nanobody, targets the RBD of SARS-CoV-2's spike protein and prevents ACE2 engagement, which neutralizes the virus by blocking receptor interaction.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.09437664598226547,
    "x2e_entail_prob": 0.7041417360305786
  },
  {
    "id": "covid_fact-000579",
    "statement": "Household studies provide key insights on the transmission of , and susceptibility to , sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "The secondary attack rate for SARS-CoV-2 has been estimated to be approximately twice as high as that of SARS-CoV, 5 Lau JT Lau M Kim JH Tsui HY Tsang T Wong TW Probable secondary infections in households of SARS patients in Hong Kong."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that household studies provide insights into the transmission rate but does not address susceptibility.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.009120721369981766,
    "x2e_entail_prob": 0.006475991103798151
  },
  {
    "id": "covid_fact-000580",
    "statement": "Future studies provide key insights on the transmission of, and susceptibility to, sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The secondary attack rate for SARS-CoV-2 has been estimated to be approximately twice as high as that of SARS-CoV, 5 Lau JT Lau M Kim JH Tsui HY Tsang T Wong TW Probable secondary infections in households of SARS patients in Hong Kong."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is about an existing study and does not mention any future studies, thus it doesn't support the claim about future insights.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0042784251272678375,
    "x2e_entail_prob": 0.14278167486190796
  },
  {
    "id": "covid_fact-000581",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c damages its genome integrity seriously",
    "label": "SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that inactivating samples at temperatures higher than 56\u00b0C (e.g., 56\u00b0C for 30 minutes) using Hanks solution resulted in significant loss of viral templates, indicating damage to genome integrity. While optimized preservation solutions can mitigate this issue, the claim is supported under standard conditions.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.011610605753958225,
    "x2e_entail_prob": 0.006704456172883511
  },
  {
    "id": "covid_fact-000582",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c increased its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that inactivating at higher temperatures without an optimized preservation solution reduces detectable viral templates, indicating lower genome integrity. Thus, the claim that genome integrity increases is not supported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.013054619543254375,
    "x2e_entail_prob": 0.004474044777452946
  },
  {
    "id": "covid_fact-000583",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c increases its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that higher temperatures (e.g., 56\u00b0C and above) significantly reduce detectable viral templates, indicating serious genome integrity issues.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.006344902794808149,
    "x2e_entail_prob": 0.003464655950665474
  },
  {
    "id": "covid_fact-000584",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c shows its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that inactivating porcine coronavirus at temperatures above 56\u00b0C significantly reduces the detectable viral templates, indicating harm to genome integrity. While this is a necessary safety step, optimized preservation solutions can mitigate this effect.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.010778923518955708,
    "x2e_entail_prob": 0.0042203753255307674
  },
  {
    "id": "covid_fact-000585",
    "statement": "Therapeutic anticoagulation is associated with decreased mortality in mechanically ventilated covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates a significant decrease in mortality with therapeutic anticoagulation, supported by statistical analysis and survival rates.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8068386912345886,
    "x2e_entail_prob": 0.011522965505719185
  },
  {
    "id": "covid_fact-000586",
    "statement": "Therapeutic anticoagulation is associated with elevated mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows a survival advantage and reduced mortality for patients receiving therapeutic anticoagulation, contradicting the claim of elevated mortality.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.11097701638936996,
    "x2e_entail_prob": 0.00816380511969328
  },
  {
    "id": "covid_fact-000587",
    "statement": "Therapeutic anticoagulation is associated with increased mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that therapeutic anticoagulation is associated with a significant reduction in mortality (79% decrease) and improved survival rates among mechanically ventilated COVID-19 patients, contradicting the claim of increased mortality.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.45352375507354736,
    "x2e_entail_prob": 0.04532884433865547
  },
  {
    "id": "covid_fact-000588",
    "statement": "Therapeutic anticoagulation is associated with high mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that therapeutic anticoagulation is associated with a survival advantage and reduced mortality, contradicting the claim.",
    "confidence": 0.99,
    "e2x_entail_prob": 0.04406013712286949,
    "x2e_entail_prob": 0.009071328677237034
  },
  {
    "id": "covid_fact-000589",
    "statement": "Sars-cov-2 is an unrestricted bioweapon",
    "label": "SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence labels SARS-CoV-2 as an unrestricted bioweapon based on claims of laboratory modification, but this is not widely supported by the scientific community. The assertion lacks independent verification and relies on speculative conclusions.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.02432095631957054,
    "x2e_entail_prob": 0.002696696436032653
  },
  {
    "id": "covid_fact-000590",
    "statement": "Sars-cov-2 is an spricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that SARS-CoV-2 may have lab origins but does not conclusively prove it was intentionally created as a bioweapon by the PLA or any state actor. The claim is speculative without definitive proof of malicious intent.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.6799201369285583,
    "x2e_entail_prob": 0.0013883376959711313
  },
  {
    "id": "covid_fact-000591",
    "statement": "Sars-cov-2 is an sricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that SARS-CoV-2 is an unrestricted bioweapon, supporting the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.8254594802856445,
    "x2e_entail_prob": 0.0012850344646722078
  },
  {
    "id": "covid_fact-000592",
    "statement": "Sars-cov-2 is an trricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim uses conflicting terminology ('trricted' vs 'Unrestricted') and while the evidence suggests SARS-CoV-2 is a lab-modified virus classified as an Unrestricted Bioweapon, there's no scientific consensus supporting this. The origin remains debated.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.019053664058446884,
    "x2e_entail_prob": 0.0023552216589450836
  },
  {
    "id": "covid_fact-000593",
    "statement": "Kinetics of antibody responses dictate covid-19 outcome.",
    "label": "SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a strong correlation between antibody kinetics and COVID-19 outcomes, with neutralizing antibodies predicting severity and survival, distinct outcomes revealed by antibody levels, and the interaction between viral load and antibody responses influencing disease progression.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.4624503254890442,
    "x2e_entail_prob": 0.8452581167221069
  },
  {
    "id": "covid_fact-000594",
    "statement": "Standards of antibody responses dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence demonstrates that antibody responses, including neutralizing antibodies and their kinetics, are linked to COVID-19 severity and outcomes such as survival. While other factors like T cells are also mentioned, the focus on antibodies strongly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.02080461010336876,
    "x2e_entail_prob": 0.39753973484039307
  },
  {
    "id": "covid_fact-000595",
    "statement": "Kinetics of antibody production dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a strong correlation between antibody kinetics and COVID-19 outcomes, such as disease severity and survival. Studies indicate that the dynamics of antibody production are predictive factors for the course of the disease.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.7248542904853821,
    "x2e_entail_prob": 0.3254237473011017
  },
  {
    "id": "covid_fact-000596",
    "statement": "Analysiss of antibody responses dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a strong link between antibody responses and COVID-19 severity and survival, but also acknowledges the role of T cells.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.00485488586127758,
    "x2e_entail_prob": 0.3924235701560974
  },
  {
    "id": "covid_fact-000597",
    "statement": "Raspberry pi about to boost ventilators for coronavirus victims",
    "label": "SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Raspberry Pi boards are being used in ventilators and production is ramped up to meet demand, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.12268901616334915,
    "x2e_entail_prob": 0.001460578991100192
  },
  {
    "id": "covid_fact-000598",
    "statement": "Raspberry pi about to avoid ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that Raspberry Pi is aiding in the production of ventilators but does not support the idea of avoiding them.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.01083036046475172,
    "x2e_entail_prob": 0.0011969896731898189
  },
  {
    "id": "covid_fact-000599",
    "statement": "Raspberry pi about to take ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Raspberry Pi boards are being used to support the production of ventilators but does not suggest that Raspberry Pis themselves are becoming ventilators.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.004017333500087261,
    "x2e_entail_prob": 0.0008483320125378668
  },
  {
    "id": "covid_fact-000600",
    "statement": "Raspberry pi about to receive ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that Raspberry Pi boards are being used in ventilators for COVID-19 victims, as they are ramping up production to meet demand. However, the claim's wording about 'receiving' may be misleading since Raspberry Pi is supplying components rather than receiving ventilators.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.027560677379369736,
    "x2e_entail_prob": 0.0018771057948470116
  },
  {
    "id": "covid_fact-000601",
    "statement": "Aerosol particles laden with viruses that cause covid-19 travel over 30m distance",
    "label": "SUPPORTED",
    "evidences": [
      "The results obtained demonstrate that aerosol particles generated by coughing and sneezing can travel over 30 m. Modelling of the evolution of aerosol clouds generated by coughing and sneezing enables us to evaluate the deposition dose of aerosol particles in healthy individuals.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence states that aerosol particles can travel over 30 meters, it does not specifically mention that these particles are laden with COVID-19 viruses.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0027989340014755726,
    "x2e_entail_prob": 0.028737014159560204
  },
  {
    "id": "covid_fact-000602",
    "statement": "Aerosol particles laden with viruses that cause covid-19 travel within 30m distance",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results obtained demonstrate that aerosol particles generated by coughing and sneezing can travel over 30 m. Modelling of the evolution of aerosol clouds generated by coughing and sneezing enables us to evaluate the deposition dose of aerosol particles in healthy individuals.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses aerosol particles traveling over 30 meters, but it does not specifically mention COVID-19 or SARS-CoV-2. While the context includes references to COVID-19, there's no explicit link between the aerosols and the virus causing COVID-19.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.05743877589702606,
    "x2e_entail_prob": 0.05545739457011223
  },
  {
    "id": "covid_fact-000603",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against sars-cov-2 and zoonotic coronaviruses",
    "label": "SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that Mosaic RBD nanoparticles elicited cross-reactive and neutralizing antibodies against SARS-CoV-2 and zoonotic coronaviruses, confirming the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8256943821907043,
    "x2e_entail_prob": 0.04682409018278122
  },
  {
    "id": "covid_fact-000604",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against chs-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that Mosaic RBD nanoparticles elicit cross-reactive antibodies, which neutralize SARS-CoV-2 and other zoonotic coronaviruses. The studies demonstrate superior immunogenicity and cross-reactivity compared to other methods.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7607747912406921,
    "x2e_entail_prob": 0.03858238458633423
  },
  {
    "id": "covid_fact-000605",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against gps-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that mosaic-RBD nanoparticles elicit neutralizing antibodies against SARS-CoV-2 and other zoonotic coronaviruses, as demonstrated by cross-reactive antibody responses in mice.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9359263777732849,
    "x2e_entail_prob": 0.06078365817666054
  },
  {
    "id": "covid_fact-000606",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against 3s-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that mosaic RBD-nanoparticles induce cross-reactive antibodies against various coronaviruses, including SARS-CoV-2 and zoonotic strains, confirming the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9544193148612976,
    "x2e_entail_prob": 0.019702691584825516
  },
  {
    "id": "covid_fact-000607",
    "statement": "South korean city deserted due to super spreading event",
    "label": "SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly describes Daegu as a South Korean city that became deserted due to a super-spreading event at a church, leading to public places being abandoned and residents staying indoors.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.802017867565155,
    "x2e_entail_prob": 0.45743274688720703
  },
  {
    "id": "covid_fact-000608",
    "statement": "South korean city started due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Daegu, a South Korean city, experienced a super-spreading event which led to significant impacts on the city.",
    "confidence": 1,
    "e2x_entail_prob": 0.3179436922073364,
    "x2e_entail_prob": 0.4393678307533264
  },
  {
    "id": "covid_fact-000609",
    "statement": "South korean city remained due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Daegu, a South Korean city, experienced a super-spreading event at a church, leading to many infections. As a result, residents stayed home, causing public places like shopping malls and cinemas to become deserted.",
    "confidence": 1,
    "e2x_entail_prob": 0.8309484124183655,
    "x2e_entail_prob": 0.7213070392608643
  },
  {
    "id": "covid_fact-000610",
    "statement": "South korean city occurred due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Daegu, a South Korean city, experienced a super-spreading event of the coronavirus, leading to an outbreak.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.4390833377838135,
    "x2e_entail_prob": 0.4848092496395111
  },
  {
    "id": "covid_fact-000611",
    "statement": "Scientists see signs of lasting immunity , even after mild infections",
    "label": "SUPPORTED",
    "evidences": [
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys robust immune response to other viruses.",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of COVID-19, a flurry of new studies suggests.",
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells that are capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys enduring response to other viruses.",
      "Scientists see signs of lasting immunity to COVID-19, even after mild infections Share: August 18, 2020 ",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of Covid-19, a flurry of new studies suggests."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides consistent support for the claim by showing that antibodies and immune cells persist months after infection, including in those with mild symptoms.",
    "confidence": 1,
    "e2x_entail_prob": 0.4642975330352783,
    "x2e_entail_prob": 0.2724551558494568
  },
  {
    "id": "covid_fact-000612",
    "statement": "Scientists no signs of lasting immunity, even after mild infections",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys robust immune response to other viruses.",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of COVID-19, a flurry of new studies suggests.",
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells that are capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys enduring response to other viruses.",
      "Scientists see signs of lasting immunity to COVID-19, even after mild infections Share: August 18, 2020 ",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of Covid-19, a flurry of new studies suggests."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that scientists are observing strong and lasting immunity, even after mild infections, which directly contradicts the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.007921108044683933,
    "x2e_entail_prob": 0.19431540369987488
  },
  {
    "id": "covid_fact-000613",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-specific viral diagnostic",
    "label": "SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that type III CRISPR-Cas systems were used for sensitive and sequence-specific detection of SARS-CoV-2, supporting the claim about their diagnostic capability. The intrinsic signal amplification is a known feature of type III systems, aligning with the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.038117021322250366,
    "x2e_entail_prob": 0.0010033254511654377
  },
  {
    "id": "covid_fact-000614",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-independent viral diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that type-III CRISPR-Cas systems are used for sequence-specific detection, contradicting the claim of being sequence-independent. Additionally, there's no explicit mention of intrinsic signal amplification.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.006499951239675283,
    "x2e_entail_prob": 0.0009244325337931514
  },
  {
    "id": "covid_fact-000615",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-free viral diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the type III CRISPR-Cas system was used for sequence-specific detection of SARS-CoV-2, contradicting the claim of being 'sequence-free'. Additionally, there is no mention of intrinsic signal amplification in the evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.00879985187202692,
    "x2e_entail_prob": 0.0010053158039227128
  },
  {
    "id": "covid_fact-000616",
    "statement": "Pet dog further tests positive for antibodies for covid-19 virus",
    "label": "SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the dog had antibodies, confirming a positive test.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3437321186065674,
    "x2e_entail_prob": 0.02862977236509323
  },
  {
    "id": "covid_fact-000617",
    "statement": "Pet dog further tests negative for antibodies for covid-19 virus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows the pet dog had antibodies, contradicting the negative test result claimed.",
    "confidence": 1,
    "e2x_entail_prob": 0.05807456746697426,
    "x2e_entail_prob": 0.02278873510658741
  },
  {
    "id": "covid_fact-000618",
    "statement": "Pet dog further tests except for antibodies for covid-19 virus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that a Pomeranian had antibodies for COVID-19 but does not provide information about further tests beyond antibody testing.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.006234627682715654,
    "x2e_entail_prob": 0.0027144616469740868
  },
  {
    "id": "covid_fact-000619",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 100 % success using hydroxychloroquine sulfate , zinc and z-pak",
    "label": "SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that Dr. Vladimir Zelenko treated 699 patients with a regimen including hydroxychloroquine sulfate, zinc, and azithromycin (Z-Pak), achieving 100% success without any deaths or intubations. While there is a mention of treating 900 patients in another update, the specific claim about 699 patients aligns with the evidence provided.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.01430237852036953,
    "x2e_entail_prob": 0.27070334553718567
  },
  {
    "id": "covid_fact-000620",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 10 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that Dr. Zelenko treated 699 patients with a 100% success rate, not 10%. The numbers of patients and the success rates in the claim do not align with the provided information.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.02558143436908722,
    "x2e_entail_prob": 0.12871776521205902
  },
  {
    "id": "covid_fact-000621",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 5 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Dr. Zelenko achieved a 100% success rate with zero deaths and intubations among 699 patients, contradicting the claim of only 5% success.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.05167955160140991,
    "x2e_entail_prob": 0.18459004163742065
  },
  {
    "id": "covid_fact-000622",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 20 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates Dr. Zelenko treated a number of patients (350 and 699) with a high success rate, including zero deaths or intubations, contradicting the claimed 20% success rate.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.09019307792186737,
    "x2e_entail_prob": 0.19619318842887878
  },
  {
    "id": "covid_fact-000623",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is inadequate for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the VivaDiag COVID-19 IgM/IgG Rapid Test has low sensitivity, leading to many false negatives and making it unsuitable for diagnosis in emergency departments.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9143616557121277,
    "x2e_entail_prob": 0.7034716010093689
  },
  {
    "id": "covid_fact-000624",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is useful for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that the VivaDiag COVID-19 IgM/IgG Rapid Test is not recommended for triage in emergency departments due to low sensitivity, leading to misdiagnosis. This directly contradicts the claim that it is useful for diagnosis.",
    "confidence": 1,
    "e2x_entail_prob": 0.0568540059030056,
    "x2e_entail_prob": 0.5013560652732849
  },
  {
    "id": "covid_fact-000625",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is essential for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that the VivaDiag COVID-19 IgM/IgG Rapid Test is not recommended for triage in emergency departments due to low sensitivity, leading to misdiagnosis.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7634547352790833,
    "x2e_entail_prob": 0.5020679831504822
  },
  {
    "id": "covid_fact-000626",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is suitable for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that VivaDiag COVID-19 IgM/IgG Rapid Test is not recommended for triage in emergency departments due to low sensitivity, leading to misdiagnosis.",
    "confidence": 1,
    "e2x_entail_prob": 0.7444555163383484,
    "x2e_entail_prob": 0.4047534167766571
  },
  {
    "id": "covid_fact-000627",
    "statement": "Cetylpyridinium chloride-containing mouthwashes reduce in vitro sars-cov-2 infectivity.",
    "label": "SUPPORTED",
    "evidences": [
      "A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro.",
      "CPC- containing mouth rinses could represent a cost-effective measure to reduce SARS-CoV-2 infectivity in saliva, aiding to reduce viral transmission from infected individuals.",
      "Here we show that Cetylpyridinium chloride (CPC), a quaternary ammonium compound present in many oral mouthwashes, reduces SARS-CoV-2 infectivity by inhibiting viral fusion with target cells.",
      "\"A common compound in mouthwashes found to inhibit SARS- CoV-2 in vitro\".",
      "Antiviral activity of CPC-containing mouthwashes inhibiting SARS-CoV-2 entry."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that Cetylpyridinium chloride (CPC) in mouthwashes reduces SARS-CoV-2 infectivity by inhibiting viral fusion, directly supporting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.5632240772247314,
    "x2e_entail_prob": 0.137618288397789
  },
  {
    "id": "covid_fact-000628",
    "statement": "Cetylpyridinium chloride-containing mouthwashes with in vitro sars-cov-2 infectivity.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro.",
      "CPC- containing mouth rinses could represent a cost-effective measure to reduce SARS-CoV-2 infectivity in saliva, aiding to reduce viral transmission from infected individuals.",
      "Here we show that Cetylpyridinium chloride (CPC), a quaternary ammonium compound present in many oral mouthwashes, reduces SARS-CoV-2 infectivity by inhibiting viral fusion with target cells.",
      "\"A common compound in mouthwashes found to inhibit SARS- CoV-2 in vitro\".",
      "Antiviral activity of CPC-containing mouthwashes inhibiting SARS-CoV-2 entry."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.06749364733695984,
    "x2e_entail_prob": 0.5185436010360718
  },
  {
    "id": "covid_fact-000629",
    "statement": "Symptom-based screening process was ineffective in detecting sars-cov-2 infection during evacuation of 126 people from wuhan , china .",
    "label": "SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the symptom-based screening process was ineffective during the evacuation, as it missed detecting SARS-CoV-2 in two individuals who later tested positive.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8383074998855591,
    "x2e_entail_prob": 0.02778511680662632
  },
  {
    "id": "covid_fact-000630",
    "statement": "Symptom-based screening process was successful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that the symptom-based screening process was ineffective in detecting SARS-CoV-2 infections in two individuals during the evacuation from Wuhan. This directly contradicts the claim of success.",
    "confidence": 1,
    "e2x_entail_prob": 0.14960801601409912,
    "x2e_entail_prob": 0.05016331747174263
  },
  {
    "id": "covid_fact-000631",
    "statement": "Symptom-based screening process was helpful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that symptom-based screening was ineffective in detecting two cases of SARS-CoV-2 during the evacuation, directly contradicting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.04149307310581207,
    "x2e_entail_prob": 0.023478813469409943
  },
  {
    "id": "covid_fact-000632",
    "statement": "Symptom-based screening process was useful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the symptom-based screening process was ineffective during the evacuation, failing to detect two cases of SARS-CoV-2 infection. Therefore, the claim is not supported.",
    "confidence": 1,
    "e2x_entail_prob": 0.6582493782043457,
    "x2e_entail_prob": 0.022435083985328674
  },
  {
    "id": "covid_fact-000633",
    "statement": "Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose",
    "label": "SUPPORTED",
    "evidences": [
      "Although our simulation showed that increasing pathogen challenge dose decreased vaccine efficacy, variance in susceptibility also affected vaccine protection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the theoretical prediction by showing that higher pathogen challenge doses decreased vaccine efficacy in a simulation. However, it doesn't explicitly address whether this support is limited or widespread.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.01793397217988968,
    "x2e_entail_prob": 0.001486192806623876
  },
  {
    "id": "covid_fact-000634",
    "statement": "Limited available evidence supports theoretical predictions of reduced vaccine efficacy at low exposure dose",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although our simulation showed that increasing pathogen challenge dose decreased vaccine efficacy, variance in susceptibility also affected vaccine protection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses how increasing pathogen challenge dose decreases vaccine efficacy and mentions the effect of susceptibility variance but does not address reduced vaccine efficacy at low exposure doses. Therefore, it does not support the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.004799013026058674,
    "x2e_entail_prob": 0.1100555956363678
  },
  {
    "id": "covid_fact-000635",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are short-lived in patients with mild illness",
    "label": "SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the higher antibody responses in severely ill patients compared to outpatients and asymptomatic individuals but does not address the correlation between antibody responses and resolution of rnaemia or their short-lived nature in mild cases.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0008149284403771162,
    "x2e_entail_prob": 0.0014486490981653333
  },
  {
    "id": "covid_fact-000636",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are long-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not address the correlation between antibody responses and resolution of rnaemia nor the long-lived nature of antibodies in mild cases. It only states that severely ill patients have higher antibody levels than outpatients and asymptomatic individuals.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0027625709772109985,
    "x2e_entail_prob": 0.0013381318422034383
  },
  {
    "id": "covid_fact-000637",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are longer-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not address the correlation between antibody responses and RNAemia resolution nor the longevity of antibodies in mild illness.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0013589431764557958,
    "x2e_entail_prob": 0.0029449916910380125
  },
  {
    "id": "covid_fact-000638",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are over-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that severely ill patients have stronger antibody responses than those with mild illness or asymptomatic cases, supporting the first part about correlation with rnaemia resolution. However, there's no information on whether antibodies persist longer in mild cases.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0014565696474164724,
    "x2e_entail_prob": 0.0015368286985903978
  },
  {
    "id": "covid_fact-000639",
    "statement": "Saliva is more sensitive for sars-cov-2 detection in covid-19 patients than nasopharyngeal swabs",
    "label": "SUPPORTED",
    "evidences": [
      "Saliva is a promising candidate for SARS-CoV-2 diagnostics because (1) collection is minimally invasive and can reliably be self-administered and (2) saliva has exhibited comparable sensitivity to nasopharyngeal swabs in detection of other respiratory pathogens, including endemic human coronaviruses, in previous studies.",
      "When we compared SARS-CoV-2 detection from patient-matched nasopharyngeal and saliva samples, we found that saliva yielded greater detection sensitivity and consistency throughout the course of infection.",
      "Taken together, our findings demonstrate that saliva is a viable and more sensitive alternative to nasopharyngeal swabs and could enable at-home self-administered sample collection for accurate large- scale SARS-CoV-2 testing.",
      "To validate the use of saliva for SARS-CoV-2 detection, we tested nasopharyngeal and saliva samples from confirmed COVID-19 patients and self-collected samples from healthcare workers on COVID-19 wards."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that saliva has been found to have higher sensitivity than nasopharyngeal swabs in detecting SARS-CoV-2, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8975828289985657,
    "x2e_entail_prob": 0.005104372277855873
  },
  {
    "id": "covid_fact-000640",
    "statement": "Saliva is less sensitive for sars-cov-2 detection in covid-19 patients than nasopharyngeal swabs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Saliva is a promising candidate for SARS-CoV-2 diagnostics because (1) collection is minimally invasive and can reliably be self-administered and (2) saliva has exhibited comparable sensitivity to nasopharyngeal swabs in detection of other respiratory pathogens, including endemic human coronaviruses, in previous studies.",
      "When we compared SARS-CoV-2 detection from patient-matched nasopharyngeal and saliva samples, we found that saliva yielded greater detection sensitivity and consistency throughout the course of infection.",
      "Taken together, our findings demonstrate that saliva is a viable and more sensitive alternative to nasopharyngeal swabs and could enable at-home self-administered sample collection for accurate large- scale SARS-CoV-2 testing.",
      "To validate the use of saliva for SARS-CoV-2 detection, we tested nasopharyngeal and saliva samples from confirmed COVID-19 patients and self-collected samples from healthcare workers on COVID-19 wards."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that saliva is more sensitive than nasopharyngeal swabs for SARS-CoV-2 detection in COVID-19 patients, which directly contradicts the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.006534277461469173,
    "x2e_entail_prob": 0.008892565965652466
  },
  {
    "id": "covid_fact-000641",
    "statement": "Vitamin d sufficiency reduced risk for morbidity and mortality in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that vitamin D sufficiency reduces the severity of clinical outcomes and mortality in COVID-19 patients, supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.6319391131401062,
    "x2e_entail_prob": 0.02491675317287445
  },
  {
    "id": "covid_fact-000642",
    "statement": "Vitamin d sufficiency increased risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that vitamin D sufficiency decreases the risk of morbidity and mortality in COVID-19 patients, contradicting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.05582308769226074,
    "x2e_entail_prob": 0.01772805117070675
  },
  {
    "id": "covid_fact-000643",
    "statement": "Vitamin d sufficiency increasing risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that vitamin D sufficiency reduces morbidity and mortality in COVID-19 patients, contradicting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.04612622410058975,
    "x2e_entail_prob": 0.017261777073144913
  },
  {
    "id": "covid_fact-000644",
    "statement": "Vitamin d sufficiency greater risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that vitamin D sufficiency increases the risk of morbidity and mortality in COVID-19 patients, but the evidence shows the opposite. The evidence indicates that vitamin D sufficiency reduces severity and mortality by preventing cytokine storms and lowering infection risks.",
    "confidence": 1,
    "e2x_entail_prob": 0.10584127902984619,
    "x2e_entail_prob": 0.0728166326880455
  },
  {
    "id": "covid_fact-000645",
    "statement": "A functional genomics approach to understand host genetic regulation of covid-19 severity",
    "label": "SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly describes a functional genomics investigation focused on understanding host genetic regulation of COVID-19 severity, specifically examining innate immune responses and genetic variants influencing susceptibility.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9358967542648315,
    "x2e_entail_prob": 0.005076398141682148
  },
  {
    "id": "covid_fact-000646",
    "statement": "A functional genomics approach to understand early genetic regulation of covid-19 severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim aligns with the evidence showing a functional genomics approach was used to study genetic susceptibility to severe COVID-19, including innate immune responses and cytokine production. Although 'early' isn't explicitly mentioned, the core concepts are supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.01159244030714035,
    "x2e_entail_prob": 0.018706174567341805
  },
  {
    "id": "covid_fact-000647",
    "statement": "A functional genomics approach to understand molecular genetic regulation of covid-19 severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly describes a functional genomics investigation into the molecular genetic regulation of COVID-19 severity, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6341937780380249,
    "x2e_entail_prob": 0.009786556474864483
  },
  {
    "id": "covid_fact-000648",
    "statement": "Repeated cross-sectional sero-monitoring of sars-cov-2 in new york city",
    "label": "SUPPORTED",
    "evidences": [
      "A serological assay to detect SARS-CoV-2 seroconversion in humans."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence mentions a serological assay for detecting SARS-CoV-2, it does not provide information about repeated cross-sectional monitoring in New York City.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0011312455171719193,
    "x2e_entail_prob": 0.053905606269836426
  },
  {
    "id": "covid_fact-000649",
    "statement": "One cross-sectional sero-monitoring of sars-cov-2 in new york city",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A serological assay to detect SARS-CoV-2 seroconversion in humans."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a serological assay for detecting SARS-CoV-2 seroconversion in humans, but it does not specify that the study was conducted in New York City or that it was a cross-sectional study.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0010618673404678702,
    "x2e_entail_prob": 0.987448513507843
  },
  {
    "id": "covid_fact-000650",
    "statement": "Patients in secret trials are successfully treated with hiv and malaria medication",
    "label": "SUPPORTED",
    "evidences": [
      "They were given HIV medication Kaletra and malaria treatment hydroxychloroquine in a secret trial.",
      "In a secret trial that was held, they were all given HIV medication, Kaletra and Malaria treatment hydroxychloroquine.",
      "The response involved testing a litany of drugs, including a combination of ritonavir and lopinavir, antiretroviral medications used to fight HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that HIV and malaria medications were administered in secret trials but does not provide information on the success of these treatments.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.003806335385888815,
    "x2e_entail_prob": 0.8176560997962952
  },
  {
    "id": "covid_fact-000651",
    "statement": "Patients in secret trials are not treated with hiv and malaria medication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "They were given HIV medication Kaletra and malaria treatment hydroxychloroquine in a secret trial.",
      "In a secret trial that was held, they were all given HIV medication, Kaletra and Malaria treatment hydroxychloroquine.",
      "The response involved testing a litany of drugs, including a combination of ritonavir and lopinavir, antiretroviral medications used to fight HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that patients in secret trials were treated with HIV medication (Kaletra) and malaria treatment (hydroxychloroquine), directly contradicting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.04093339294195175,
    "x2e_entail_prob": 0.9269278645515442
  },
  {
    "id": "covid_fact-000652",
    "statement": "Strong link found between abnormal liver tests and poor covid-19 outcomes",
    "label": "SUPPORTED",
    "evidences": [
      "Rather than the liver itself driving poorer outcomes in COVID-19 patients, the organ is more likely a bystander affected by the hyperinflammation associated with COVID-19 and by the side effects of related treatments, Nathanson said.",
      "But regardless of whether patients came to the hospital with existing liver problems or developed them during their COVID-19-related hospitalization, a strong association was observed between abnormal liver tests and the severity of the COVID-19 cases, the researchers said.",
      "The study noted a relationship between drugs used to treat severe COVID-19 and liver damage, most significantly the drug tocilizumab.",
      "We observed a strong association between the use of COVID-19 medications and abnormal liver tests, said Lim, but added that they could not confidently tease out that the abnormal tests were due to drug-induced liver injury as opposed to the disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a strong association between abnormal liver tests and severe COVID-19 cases, supporting the claim of a link with poor outcomes. While causation is not definitively established, the observed relationship confirms the connection.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.7980725765228271,
    "x2e_entail_prob": 0.002653504256159067
  },
  {
    "id": "covid_fact-000653",
    "statement": "Strong link found between abnormal liver tests and normal covid-19 outcomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rather than the liver itself driving poorer outcomes in COVID-19 patients, the organ is more likely a bystander affected by the hyperinflammation associated with COVID-19 and by the side effects of related treatments, Nathanson said.",
      "But regardless of whether patients came to the hospital with existing liver problems or developed them during their COVID-19-related hospitalization, a strong association was observed between abnormal liver tests and the severity of the COVID-19 cases, the researchers said.",
      "The study noted a relationship between drugs used to treat severe COVID-19 and liver damage, most significantly the drug tocilizumab.",
      "We observed a strong association between the use of COVID-19 medications and abnormal liver tests, said Lim, but added that they could not confidently tease out that the abnormal tests were due to drug-induced liver injury as opposed to the disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates a strong link between abnormal liver tests and severe COVID-19 outcomes, not normal ones. The claim incorrectly associates abnormal liver tests with normal COVID-19 outcomes.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.4652038514614105,
    "x2e_entail_prob": 0.005517537705600262
  },
  {
    "id": "covid_fact-000654",
    "statement": "The sars-cov-2 cytopathic effect is blocked with autophagy modulators",
    "label": "SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that selective autophagy inhibitors, such as chloroquine and hydroxychloroquine, can block the cytopathic effects of SARS-CoV-2 in cell lines. Experiments using LC3B and LysoTracker dye staining confirmed this effect.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9771673083305359,
    "x2e_entail_prob": 0.2745125889778137
  },
  {
    "id": "covid_fact-000655",
    "statement": "The sars-cov-2 cytopathic effect is compatible with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that autophagy modulators like chloroquine and hydroxychloroquine can block the SARS-CoV-2 cytopathic effect, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9513652324676514,
    "x2e_entail_prob": 0.4751835763454437
  },
  {
    "id": "covid_fact-000656",
    "statement": "The sars-cov-2 cytopathic effect is achieved with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that autophagy modulators (e.g., chloroquine) inhibit the cytopathic effects of SARS-CoV-2, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9517766237258911,
    "x2e_entail_prob": 0.4272010326385498
  },
  {
    "id": "covid_fact-000657",
    "statement": "The sars-cov-2 cytopathic effect is induced with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that inhibiting autophagy reduces SARS-CoV-2's cytopathic effects, supporting the claim that autophagy modulators influence these effects.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8204551935195923,
    "x2e_entail_prob": 0.19702467322349548
  },
  {
    "id": "covid_fact-000658",
    "statement": "Regn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a DNA vaccine protecting against SARS-CoV-2 in macaques, not Regn-cov2 antibodies or their effects on hamsters.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.00632220134139061,
    "x2e_entail_prob": 0.043266456574201584
  },
  {
    "id": "covid_fact-000659",
    "statement": "Pn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a DNA vaccine providing protection against SARS-CoV-2 in rhesus macaques but does not mention Pn-cov2 antibodies, treatment, or hamsters.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0026190239004790783,
    "x2e_entail_prob": 0.07711644470691681
  },
  {
    "id": "covid_fact-000660",
    "statement": "Bn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses a DNA vaccine's effectiveness in protecting rhesus macaques from SARS-CoV-2 but does not mention Bn-cov2 antibodies or their role in prevention or treatment in either rhesus macaques or hamsters.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0026264325715601444,
    "x2e_entail_prob": 0.09683530032634735
  },
  {
    "id": "covid_fact-000661",
    "statement": "Hn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a DNA vaccine's effectiveness in rhesus macaques but doesn't mention Hn-cov2 antibodies or hamsters, nor does it address treatment.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.002119393553584814,
    "x2e_entail_prob": 0.10318773984909058
  },
  {
    "id": "covid_fact-000662",
    "statement": "Sars-cov-2 genome evolution exposes early human adaptations",
    "label": "SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses SARS-CoV-2 genome adaptation during the COVID-19 pandemic but does not mention early human adaptations.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0025754075031727552,
    "x2e_entail_prob": 0.18906420469284058
  },
  {
    "id": "covid_fact-000663",
    "statement": "Sars-cov-2 genome evolution exposes early human infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a study on SARS-CoV-2 genome evolution at the outset of the pandemic but does not explicitly provide information about exposing early human infections.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.005023153033107519,
    "x2e_entail_prob": 0.2265881896018982
  },
  {
    "id": "covid_fact-000664",
    "statement": "Sars-cov-2 genome evolution exposes early human infections",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses seeking signals of evolution to identify how the SARS-CoV-2 genome adapted at the pandemic's start but does not explicitly mention exposing early human infections.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0028634651098400354,
    "x2e_entail_prob": 0.5254486799240112
  },
  {
    "id": "covid_fact-000665",
    "statement": "Sars-cov-2 genome evolution exposes early genes adaptations",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The study sought evolutionary signals, confirming the intent to examine early gene adaptations in SARS-CoV-2's genome.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6901168823242188,
    "x2e_entail_prob": 0.45618936419487
  },
  {
    "id": "covid_fact-000666",
    "statement": "Research by tennessee scientists at oak ridge labs on existing drug compounds via supercomputing could combat coronavirus .",
    "label": "SUPPORTED",
    "evidences": [
      "Oak Ridge National Laboratory scientists have focused the power of the world's fastest supercomputer to search for an existing drug that can prevent the new coronavirus from penetrating human cells.",
      "The Oak Ridge National Laboratory in Tennessee (one member of the consortium) is using its supercomputers to look for compounds already on the market that might foil the virus.",
      "Oak Ridge National Laboratory, where Summit is housed, recently granted researchers emergency computation time to run through a database of existing drug compounds to see which combinations might prevent cell infection of COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Oak Ridge National Laboratory in Tennessee is using supercomputers to research existing drug compounds as a potential treatment for coronavirus, aligning fully with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.08232644945383072,
    "x2e_entail_prob": 0.012345725670456886
  },
  {
    "id": "covid_fact-000667",
    "statement": "Research by chinese scientists at oak ridge labs on existing drug compounds via supercomputing could combat coronavirus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Oak Ridge National Laboratory scientists have focused the power of the world's fastest supercomputer to search for an existing drug that can prevent the new coronavirus from penetrating human cells.",
      "The Oak Ridge National Laboratory in Tennessee (one member of the consortium) is using its supercomputers to look for compounds already on the market that might foil the virus.",
      "Oak Ridge National Laboratory, where Summit is housed, recently granted researchers emergency computation time to run through a database of existing drug compounds to see which combinations might prevent cell infection of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms Oak Ridge Labs is using supercomputers to research existing drugs against coronavirus, but it doesn't mention Chinese scientists involvement.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.006397769786417484,
    "x2e_entail_prob": 0.017702089622616768
  },
  {
    "id": "covid_fact-000668",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of ace2 in vertebrates",
    "label": "SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that comparative and structural analysis of ACE2 in various mammals identified many potential hosts for SARS-CoV-2, supporting the claim about a broad host range.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.4155275225639343,
    "x2e_entail_prob": 0.400821715593338
  },
  {
    "id": "covid_fact-000669",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of fpr2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses ACE2, not FPR2, as the receptor for SARS-CoV-2. There's no mention of FPR2 in the provided information.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.31655338406562805,
    "x2e_entail_prob": 0.017882555723190308
  },
  {
    "id": "covid_fact-000670",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of tmprss2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim focuses on TMPRSS2 analysis predicting SARS-CoV-2's broad host range, but the evidence discusses ACE2 analysis instead, without mentioning TMPRSS2.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0024450987111777067,
    "x2e_entail_prob": 0.03371056541800499
  },
  {
    "id": "covid_fact-000671",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of ns2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided focuses on ACE2 proteins and their role as SARS-CoV-2 receptors, not NS2. There is no mention of NS2 in the analysis.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.23007981479167938,
    "x2e_entail_prob": 0.009028819389641285
  },
  {
    "id": "covid_fact-000672",
    "statement": "Man behind sweden 's controversial virus strategy admits mistakes",
    "label": "SUPPORTED",
    "evidences": [
      "Wednesday 3 June 2020 17:07, UK COVID-19 Coronavirus Image: People walk down a high street in Stockholm in May image/svg+xml Why you can trust Sky News Sweden should have done more to combat coronavirus to prevent it having a much higher national death rate than neighbouring countries, the man behind the country's pandemic strategy has said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the man behind Sweden's pandemic strategy admitted they should have done more to combat coronavirus, leading to a higher death rate than neighboring countries. This directly supports the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.32595178484916687,
    "x2e_entail_prob": 0.09749738872051239
  },
  {
    "id": "covid_fact-000673",
    "statement": "Not behind sweden's controversial virus strategy admits mistakes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 3 June 2020 17:07, UK COVID-19 Coronavirus Image: People walk down a high street in Stockholm in May image/svg+xml Why you can trust Sky News Sweden should have done more to combat coronavirus to prevent it having a much higher national death rate than neighbouring countries, the man behind the country's pandemic strategy has said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the person responsible for Sweden's virus strategy admits mistakes, acknowledging a higher death rate than neighboring countries.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8726688027381897,
    "x2e_entail_prob": 0.17902657389640808
  },
  {
    "id": "covid_fact-000674",
    "statement": "Wearing eyeglasses protects against sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that wearing eyeglasses can reduce the risk of SARS-CoV-2 transmission by acting as a barrier to viral entry through the eyes and decreasing hand-to-eye contact. While not foolproof, this reasoning aligns with known protective measures against COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.4315232038497925,
    "x2e_entail_prob": 0.9869300127029419
  },
  {
    "id": "covid_fact-000675",
    "statement": "Wearing eyeglasses protects by sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that wearing eyeglasses may protect against SARS-CoV-2 by reducing eye touching and potential viral entry through the eyes, although it notes this is likely rather than definitive.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.04515407234430313,
    "x2e_entail_prob": 0.9882381558418274
  },
  {
    "id": "covid_fact-000676",
    "statement": "Wearing eyeglasses exposed against sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that wearing eyeglasses can reduce viral entry through the eyes by acting as a barrier and preventing frequent hand-to-eye contact, thus lowering the risk of SARS-CoV-2 transmission.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9308035373687744,
    "x2e_entail_prob": 0.9913771152496338
  },
  {
    "id": "covid_fact-000677",
    "statement": "Butantan vaccine reaches the final stage",
    "label": "SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that the CoronaVac vaccine, developed by Butantan Institute and Sinovac, has reached its final clinical trial stage, directly supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1803617924451828,
    "x2e_entail_prob": 0.18236859142780304
  },
  {
    "id": "covid_fact-000678",
    "statement": "Butantan vaccine reaches the first stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the Butantan vaccine's clinical trial has reached its final stage, not the first stage as claimed.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.4897269010543823,
    "x2e_entail_prob": 0.25629884004592896
  },
  {
    "id": "covid_fact-000679",
    "statement": "Butantan vaccine reaches the challenge stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the CoronaVac vaccine has reached its final clinical trial stage (Phase 3), supporting the claim that it has reached an advanced or challenge stage.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.31233763694763184,
    "x2e_entail_prob": 0.17908360064029694
  },
  {
    "id": "covid_fact-000680",
    "statement": "Butantan vaccine reaches the second stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the Butantan vaccine has reached its final stage of clinical trials (Phase III), contradicting the claim about reaching the second stage.",
    "confidence": 1,
    "e2x_entail_prob": 0.07562554627656937,
    "x2e_entail_prob": 0.21651820838451385
  },
  {
    "id": "covid_fact-000681",
    "statement": "Adaptive immune responses to sars-cov-2 in recovered severe covid-19 patients.",
    "label": "SUPPORTED",
    "evidences": [
      "Sequencing and functional data revealed SARS-CoV-2-specific T-cell immune memory in the convalescent COVID-19 patients.",
      "1 Characterization of T- and B-cell immune repertoires in COVID-19 convalescent patients.",
      "Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.",
      "Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients.",
      "Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides multiple studies confirming SARS-CoV-2-specific T-cell and humoral immunity in convalescent COVID-19 patients, directly supporting the claim of adaptive immune responses.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.03415714576840401,
    "x2e_entail_prob": 0.5675316452980042
  },
  {
    "id": "covid_fact-000682",
    "statement": "No immune responses to sars-cov-2 in recovered severe covid-19 patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Sequencing and functional data revealed SARS-CoV-2-specific T-cell immune memory in the convalescent COVID-19 patients.",
      "1 Characterization of T- and B-cell immune repertoires in COVID-19 convalescent patients.",
      "Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.",
      "Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients.",
      "Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly demonstrates the presence of SARS-CoV-2-specific T-cell and B-cell immune responses in recovered patients, contradicting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.09052363783121109,
    "x2e_entail_prob": 0.5412982106208801
  },
  {
    "id": "covid_fact-000683",
    "statement": "Estimated sars-cov-2 seroprevalence in the us",
    "label": "SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is specific to a subset of patients in Los Angeles and does not represent the entire US population, making it insufficient to support the claim about national seroprevalence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.006721614394336939,
    "x2e_entail_prob": 0.008716264739632607
  },
  {
    "id": "covid_fact-000684",
    "statement": "Estimated pcvs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided focuses on a specific medical center in Los Angeles and does not provide data or estimates for the entire US.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.056866604834795,
    "x2e_entail_prob": 0.01865217462182045
  },
  {
    "id": "covid_fact-000685",
    "statement": "Estimated cpvs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence is specific to a Los Angeles medical center in March 2020 and does not provide data representative of the entire US population or other regions.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.01902729831635952,
    "x2e_entail_prob": 0.021469587460160255
  },
  {
    "id": "covid_fact-000686",
    "statement": "Estimated xs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides data on a specific group in Los Angeles and cannot represent the entire US population.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.03106670454144478,
    "x2e_entail_prob": 0.011088515631854534
  },
  {
    "id": "covid_fact-000687",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination reduces shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports each part of the claim, confirming that intranasal ChAdOx1 nCoV-19 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques.",
    "confidence": 1,
    "e2x_entail_prob": 0.0599617138504982,
    "x2e_entail_prob": 0.011624454520642757
  },
  {
    "id": "covid_fact-000688",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination increased shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that intranasal vaccination reduced shedding in two animal models. This directly contradicts the claim that the vaccination increased shedding.",
    "confidence": 1,
    "e2x_entail_prob": 0.04781869053840637,
    "x2e_entail_prob": 0.004775640554726124
  },
  {
    "id": "covid_fact-000689",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination enhanced shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that intranasal vaccination reduced shedding, which contradicts the claim of enhanced shedding.",
    "confidence": 1,
    "e2x_entail_prob": 0.025044508278369904,
    "x2e_entail_prob": 0.04500898718833923
  },
  {
    "id": "covid_fact-000690",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination caused shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that intranasal vaccination reduced shedding, contradicting the claim that it caused shedding.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.38727259635925293,
    "x2e_entail_prob": 0.03756048157811165
  },
  {
    "id": "covid_fact-000691",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-free sars-cov-2 rt-qpcr",
    "label": "SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that extraction-free SARS-CoV-2 RT-PCR can increase testing capacity and feasibility for massive and rapid COVID-19 testing during a pandemic.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.131123885512352,
    "x2e_entail_prob": 0.7363654375076294
  },
  {
    "id": "covid_fact-000692",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-specific sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports massive and rapid COVID-19 testing via extraction-free RT-PCR, not extraction-specific as claimed. The term 'extraction-specific' contradicts the evidence which emphasizes extraction-free methods.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6517738103866577,
    "x2e_entail_prob": 0.006237767171114683
  },
  {
    "id": "covid_fact-000693",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-based sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence specifically mentions extraction-free SARS-CoV-2 RT-PCR as feasible for massive and rapid testing, contradicting the claim's reference to extraction-based methods.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.009508681483566761,
    "x2e_entail_prob": 0.03863459825515747
  },
  {
    "id": "covid_fact-000694",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-2 sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly supports the claim by stating that extraction-free SARS-CoV-2 RT-PCR enables massive and rapid COVID-19 testing, which aligns with the assertion in the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.21753156185150146,
    "x2e_entail_prob": 0.011021831072866917
  },
  {
    "id": "covid_fact-000695",
    "statement": "Dutch scientists find new role for ace2 receptors in covid disease process",
    "label": "SUPPORTED",
    "evidences": [
      "(21,22) The protease TMPRSS2 produced by the host cells plays an important role in proteolytic processing of S protein priming to the receptor ACE2 binding in human cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence discusses the role of ACE2 receptors in COVID, it does not mention any findings by Dutch scientists or a new role discovered.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0028527809772640467,
    "x2e_entail_prob": 0.03664657473564148
  },
  {
    "id": "covid_fact-000696",
    "statement": "Dutch models find new role for ace2 receptors in covid disease process",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "(21,22) The protease TMPRSS2 produced by the host cells plays an important role in proteolytic processing of S protein priming to the receptor ACE2 binding in human cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the role of ACE2 receptors in COVID but does not mention Dutch models discovering a new role for them.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.001482022344134748,
    "x2e_entail_prob": 0.03143755719065666
  },
  {
    "id": "covid_fact-000697",
    "statement": "Ohio health official estimates 100,000 people in state have coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that at least 1% of Ohio's population has the virus. With an approximate population of 11.7 million, this translates to about 117,000 people. The claim of 100,000 is close and aligns with the estimate.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.45493757724761963,
    "x2e_entail_prob": 0.27306443452835083
  },
  {
    "id": "covid_fact-000698",
    "statement": "Ohio health official estimates 1,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that at least 1% of Ohio's population has the virus but does not provide a specific number like 1,000. Without knowing the total population used for this percentage, we cannot confirm if 1% equals 1,000 people.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.23002393543720245,
    "x2e_entail_prob": 0.1785188913345337
  },
  {
    "id": "covid_fact-000699",
    "statement": "Ohio health official estimates 2,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Ohio's health official estimated at least 1% of the population has coronavirus, which translates to over 100,000 people, not 2,000 as stated in the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.00699628284201026,
    "x2e_entail_prob": 0.2913736402988434
  },
  {
    "id": "covid_fact-000700",
    "statement": "Ohio health official estimates 15,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states an estimate of 15,000 people in Ohio having coronavirus based on a health official's 1% estimate. However, without the exact population figure used for this percentage, we can't verify if 1% equates to 15,000, leading to uncertainty about the accuracy of the specific number.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.017504282295703888,
    "x2e_entail_prob": 0.17429175972938538
  },
  {
    "id": "covid_fact-000701",
    "statement": "Google releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Google released COVID-19 Community Mobility Reports to show local movement trends during the pandemic, in response to feedback from public health officials.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.06292952597141266,
    "x2e_entail_prob": 0.006312245037406683
  },
  {
    "id": "covid_fact-000702",
    "statement": "Who releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Google released the COVID-19 Community Mobility Reports in response to public health feedback. These reports provide local movement trends during the pandemic, confirming the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.03185253590345383,
    "x2e_entail_prob": 0.004365176893770695
  },
  {
    "id": "covid_fact-000703",
    "statement": "China releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Google, not China, released COVID-19 Community Mobility Reports. The reports are part of an initiative by Google to assist public health officials, which contradicts the claim attributing them to China.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.2658556401729584,
    "x2e_entail_prob": 0.003633020678535104
  },
  {
    "id": "covid_fact-000704",
    "statement": "Exhaled aerosol increases with covid-19 infection , and risk factors of disease symptom severity",
    "label": "SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that exhaled aerosol increases with COVID-19 infection and factors like aging and high BMI. However, it doesn't explicitly link these factors to disease symptom severity.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.001709966454654932,
    "x2e_entail_prob": 0.0051093194633722305
  },
  {
    "id": "covid_fact-000705",
    "statement": "Acute aerosol increases with covid-19 infection, and risk factors of disease symptom severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported as the evidence shows that COVID-19 infection increases exhaled aerosols, and risk factors like aging and high BMI are linked to higher aerosol levels. While the evidence doesn't directly tie these factors to symptom severity, it's inferred from known associations.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.006355443503707647,
    "x2e_entail_prob": 0.01075189933180809
  },
  {
    "id": "covid_fact-000706",
    "statement": "Chronic aerosol increases with covid-19 infection, and risk factors of disease symptom severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that COVID-19 infection increases exhaled aerosols and identifies aging, high BMI as factors affecting these particles. While it connects these to disease risk, the link to symptom severity isn't explicitly stated but is a reasonable inference.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0013410671381279826,
    "x2e_entail_prob": 0.004447492770850658
  },
  {
    "id": "covid_fact-000707",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year , ignoring pandemic warning signs",
    "label": "SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that U.S. manufacturers shipped millions of dollars' worth of face masks to China in January and February, which aligns with the first part of the claim. Additionally, the evidence indicates that pandemic warning signs were ignored, as shown by China's silence on the crisis and the efforts to acquire PPE supplies despite downplayed risks.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.41560328006744385,
    "x2e_entail_prob": 0.0024463303852826357
  },
  {
    "id": "covid_fact-000708",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, for pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that U.S. manufacturers shipped millions of dollars' worth of face masks to China in January and February, which aligns with the claim about sending significant amounts early this year despite pandemic warning signs.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6258350014686584,
    "x2e_entail_prob": 0.0030754997860640287
  },
  {
    "id": "covid_fact-000709",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, following pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that U.S. manufacturers sent millions of dollars' worth of face masks to China in January and February 2020, despite early warnings of the pandemic.",
    "confidence": 1,
    "e2x_entail_prob": 0.3745223879814148,
    "x2e_entail_prob": 0.004364879336208105
  },
  {
    "id": "covid_fact-000710",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, under pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly confirms that U.S. manufacturers shipped millions of dollars' worth of face masks to China in January and February, under pandemic warning signs.",
    "confidence": 1,
    "e2x_entail_prob": 0.528648853302002,
    "x2e_entail_prob": 0.0035574613139033318
  },
  {
    "id": "covid_fact-000711",
    "statement": "Fox news falls out of love with hydroxychloroquine",
    "label": "SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that Fox News has fallen out of love with hydroxychloroquine, which matches the claim exactly.",
    "confidence": 1,
    "e2x_entail_prob": 0.07287007570266724,
    "x2e_entail_prob": 0.9895227551460266
  },
  {
    "id": "covid_fact-000712",
    "statement": "Fox news falls out of patients with hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that Fox News has fallen out of love with hydroxychloroquine.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.041479066014289856,
    "x2e_entail_prob": 0.99024897813797
  },
  {
    "id": "covid_fact-000713",
    "statement": "Fox news falls out of contacts with hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that Fox News has 'fallen out of love' with hydroxychloroquine, which supports the claim that they have distanced themselves from it.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.00829280074685812,
    "x2e_entail_prob": 0.9929301142692566
  },
  {
    "id": "covid_fact-000714",
    "statement": "Autopsies show varied forms of heart damage in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim by showing elevated troponin levels, cardiovascular damage in non-previously affected individuals, and macrophage-related inflammation in heart tissues of COVID-19 patients.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.6125558614730835,
    "x2e_entail_prob": 0.0017330764094367623
  },
  {
    "id": "covid_fact-000715",
    "statement": "Autopsies show common forms of heart damage in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that autopsies of COVID-19 patients frequently show heart damage, with elevated troponin levels, observed cardiovascular issues, and macrophage inflammation in the hearts of many patients.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.5694898962974548,
    "x2e_entail_prob": 0.0018835352966561913
  },
  {
    "id": "covid_fact-000716",
    "statement": "Autopsies show typical forms of heart damage in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that COVID-19 patients experienced heart damage, as shown by elevated troponin levels and inflammation in heart tissue post-mortem. While the term 'autopsies' isn't explicitly used, the findings strongly suggest heart damage in these patients.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.08377145230770111,
    "x2e_entail_prob": 0.0014777065953239799
  },
  {
    "id": "covid_fact-000717",
    "statement": "Genomic study points to natural origin of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from genomic studies indicates that COVID-19 originated naturally, as shown by the spike protein adaptations and genome similarity to a bat coronavirus.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9773597121238708,
    "x2e_entail_prob": 0.1503460854291916
  },
  {
    "id": "covid_fact-000718",
    "statement": "Genomic study points to human origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the coronavirus causing COVID-19 originated in nature and is closely related to a bat coronavirus, contradicting the claim of human origin.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.077708400785923,
    "x2e_entail_prob": 0.005540786776691675
  },
  {
    "id": "covid_fact-000719",
    "statement": "Genomic study points to recent origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that COVID-19 originated in nature and shares similarities with a bat coronavirus, suggesting a recent emergence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.06290601938962936,
    "x2e_entail_prob": 0.006076985504478216
  },
  {
    "id": "covid_fact-000720",
    "statement": "Genomic study points to geographic origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses genomic data showing the virus likely originated in nature and is related to a bat coronavirus, but it does not specify a geographic origin.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.01617196388542652,
    "x2e_entail_prob": 0.0030546842608600855
  },
  {
    "id": "covid_fact-000721",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the recovery trial",
    "label": "SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that colchicine is being investigated in the RECOVERY trial for its potential as a COVID-19 treatment, which directly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.030173037201166153,
    "x2e_entail_prob": 0.017002150416374207
  },
  {
    "id": "covid_fact-000722",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the icu trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that colchicine is being tested in the RECOVERY trial as a potential COVID-19 treatment. While it doesn't explicitly mention 'icu trial,' the context of severe consequences and large-scale recruitment suggests it includes ICU patients.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.23507007956504822,
    "x2e_entail_prob": 0.029769325628876686
  },
  {
    "id": "covid_fact-000723",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the present trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that colchicine is being investigated in the RECOVERY trial for its potential benefits against severe COVID-19 outcomes.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.22092173993587494,
    "x2e_entail_prob": 0.20324647426605225
  },
  {
    "id": "covid_fact-000724",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the patient trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that colchicine is included in the RECOVERY trial to investigate its effectiveness against COVID-19. The trial involves a significant number of patients, supporting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.2560277581214905,
    "x2e_entail_prob": 0.10880861431360245
  },
  {
    "id": "covid_fact-000725",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in mice and nonhuman primates",
    "label": "SUPPORTED",
    "evidences": [
      "These data suggest that a 250-\u03bcg prime-only dose or a 50-\u03bcg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that an alphavirus-derived replicon RNA vaccine induces neutralizing antibodies in nonhuman primates but does not mention T cell responses or mice.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.005900125950574875,
    "x2e_entail_prob": 0.0028456600848585367
  },
  {
    "id": "covid_fact-000726",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in humans and nonhuman primates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest that a 250-\u03bcg prime-only dose or a 50-\u03bcg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that the vaccine induces neutralizing antibodies in nonhuman primates but does not mention T cell responses or human studies.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0015975355636328459,
    "x2e_entail_prob": 0.0019022207707166672
  },
  {
    "id": "covid_fact-000727",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in human and nonhuman primates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest that a 250-\u03bcg prime-only dose or a 50-\u03bcg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that the vaccine induces neutralizing antibodies in nonhuman primates but does not mention human trials or T cell responses.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.001512042828835547,
    "x2e_entail_prob": 0.0019287802278995514
  },
  {
    "id": "covid_fact-000728",
    "statement": "Coronavirus antibodies fall dramatically in first 3 months after mild cases of covid-19 according to new ucla study .",
    "label": "SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim that antibodies fall dramatically in the first three months after mild COVID-19, as shown by the UCLA study.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8379681706428528,
    "x2e_entail_prob": 0.0667797327041626
  },
  {
    "id": "covid_fact-000729",
    "statement": "Coronavirus antibodies increased dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows a decrease in antibodies, contradicting the claim of an increase.",
    "confidence": 1,
    "e2x_entail_prob": 0.007146559190005064,
    "x2e_entail_prob": 0.00279348436743021
  },
  {
    "id": "covid_fact-000730",
    "statement": "Coronavirus antibodies increase dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that antibodies drop sharply over the first three months after mild COVID-19 cases, contradicting the claim of a dramatic increase.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0035930147860199213,
    "x2e_entail_prob": 0.0018395280931144953
  },
  {
    "id": "covid_fact-000731",
    "statement": "Coronavirus antibodies peaked dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a sharp decline in antibodies but does not mention a peak occurring before this decline, which is crucial for supporting the claim about peaking.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0007001004414632916,
    "x2e_entail_prob": 0.00334649789147079
  },
  {
    "id": "covid_fact-000732",
    "statement": "Coronavirus fears have led to a golden age of hand-washing psas",
    "label": "SUPPORTED",
    "evidences": [
      "His Chaplinesque performance infuses high art and physical comedy into the subject of hygiene.",
      "Some are extremely winning, like the hand-washing dance created by Vietnamese choreographer Quang \u0110\u0103ng.",
      "Because the coronavirus is a global concern, video PSAs are emerging from all corners of the globe, all at once."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions video PSAs emerging globally due to coronavirus fears and provides an example of a hand-washing dance, supporting the claim of a golden age in such campaigns.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.33376720547676086,
    "x2e_entail_prob": 0.006678758189082146
  },
  {
    "id": "covid_fact-000733",
    "statement": "Coronavirus fears have led to a golden loss of hand-washing psas",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "His Chaplinesque performance infuses high art and physical comedy into the subject of hygiene.",
      "Some are extremely winning, like the hand-washing dance created by Vietnamese choreographer Quang \u0110\u0103ng.",
      "Because the coronavirus is a global concern, video PSAs are emerging from all corners of the globe, all at once."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates a surge in video PSAs related to hand-washing as a response to global coronavirus concerns, supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.3363891839981079,
    "x2e_entail_prob": 0.002570952055975795
  },
  {
    "id": "covid_fact-000734",
    "statement": "A human neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms the existence of a human monoclonal antibody that blocks SARS-CoV-2 infection but does not specify that it targets the receptor binding site.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0035455909091979265,
    "x2e_entail_prob": 0.9810488224029541
  },
  {
    "id": "covid_fact-000735",
    "statement": "A rabbit neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim specifies a rabbit neutralizing antibody targeting the receptor binding site, but the evidence only refers to a human monoclonal antibody without mentioning rabbits or the target site.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.004653773736208677,
    "x2e_entail_prob": 0.01692189648747444
  },
  {
    "id": "covid_fact-000736",
    "statement": "A mouse neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a human monoclonal antibody that blocks SARS-CoV-2 infection but does not specify that it targets the receptor binding site. Additionally, the claim refers to a mouse-derived antibody, which is not mentioned in the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.002623717999085784,
    "x2e_entail_prob": 0.961427628993988
  },
  {
    "id": "covid_fact-000737",
    "statement": "A human neutralizing antibody targets the peptide binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a human monoclonal antibody blocks SARS-CoV-2 infection, suggesting it likely targets the peptide binding site. While not explicitly stated, such antibodies typically target critical regions like the RBD.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.014990409836173058,
    "x2e_entail_prob": 0.9819117784500122
  },
  {
    "id": "covid_fact-000738",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a human brain organoid model",
    "label": "SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that SARS-CoV-2 infects human brain organoids and causes metabolic changes, confirming its neuroinvasive potential.",
    "confidence": 1,
    "e2x_entail_prob": 0.03578374534845352,
    "x2e_entail_prob": 0.09169921278953552
  },
  {
    "id": "covid_fact-000739",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a canine brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses human brain organoids infected with SARS-CoV-2, not canine models, thus does not support the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0022983206436038017,
    "x2e_entail_prob": 0.004495792090892792
  },
  {
    "id": "covid_fact-000740",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a rat brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses human brain organoids, not rat models, so it doesn't support the claim about rats.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0011080177500844002,
    "x2e_entail_prob": 0.0009453222737647593
  },
  {
    "id": "covid_fact-000741",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a mouse brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses infection in human brain organoids but does not mention mouse models or neuroinvasive potential in mice.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0016078668413683772,
    "x2e_entail_prob": 0.002360662678256631
  },
  {
    "id": "covid_fact-000742",
    "statement": "Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses a study focused solely on SARS-CoV-2, using techniques like RNAi and CRISPR to identify host factors involved in infection. However, the claim involves comparative analysis across different coronaviruses to uncover pan-viral mechanisms. The provided evidence does not include data or discussion about other coronaviruses, making it insufficient to support the comparative aspect of the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.08766967058181763,
    "x2e_entail_prob": 0.003772566793486476
  },
  {
    "id": "covid_fact-000743",
    "statement": "Comparative anti-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses studies on SARS-CoV-2 interactions but does not mention comparative analysis across multiple coronaviruses or other viruses to identify pan-viral mechanisms.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0018897241679951549,
    "x2e_entail_prob": 0.0024742321111261845
  },
  {
    "id": "covid_fact-000744",
    "statement": "Comparative non-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses functional connections in SARS-CoV-2 infection but does not provide information on comparative non-coronavirus networks or pan-viral mechanisms.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.002344149397686124,
    "x2e_entail_prob": 0.0025490231346338987
  },
  {
    "id": "covid_fact-000745",
    "statement": "Comparative beta-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses interactions with SARS-CoV-2 but does not provide information on other beta-coronaviruses, making it impossible to confirm pan-viral mechanisms.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.0021420842967927456,
    "x2e_entail_prob": 0.0028320602141320705
  },
  {
    "id": "covid_fact-000746",
    "statement": "Covid vaccine needs horseshoe crab blood but the ecosystem may suffer",
    "label": "SUPPORTED",
    "evidences": [
      "He said horseshoe crabs are vital in the process to find a coronavirus vaccine because their immune system is the most sensitive in the world.",
      "But she and other conservationists fear that without rFC or other alternatives available, the ongoing burden on horseshoe crab blood for COVID-19 vaccines and related therapeutics may imperil the crabs and the marine ecosystems that depend on them."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that horseshoe crab blood is crucial for Covid vaccine production and highlights conservationists' concerns about ecological impacts from this reliance.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8745121359825134,
    "x2e_entail_prob": 0.0011729247635230422
  },
  {
    "id": "covid_fact-000747",
    "statement": "Covid vaccine needs horseshoe crab blood but the ecosystem may benefit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He said horseshoe crabs are vital in the process to find a coronavirus vaccine because their immune system is the most sensitive in the world.",
      "But she and other conservationists fear that without rFC or other alternatives available, the ongoing burden on horseshoe crab blood for COVID-19 vaccines and related therapeutics may imperil the crabs and the marine ecosystems that depend on them."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence confirms that horseshoe crab blood is essential for Covid vaccine development, it also indicates concerns about potential harm to the ecosystem and horseshoe crab populations if alternatives aren't used. The claim's suggestion of an ecological benefit isn't supported by the evidence provided.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.8682451844215393,
    "x2e_entail_prob": 0.001031131367199123
  },
  {
    "id": "covid_fact-000748",
    "statement": "Breakthrough needle-less vaccine could help in mass distribution",
    "label": "SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses cost-effective production of films for vaccines but does not mention a needle-less vaccine or its impact on mass distribution.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.00145813450217247,
    "x2e_entail_prob": 0.000874649325851351
  },
  {
    "id": "covid_fact-000749",
    "statement": "Breakthrough needle-specific vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports the idea that making vaccines more affordable could aid in mass distribution, but it does not specifically address or confirm that this relates to a 'needle-specific' vaccine.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.003939872607588768,
    "x2e_entail_prob": 0.0008675752324052155
  },
  {
    "id": "covid_fact-000750",
    "statement": "Breakthrough needle-driven vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses cost-effectiveness due to inexpensive ingredients and a simple process but does not mention needle-free technology or its impact on mass distribution.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0009175426093861461,
    "x2e_entail_prob": 0.005229645408689976
  },
  {
    "id": "covid_fact-000751",
    "statement": "Breakthrough needle-coated vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions cost-effective ingredients and a simple process making vaccine campaigns affordable but doesn't explicitly link these factors to a needle-coated vaccine breakthrough or mass distribution.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.002103201812133193,
    "x2e_entail_prob": 0.11322778463363647
  },
  {
    "id": "covid_fact-000752",
    "statement": "Recovery of monocyte exhaustion is associated with resolution of lung injury in covid-19 convalescence .",
    "label": "SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that monocyte function changes during COVID-19 recovery and that targeting them might aid in therapy. However, the direct association between monocyte exhaustion recovery and lung injury resolution isn't clearly established due to incomplete information.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0075158230029046535,
    "x2e_entail_prob": 0.1115885004401207
  },
  {
    "id": "covid_fact-000753",
    "statement": "Recovery of monocyte exhaustion is associated without resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 convalescence, which directly contradicts the claim that it occurs without such resolution.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.005829440895467997,
    "x2e_entail_prob": 0.010930499993264675
  },
  {
    "id": "covid_fact-000754",
    "statement": "Recovery of monocyte proliferation is associated with resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses monocyte exhaustion and migration, not proliferation. It shows that recovered monocyte function is linked to lung injury resolution but does not support the specific claim about proliferation.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.018511435016989708,
    "x2e_entail_prob": 0.012168456800282001
  },
  {
    "id": "covid_fact-000755",
    "statement": "Recovery of monocyte activation is associated with resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that recovery of monocyte exhaustion is associated with resolving lung injury in COVID-19 convalescence, supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9124946594238281,
    "x2e_entail_prob": 0.006463616620749235
  },
  {
    "id": "covid_fact-000756",
    "statement": "Imperial college mrna vaccine technology could protect against future pandemics",
    "label": "SUPPORTED",
    "evidences": [
      "If our approach works and the vaccine provides effective protection against disease, it could revolutionise how we respond to disease outbreaks in future.\"",
      "If these trials are successful a vaccine will not only help us tackle coronavirus but also emerging diseases now and into the future.\"",
      "Now scientists say the technology, a slow-motion revolution in the making since the discovery of mRNA nearly 60 years ago, could speed up the development of new vaccines.",
      "It will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Imperial College's mRNA technology can accelerate vaccine development and effectively respond to future disease outbreaks, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.012505967170000076,
    "x2e_entail_prob": 0.3983561098575592
  },
  {
    "id": "covid_fact-000757",
    "statement": "Imperial college mrna vaccine technology cannot protect against future pandemics",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If our approach works and the vaccine provides effective protection against disease, it could revolutionise how we respond to disease outbreaks in future.\"",
      "If these trials are successful a vaccine will not only help us tackle coronavirus but also emerging diseases now and into the future.\"",
      "Now scientists say the technology, a slow-motion revolution in the making since the discovery of mRNA nearly 60 years ago, could speed up the development of new vaccines.",
      "It will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Imperial College's mRNA vaccine technology has the potential to protect against future pandemics by enabling faster responses to emerging diseases and revolutionizing vaccine development. The claim contradicts this, hence it is not supported.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.006422131322324276,
    "x2e_entail_prob": 0.21120265126228333
  },
  {
    "id": "covid_fact-000758",
    "statement": "Dr. fauci predicts drugmakers will likely produce 1 billion covid-19 vaccines by the end of 2021",
    "label": "SUPPORTED",
    "evidences": [
      "But as we get into 2021, the manufacturers tell us that they will have hundreds of millions and likely a billion doses by the end of 2021,\" Fauci said in an interview with Reuters.",
      "Drugmakers will likely have produced a billion doses of a COVID-19 vaccine by the end of next year, Dr. Anthony Fauci, the United States' top infectious disease official, said Wednesday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Dr. Anthony Fauci stated that drugmakers are expected to produce a billion doses of COVID-19 vaccines by the end of 2021, which aligns with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7589817643165588,
    "x2e_entail_prob": 0.007743048015981913
  },
  {
    "id": "covid_fact-000759",
    "statement": "Dr. fauci predicts drugmakers will not produce 1 billion covid-19 vaccines by the end of 2021",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "But as we get into 2021, the manufacturers tell us that they will have hundreds of millions and likely a billion doses by the end of 2021,\" Fauci said in an interview with Reuters.",
      "Drugmakers will likely have produced a billion doses of a COVID-19 vaccine by the end of next year, Dr. Anthony Fauci, the United States' top infectious disease official, said Wednesday."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "Dr. Fauci explicitly stated that drugmakers will likely produce a billion doses of COVID-19 vaccines by the end of 2021, directly contradicting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.03503912314772606,
    "x2e_entail_prob": 0.011749702505767345
  },
  {
    "id": "covid_fact-000760",
    "statement": "White house 's opening up america again guidelines",
    "label": "SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly mentions the White House's 'Opening Up America Again' guidelines, detailing their purpose to ease stay-at-home restrictions and outlining three phases for reopening. The claim is fully supported.",
    "confidence": 1,
    "e2x_entail_prob": 0.01842961087822914,
    "x2e_entail_prob": 0.029374342411756516
  },
  {
    "id": "covid_fact-000761",
    "statement": "Each house's opening up america again guidelines",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the White House's 'Opening Up America Again' guidelines aimed at states and regions, not individual houses. It does not mention each house having its own set of guidelines.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.02576969377696514,
    "x2e_entail_prob": 0.008549649268388748
  },
  {
    "id": "covid_fact-000762",
    "statement": "Any house's opening up america again guidelines",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly mentions the 'Opening Up America Again' guidelines from the White House, detailing their purpose and structure.",
    "confidence": 1,
    "e2x_entail_prob": 0.010373584926128387,
    "x2e_entail_prob": 0.007914777845144272
  },
  {
    "id": "covid_fact-000763",
    "statement": "Scientists are turning to existing drugs to combat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that scientists are repurposing existing drugs to combat COVID-19, specifically mentioning protease inhibitors like ritonavir and lopinavir originally used for HIV.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.807969868183136,
    "x2e_entail_prob": 0.0025166997220367193
  },
  {
    "id": "covid_fact-000764",
    "statement": "Scientists are turning to new drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes the repurposing of existing drugs, not the creation of entirely new ones, which doesn't fully support the claim about new drugs.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.009281422011554241,
    "x2e_entail_prob": 0.000973486399743706
  },
  {
    "id": "covid_fact-000765",
    "statement": "Scientists are turning to developing drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that scientists are developing drugs to combat COVID-19, while the evidence discusses repurposing existing drugs for this purpose. Although not identical, both focus on using drug-based solutions against the virus.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.29405927658081055,
    "x2e_entail_prob": 0.0013627320295199752
  },
  {
    "id": "covid_fact-000766",
    "statement": "Scientists are turning to develop drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that scientists are indeed working on developing treatments for COVID-19 by repurposing existing drugs. While the term 'develop' in the claim could imply creating new drugs, the process of repurposing is a valid form of drug development tailored for COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.3730860650539398,
    "x2e_entail_prob": 0.0017589597264304757
  },
  {
    "id": "covid_fact-000767",
    "statement": "Indomethacin has a potent antiviral activity against sars coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions: The results identify INDO as a potent inhibitor of coronavirus replication and suggest that, having both anti-inflammatory and antiviral activity, INDO could be beneficial in SARS therapy.",
      "Results: Unexpectedly, we found that INDO has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that Indomethacin (INDO) has potent antiviral activity against SARS-CoV, confirming its effectiveness as an inhibitor of coronavirus replication.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.948060154914856,
    "x2e_entail_prob": 0.0824974924325943
  },
  {
    "id": "covid_fact-000768",
    "statement": "Indomethacin has a weak antiviral activity against sars coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions: The results identify INDO as a potent inhibitor of coronavirus replication and suggest that, having both anti-inflammatory and antiviral activity, INDO could be beneficial in SARS therapy.",
      "Results: Unexpectedly, we found that INDO has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that indomethacin has a potent antiviral activity against SARS-CoV, contradicting the claim of weak activity.",
    "confidence": 1,
    "e2x_entail_prob": 0.08062191307544708,
    "x2e_entail_prob": 0.2110956758260727
  },
  {
    "id": "covid_fact-000769",
    "statement": "Coronavirus inflicts a short , sharp recession on global economy - cre herald",
    "label": "SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a sharp decline in global GDP during Q1 and projected decline in Q2 of 2020, supporting the 'sharp' aspect of the claim. However, without information on recovery duration, the 'short' part is less certain but contextually plausible.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.00803045742213726,
    "x2e_entail_prob": 0.00439549470320344
  },
  {
    "id": "covid_fact-000770",
    "statement": "Coronavirus inflicts a world, sharp recession on global economy - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a sharp contraction in global GDP due to Coronavirus, with Q1 and Q2 contractions exceeding those of the financial crisis.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0016072294674813747,
    "x2e_entail_prob": 0.004626589361578226
  },
  {
    "id": "covid_fact-000771",
    "statement": "Coronavirus inflicts a pandemic, sharp recession on global economy - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that there was an economic contraction and recession in early 2020, but it does not explicitly establish that this was directly caused by the Coronavirus pandemic.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0020757850725203753,
    "x2e_entail_prob": 0.0023125088773667812
  },
  {
    "id": "covid_fact-000772",
    "statement": "Coronavirus inflicts a short, sharp recession on global health - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses economic contraction due to COVID-19 but does not address the impact on global health.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0027078292332589626,
    "x2e_entail_prob": 0.005894618108868599
  },
  {
    "id": "covid_fact-000773",
    "statement": "Onerace , the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19 .",
    "label": "SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention Onerace or any Sydney research team launching a crowdfunding campaign for COVID-19. Instead, it discusses a GoFundMe campaign related to building a border wall and general news about the pandemic.",
    "confidence": 1,
    "e2x_entail_prob": 0.009418527595698833,
    "x2e_entail_prob": 0.04077642783522606
  },
  {
    "id": "covid_fact-000774",
    "statement": "Onerace, the sydney training team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention Onerace, a Sydney training team, or any crowdfunding campaign related to COVID-19. It discusses unrelated topics such as a border wall and other news items.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.005594198126345873,
    "x2e_entail_prob": 0.030470488592982292
  },
  {
    "id": "covid_fact-000775",
    "statement": "Irace, the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not mention Irace, the Sydney research team, or any crowdfunding campaign related to COVID-19. It discusses a different initiative involving border wall construction.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.01550781074911356,
    "x2e_entail_prob": 0.057119980454444885
  },
  {
    "id": "covid_fact-000776",
    "statement": "Rerace, the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not contain any information about Rerace, a Sydney research team launching a crowdfunding campaign related to COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.005074142478406429,
    "x2e_entail_prob": 0.12052826583385468
  },
  {
    "id": "covid_fact-000777",
    "statement": "Mva vector vaccines inhibit sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that MVA vector vaccines inhibited SARS-CoV-2 replication in both upper and lower respiratory tracts of transgenic mice and prevented severe disease, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8216844201087952,
    "x2e_entail_prob": 0.760418713092804
  },
  {
    "id": "covid_fact-000778",
    "statement": "Mva vector vaccines promote sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence demonstrates that MVA vector vaccines inhibit SARS-CoV-2 replication in transgenic mice, which contradicts the claim that they promote it.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0030008794274181128,
    "x2e_entail_prob": 0.20077937841415405
  },
  {
    "id": "covid_fact-000779",
    "statement": "Mva vector vaccines enhance sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that MVA vector vaccines inhibit SARS-CoV-2 replication and prevent lethal disease in transgenic mice, contradicting the claim that they enhance replication.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.007896536961197853,
    "x2e_entail_prob": 0.3063773214817047
  },
  {
    "id": "covid_fact-000780",
    "statement": "Mva vector vaccines induce sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly shows that MVA vector vaccines prevent SARS-CoV-2 replication in transgenic mice and prevent lethal disease, contradicting the claim which states they 'induce' replication.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.013363118283450603,
    "x2e_entail_prob": 0.3326209783554077
  },
  {
    "id": "covid_fact-000781",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to block stat nuclear import and antagonize interferon signaling",
    "label": "SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Sars-cov-2 orf6 interacts with Nup98, blocking STAT nuclear import and antagonizing interferon signaling.",
    "confidence": 1,
    "e2x_entail_prob": 0.7865124344825745,
    "x2e_entail_prob": 0.8230141401290894
  },
  {
    "id": "covid_fact-000782",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to promote stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence supports that SARS-CoV-2 ORF6 interacts with NUP98 to disrupt STAT nuclear translocation and interfere with interferon signaling, the claim incorrectly states that ORF6 promotes STAT nuclear import. This contradiction undermines the claim's accuracy.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.007756671868264675,
    "x2e_entail_prob": 0.7029563188552856
  },
  {
    "id": "covid_fact-000783",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to facilitate stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that ORF6 interacts with NUP98 and blocks STAT nuclear translocation, thereby antagonizing interferon signaling. However, the claim incorrectly states that ORF6 facilitates STAT nuclear import, which contradicts the evidence showing it blocks this process.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.00439884327352047,
    "x2e_entail_prob": 0.7155192494392395
  },
  {
    "id": "covid_fact-000784",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to induce stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 Orf6 interacts with Nup98 to block STAT nuclear translocation and disrupt interferon signaling, but it does not support the claim that this interaction induces STAT nuclear import.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.00469044828787446,
    "x2e_entail_prob": 0.7960888743400574
  },
  {
    "id": "covid_fact-000785",
    "statement": "Patients are coming in too late for treatment .",
    "label": "SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explains that late diagnosis can occur due to patient delay or misjudgment by doctors, both contributing factors to patients coming in too late for treatment.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1729462444782257,
    "x2e_entail_prob": 0.001957386266440153
  },
  {
    "id": "covid_fact-000786",
    "statement": "Patients are coming in too short for treatment.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention anything about patients' height being an issue for treatment but instead focuses on delayed diagnosis and misjudgment.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0023502521216869354,
    "x2e_entail_prob": 0.006937534548342228
  },
  {
    "id": "covid_fact-000787",
    "statement": "Patients are coming in too time for treatment.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses late diagnosis due to delays in seeking treatment or misjudgment of symptoms but does not mention patients coming at an inappropriate time for treatment.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0022803882602602243,
    "x2e_entail_prob": 0.005257682409137487
  },
  {
    "id": "covid_fact-000788",
    "statement": "Irish-developed kit that confirms covid-19 infection in 15 minutes could be released in seven days",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: PA Laura Lynott March 16 2020 02:30 AM Facebook Twitter Email An Irish company is preparing to release rapid Covid-19 testing kits, which can provide results in 15 minutes and potentially act as a \"clinical weapon\" against coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports the part about a rapid Covid-19 testing kit developed in Ireland providing results in 15 minutes but does not confirm that it could be released in seven days.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0013568352442234755,
    "x2e_entail_prob": 0.07806546241044998
  },
  {
    "id": "covid_fact-000789",
    "statement": "Irish-developed kit that confirms covid-19 infection in 15 minutes could be released in seven hours",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: PA Laura Lynott March 16 2020 02:30 AM Facebook Twitter Email An Irish company is preparing to release rapid Covid-19 testing kits, which can provide results in 15 minutes and potentially act as a \"clinical weapon\" against coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms the existence of an Irish-developed Covid-19 testing kit that provides results in 15 minutes but does not mention a seven-hour release timeframe.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.015189525671303272,
    "x2e_entail_prob": 0.0874195545911789
  },
  {
    "id": "covid_fact-000790",
    "statement": "Normally invisible saliva droplets can linger in the air , visualized by researchers using laser technology .",
    "label": "SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that researchers used laser technology to visualize normally invisible saliva droplets from speech. These droplets can linger in the air as aerosols for several minutes, confirming the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.13546474277973175,
    "x2e_entail_prob": 0.00444329809397459
  },
  {
    "id": "covid_fact-000791",
    "statement": "Normally invisible saliva droplets can spread in the air, visualized by researchers using laser technology.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that researchers used laser technology, specifically laser light scattering, to visualize speech-generated droplets which can linger in the air as aerosols.",
    "confidence": 1,
    "e2x_entail_prob": 0.9658777713775635,
    "x2e_entail_prob": 0.002757619135081768
  },
  {
    "id": "covid_fact-000792",
    "statement": "Normally invisible saliva droplets can increase in the air, visualized by researchers using laser technology.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that researchers used laser technology to visualize normally invisible saliva droplets in the air. The studies show these droplets can linger, supporting both aspects of the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.06731729954481125,
    "x2e_entail_prob": 0.0040738508105278015
  },
  {
    "id": "covid_fact-000793",
    "statement": "Sex differences in immune responses to sars-cov-2 that underlie disease outcomes",
    "label": "SUPPORTED",
    "evidences": [
      "In this study, we examined sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.",
      "Conversely, higher innate immune cytokines in female patients associated with worse disease progression, but not in male patients.",
      "In contrast, female patients mounted significantly more robust T cell activation than male patients during SARS-CoV-2 infection, which was sustained in old age."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates sex differences in immune responses to SARS-CoV-2, such as higher cytokines in females linked to worse outcomes and stronger T cell activation in females, which supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5226299166679382,
    "x2e_entail_prob": 0.0032185481395572424
  },
  {
    "id": "covid_fact-000794",
    "statement": "Sex differences in immune responses to sars-cov-2 that underlie protection outcomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this study, we examined sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.",
      "Conversely, higher innate immune cytokines in female patients associated with worse disease progression, but not in male patients.",
      "In contrast, female patients mounted significantly more robust T cell activation than male patients during SARS-CoV-2 infection, which was sustained in old age."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that there are sex differences in immune responses to SARS-CoV-2, including higher innate cytokines in females associated with worse disease progression and stronger T cell activation in females compared to males. These findings indicate that immune response differences underlie protection outcomes.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.37185004353523254,
    "x2e_entail_prob": 0.0030214658472687006
  },
  {
    "id": "covid_fact-000795",
    "statement": "Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and th17 responses",
    "label": "SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal E\u03b1Q11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, \u03b3\u03b4 T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that an adjuvant-free nanofiber vaccine induces TH17 responses in the lung but does not explicitly mention dendritic cell activation. Without confirmation of both aspects, the claim cannot be fully supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.023849457502365112,
    "x2e_entail_prob": 0.027778685092926025
  },
  {
    "id": "covid_fact-000796",
    "statement": "Adjuvant-free nanofiber vaccine knocks in situ lung dendritic cell activation and th17 responses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal E\u03b1Q11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, \u03b3\u03b4 T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that intranasal nanofiber vaccines without adjuvants elicit TH17 responses, supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9358419179916382,
    "x2e_entail_prob": 0.059706538915634155
  },
  {
    "id": "covid_fact-000797",
    "statement": "Adjuvant-free nanofiber vaccine induces in situ memory dendritic cell activation and th17 responses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal E\u03b1Q11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, \u03b3\u03b4 T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses adjuvant-free nanofiber vaccines inducing TH17 responses and CD4+ T cell priming but does not mention memory dendritic cell activation.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.004227155353873968,
    "x2e_entail_prob": 0.0225632656365633
  },
  {
    "id": "covid_fact-000798",
    "statement": "The fda has canceled emergency use of hydroxychloroquine for covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that the FDA revoked the emergency use authorization for hydroxychloroquine and chloroquine, which directly supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.02332351915538311,
    "x2e_entail_prob": 0.000933732429984957
  },
  {
    "id": "covid_fact-000799",
    "statement": "The fda has increased emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows the FDA revoked the emergency use authorization for hydroxychloroquine, not increased it.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.05203348770737648,
    "x2e_entail_prob": 0.0009689240250736475
  },
  {
    "id": "covid_fact-000800",
    "statement": "The fda has potential emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While hydroxychloroquine had an initial potential emergency use authorization by the FDA for COVID-19, it was later revoked due to concerns about effectiveness and safety. The evidence provided clearly states that the FDA revoked the EUA, indicating current opposition to its emergency use.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.018204739317297935,
    "x2e_entail_prob": 0.0009691629675216973
  },
  {
    "id": "covid_fact-000801",
    "statement": "The fda has good emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that the FDA initially allowed emergency use but later revoked it due to lack of efficacy and potential risks, contradicting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.04187438264489174,
    "x2e_entail_prob": 0.0010616203071549535
  },
  {
    "id": "covid_fact-000802",
    "statement": "Antibody testing will enhance the power and accuracy of covid-19-prevention trials",
    "label": "SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that antibody (serological) testing enhances trial outcomes by detecting seroconversion, which improves the understanding of immunity development beyond just infection prevention.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8006808757781982,
    "x2e_entail_prob": 0.007866605184972286
  },
  {
    "id": "covid_fact-000803",
    "statement": "Antibody testing will reduce the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.014588473364710808,
    "x2e_entail_prob": 0.15181678533554077
  },
  {
    "id": "covid_fact-000804",
    "statement": "Antibody testing will limit the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that serological testing can enhance the value of trials by identifying immune responses, contradicting the claim that it limits their power and accuracy.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.45415768027305603,
    "x2e_entail_prob": 0.005663179326802492
  },
  {
    "id": "covid_fact-000805",
    "statement": "Antibody testing will decrease the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that antibody testing can enhance the interpretability and value of trials by providing additional insights into immune responses, thereby contradicting the claim that it decreases power or accuracy.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.046065934002399445,
    "x2e_entail_prob": 0.0043615116737782955
  },
  {
    "id": "covid_fact-000806",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; majority of patients have demonstrated remarkable recoveries",
    "label": "SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions positive responses and impressive results but refers to them as anecdotal, lacking formal clinical data. The claim about remarkable recoveries in the majority isn't explicitly supported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.3903713822364807,
    "x2e_entail_prob": 0.003061512019485235
  },
  {
    "id": "covid_fact-000807",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; none of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports strong results from leronlimab but does not address the lack of remarkable recoveries.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0023104799911379814,
    "x2e_entail_prob": 0.004230117425322533
  },
  {
    "id": "covid_fact-000808",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; few of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that Cytodyn reported strong results from eIND COVID-19 patients treated with leronlimab, with notable recoveries observed. However, the evidence does not specify whether these recoveries are remarkable or provide exact numbers, slightly affecting confidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.011255083605647087,
    "x2e_entail_prob": 0.0026504057459533215
  },
  {
    "id": "covid_fact-000809",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; two of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that Cytodyn reported strong results from eIND COVID-19 patients treated with leronlimab and highlights impressive recoveries, though the exact number of patients is not specified.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.14870479702949524,
    "x2e_entail_prob": 0.002835635794326663
  },
  {
    "id": "covid_fact-000810",
    "statement": "Sars-cov-2 infects brain choroid plexus and disrupts the blood-csf-barrier",
    "label": "SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that SARS-CoV-2 infects choroid plexus epithelial cells expressing ACE2 and leads to barrier breakdown, confirming both aspects of the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8228827118873596,
    "x2e_entail_prob": 0.1291837990283966
  },
  {
    "id": "covid_fact-000811",
    "statement": "Sars-cov-2 infects intestinal choroid plexus and disrupts the blood-csf-barrier",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that SARS-CoV-2 infects choroid plexus epithelial cells and disrupts the blood-cerebrospinal fluid barrier, supporting the claim despite a possible error in referencing 'intestinal.'",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0025665713474154472,
    "x2e_entail_prob": 0.06865686923265457
  },
  {
    "id": "covid_fact-000812",
    "statement": "Sars-cov-2 infects brain choroid plexus and backs the blood-csf-barrier",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that SARS-CoV-2 infects choroid plexus epithelial cells and causes barrier breakdown, supporting the claim about infection and blood-CSF-barrier disruption.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8831994533538818,
    "x2e_entail_prob": 0.14164818823337555
  },
  {
    "id": "covid_fact-000813",
    "statement": "Coronial autopsies identify the indirect effects of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that coronial autopsies helped determine the contributions of COVID-19 and lockdowns to increased deaths from substance misuse, indicating indirect effects of COVID-19.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.5049885511398315,
    "x2e_entail_prob": 0.012938200496137142
  },
  {
    "id": "covid_fact-000814",
    "statement": "Coronial autopsies identify the therapeutic effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses increased mortality related to drug and alcohol misuse during lockdowns and assesses contributions of COVID-19 and lockdown restrictions, but it does not mention any therapeutic effects of COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.004604605492204428,
    "x2e_entail_prob": 0.014488318003714085
  },
  {
    "id": "covid_fact-000815",
    "statement": "Coronial autopsies identify the biological effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that coronial autopsies helped determine the contribution of undiagnosed COVID-19 to deaths, but it does not specifically mention identifying biological effects of COVID-19.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.057713091373443604,
    "x2e_entail_prob": 0.004355801269412041
  },
  {
    "id": "covid_fact-000816",
    "statement": "Coronial autopsies identify the cytotoxic effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the use of autopsy reports to determine the contributions of undiagnosed COVID-19 and lockdown restrictions on deaths but does not mention identifying cytotoxic effects of COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.005616603884845972,
    "x2e_entail_prob": 0.0053611923940479755
  },
  {
    "id": "covid_fact-000817",
    "statement": "3blue1brown provided detailed simulations of an epidemic",
    "label": "SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions an interactive inspired by 3Blue1Brown's video titled 'Simulating an Epidemic,' which suggests they provided epidemic simulations. While the evidence doesn't explicitly state that the simulations were detailed, it is plausible given their reputation for informative content.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.0018276399932801723,
    "x2e_entail_prob": 0.7346754670143127
  },
  {
    "id": "covid_fact-000818",
    "statement": "3blue1brown provided detailed simulations of an algorithm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that 3blue1brown produced a video titled 'Simulating an Epidemic,' which inspired an interactive simulation. This supports the claim that they provided detailed simulations, likely involving algorithms to model epidemic spread.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0019246432930231094,
    "x2e_entail_prob": 0.8582594990730286
  },
  {
    "id": "covid_fact-000819",
    "statement": "3blue1brown provided detailed simulations of an equation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows an epidemic simulation was inspired by 3Blue1Brown's video but does not confirm they provided detailed simulations themselves.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0038974906783550978,
    "x2e_entail_prob": 0.15302501618862152
  },
  {
    "id": "covid_fact-000820",
    "statement": "3blue1brown provided detailed simulations of an alignment",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to simulations of an 'alignment,' but the evidence provided only mentions a simulation related to epidemics, not alignment.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.007512273732572794,
    "x2e_entail_prob": 0.06443513929843903
  },
  {
    "id": "covid_fact-000821",
    "statement": "Delaware medical supplier says fema seized 400,000 n95 masks , now he 's out millions of dollars",
    "label": "SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that FEMA seized mask shipments without payment but does not mention 400,000 N95 masks or a loss of millions.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.013493271544575691,
    "x2e_entail_prob": 0.0010124025866389275
  },
  {
    "id": "covid_fact-000822",
    "statement": "Delaware medical supplier and fema seized 400,000 n95 masks, now he's out millions of dollars",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms FEMA seized masks without payment but does not mention 400,000 masks or millions in losses.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.011098829098045826,
    "x2e_entail_prob": 0.0011509500909596682
  },
  {
    "id": "covid_fact-000823",
    "statement": "Delaware medical supplier with fema seized 400,000 n95 masks, now he's out millions of dollars",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention the specific number of masks (400,000) or the exact financial loss claimed.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0028268867172300816,
    "x2e_entail_prob": 0.0009679856011644006
  },
  {
    "id": "covid_fact-000824",
    "statement": "Fauci predicts us deaths from coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports Fauci's prediction of between 100,000 to 200,000 deaths from coronavirus.",
    "confidence": 1,
    "e2x_entail_prob": 0.02921072207391262,
    "x2e_entail_prob": 0.012242256663739681
  },
  {
    "id": "covid_fact-000825",
    "statement": "Fauci predicts us deaths globally coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to 'global' deaths, while the evidence only mentions U.S. projections.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.013628863729536533,
    "x2e_entail_prob": 0.016827525570988655
  },
  {
    "id": "covid_fact-000826",
    "statement": "Fauci predicts us deaths worldwide coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports Fauci's prediction of deaths in the United States but does not mention worldwide coronavirus deaths.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.004727060906589031,
    "x2e_entail_prob": 0.020138151943683624
  },
  {
    "id": "covid_fact-000827",
    "statement": "Leronlimab used in seven patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu , removed from icu and extubated with reduced pulmonary inflammation",
    "label": "SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses preliminary results of leronlimab improving immune profiles and reducing pulmonary inflammation in COVID-19 patients, which aligns with the claim's promise. However, it doesn't provide specific details about seven NYC patients or two ICU recoveries as mentioned in the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.1872587651014328,
    "x2e_entail_prob": 0.0014490775065496564
  },
  {
    "id": "covid_fact-000828",
    "statement": "Leronlimab used in two patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses general preliminary results of Leronlimab for COVID-19 and its effectiveness in HIV patients but does not specifically mention the case of two NYC ICU patients being extubated and discharged.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.007061839569360018,
    "x2e_entail_prob": 0.0028388011269271374
  },
  {
    "id": "covid_fact-000829",
    "statement": "Leronlimab used in three patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention specific data about three patients in NYC with severe COVID-19 being treated with Leronlimab, resulting in two intubated ICU patients being extubated and removed from the ICU with reduced pulmonary inflammation.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.004714055452495813,
    "x2e_entail_prob": 0.004704108461737633
  },
  {
    "id": "covid_fact-000830",
    "statement": "Leronlimab used in four patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses preliminary results of Leronlimab in COVID-19 patients showing immune profile improvements and reduced cytokines but does not mention four NYC patients or two ICU extubations.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.00570082850754261,
    "x2e_entail_prob": 0.0028954586014151573
  },
  {
    "id": "covid_fact-000831",
    "statement": "Home testing for coronavirus to track levels of infection in the community",
    "label": "SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence discusses home testing kits and their general use, it doesn't specify their application for tracking coronavirus infections in the community.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.0019175363704562187,
    "x2e_entail_prob": 0.0008995383977890015
  },
  {
    "id": "covid_fact-000832",
    "statement": "Laboratory testing for coronavirus to track levels of infection in the community",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports laboratory testing for\u65b0\u51a0\u75c5\u6bd2 using PCR and acknowledges alternative testing methods like home kits, which contribute to tracking infection levels in the community.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.13620010018348694,
    "x2e_entail_prob": 0.0009593594004400074
  },
  {
    "id": "covid_fact-000833",
    "statement": "Studies testing for coronavirus to track levels of infection in the community",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses testing methods (PCR and home kits) but does not reference studies aimed at tracking infection levels in the community.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.003387022763490677,
    "x2e_entail_prob": 0.0008284635841846466
  },
  {
    "id": "covid_fact-000834",
    "statement": "The sars-cov-2-like virus found in captive pangolins from guangdong should be better sequenced .",
    "label": "SUPPORTED",
    "evidences": [
      "bioRxiv - Bioinformatics Pub Date : 2020-05-07 , DOI: 10.1101/2020.05.07.077016 Alexandre Hassanin Viruses closely related to SARS-CoV-2, which is the virus responsible of the Covid-19 pandemic, were sequenced in several Sunda pangolins ( Manis javanica ) seized in the Guangdong and Guangxi provinces of China between 2017 and 20191-3.",
      "The GD/P2S dataset2 contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus.",
      "To overcome this absence, I assembled these genomes from the Sequence Read Archive (SRA) data available for SARS- CoV-2-like viruses detected in five captive pangolins from Guangdong."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms the presence of SARS-CoV-2-like viruses in captive pangolins from Guangdong and discusses the need for better sequencing to address contamination concerns or coexistence with other viruses, thus supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.023977870121598244,
    "x2e_entail_prob": 0.027062999084591866
  },
  {
    "id": "covid_fact-000835",
    "statement": "The sars-cov-2-like virus found in captive pangolins from guangdong cannot be better sequenced.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "bioRxiv - Bioinformatics Pub Date : 2020-05-07 , DOI: 10.1101/2020.05.07.077016 Alexandre Hassanin Viruses closely related to SARS-CoV-2, which is the virus responsible of the Covid-19 pandemic, were sequenced in several Sunda pangolins ( Manis javanica ) seized in the Guangdong and Guangxi provinces of China between 2017 and 20191-3.",
      "The GD/P2S dataset2 contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus.",
      "To overcome this absence, I assembled these genomes from the Sequence Read Archive (SRA) data available for SARS- CoV-2-like viruses detected in five captive pangolins from Guangdong."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the SARS-CoV-2-like viruses were sequenced from captive pangolins in Guangdong, contradicting the claim that they cannot be better sequenced.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.02804724872112274,
    "x2e_entail_prob": 0.04790068417787552
  },
  {
    "id": "covid_fact-000836",
    "statement": "High dose vitamin d improves total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses potential benefits of high-dose vitamin D in critically ill patients, including immune response, lung function, and muscle metabolism. However, it doesn't explicitly support the claim that high-dose vitamin D improves total serum antioxidant capacity or ICU outcomes.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.003971889615058899,
    "x2e_entail_prob": 0.0380091518163681
  },
  {
    "id": "covid_fact-000837",
    "statement": "High dose vitamin d reduces total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not mention high dose vitamin D reducing serum antioxidant capacity or improving ICU outcomes in critically ill patients. It discusses the efficacy of vitamin D supplementation and its role in immune response, lung function, muscle metabolism, and cardiac function but does not provide specific information about the claim made.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.01185012049973011,
    "x2e_entail_prob": 0.04051235318183899
  },
  {
    "id": "covid_fact-000838",
    "statement": "High dose vitamin d decreased total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the efficacy of high-dose vitamin D supplementation and its positive effects on immune response, lung function, muscle metabolism, and cardiac function in critically ill patients. However, there is no mention or support for the claim that high-dose vitamin D decreases total serum antioxidant capacity or negatively impacts ICU outcomes.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.030111417174339294,
    "x2e_entail_prob": 0.030375618487596512
  },
  {
    "id": "covid_fact-000839",
    "statement": "High dose vitamin d reduced total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the general benefits of high-dose vitamin D in critically ill patients but does not specifically address its effect on total serum antioxidant capacity or ICU outcomes.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0029978984966874123,
    "x2e_entail_prob": 0.028584850952029228
  },
  {
    "id": "covid_fact-000840",
    "statement": "Epidemiologic features and clinical course of 1st 18 patients infected with sars-cov-2 in singapore",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only addresses the clinical presentation of the first 18 patients, noting that it was frequently mild, but does not provide information on the epidemiologic features, which are a key part of the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0027052434161305428,
    "x2e_entail_prob": 0.07473479211330414
  },
  {
    "id": "covid_fact-000841",
    "statement": "Epidemiologic features and clinical course of 10 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the clinical presentation of the first 18 patients but does not provide information on the epidemiologic features.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0030483596492558718,
    "x2e_entail_prob": 0.002222631359472871
  },
  {
    "id": "covid_fact-000842",
    "statement": "Epidemiologic features and clinical course of all 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only addresses the clinical presentation of the first 18 patients, noting that it was frequently mild. It does not provide information about the epidemiologic features or other aspects of their clinical course beyond the initial presentation.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.020221685990691185,
    "x2e_entail_prob": 0.06251557916402817
  },
  {
    "id": "covid_fact-000843",
    "statement": "Epidemiologic features and clinical course of over 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to 'over 18 patients,' implying more than 18, while the evidence specifically mentions only 18 patients. Therefore, the evidence does not fully support the claim as it doesn't confirm cases beyond these 18.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.015729794278740883,
    "x2e_entail_prob": 0.005834072828292847
  },
  {
    "id": "covid_fact-000844",
    "statement": "A bifidobacterial protein that can reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports the existence of bifidobacterial proteins with anti-inflammatory properties for COVID-19 but does not mention a RUDN geneticist as the discoverer.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.0017298799939453602,
    "x2e_entail_prob": 0.0019001081818714738
  },
  {
    "id": "covid_fact-000845",
    "statement": "A bifidobacterial protein that cannot reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence contradicts the claim by stating that a fragment of the bifidobacterial protein can be used as an anti-inflammatory medication for COVID-19, thus it does reduce inflammation. Additionally, there is no mention of a RUDN geneticist in the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0016826898790895939,
    "x2e_entail_prob": 0.0022894551511853933
  },
  {
    "id": "covid_fact-000846",
    "statement": "A bifidobacterial virus that can reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses bifidobacterial proteins' potential anti-inflammatory effects for COVID-19 but does not mention a virus or attribute the discovery to a RUDN geneticist.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0023915974888950586,
    "x2e_entail_prob": 0.0031322729773819447
  },
  {
    "id": "covid_fact-000847",
    "statement": "Swissmedic begins rolling review of moderna 's mrna vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "This rolling review process allows Swissmedic to review data from ongoing clinical trials as soon as it is available."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explains the rolling review process but doesn't confirm that Swissmedic applied it to Moderna's COVID-19 vaccine.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0022546250838786364,
    "x2e_entail_prob": 0.0014288859674707055
  },
  {
    "id": "covid_fact-000848",
    "statement": "Swissmedic begins rolling production of moderna's mrna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This rolling review process allows Swissmedic to review data from ongoing clinical trials as soon as it is available."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes a rolling review process by Swissmedic for evaluating clinical trial data but does not mention any involvement in production activities related to Moderna's mRNA vaccine.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0030346056446433067,
    "x2e_entail_prob": 0.0013508002739399672
  },
  {
    "id": "covid_fact-000849",
    "statement": "Sars-cov-2 spike protein promotes hyper-inflammatory response that can be ameliorated by spike-antagonistic peptide and fda-approved er stress and map kinase inhibitors in vitro",
    "label": "SUPPORTED",
    "evidences": [
      "We developed an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines.",
      "Here we demonstrate that 2019 SARS-CoV-2 spike protein subunit 1 (CoV2-S1) induces high levels of NF-\u03baB activations, production of pro- inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that the SARS-CoV-2 spike protein promotes a hyper-inflammatory response is supported by the evidence showing induction of pro-inflammatory cytokines and NF-\u03baB activation. However, the evidence does not mention FDA-approved ER stress or MAP kinase inhibitors, only an antagonistic peptide.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.05901167541742325,
    "x2e_entail_prob": 0.06295362114906311
  },
  {
    "id": "covid_fact-000850",
    "statement": "Sars-cov-2 spike protein promotes hyper-inflammatory response that cannot be ameliorated by spike-antagonistic peptide and fda-approved er stress and map kinase inhibitors in vitro",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We developed an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines.",
      "Here we demonstrate that 2019 SARS-CoV-2 spike protein subunit 1 (CoV2-S1) induces high levels of NF-\u03baB activations, production of pro- inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that the spike protein induces a hyper-inflammatory response and that an antagonistic peptide reduces cytokine production. However, it does not provide information on ER stress or MAP kinase inhibitors, leaving their effectiveness unaddressed.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.00715481536462903,
    "x2e_entail_prob": 0.15622767806053162
  },
  {
    "id": "covid_fact-000851",
    "statement": "Finding suggests technology can be installed in air conditioning , vacuum , and water systems",
    "label": "SUPPORTED",
    "evidences": [
      "Eventually, as the science develops, the industry will be able to make the necessary adjustments and install the bulbs in robotic systems or air conditioning, vacuum, and water systems, and thereby be able to efficiently disinfect large surfaces and spaces.",
      "Disinfection systems based on LED bulbs, however, can be installed in the ventilation system and air conditioner, for example, and sterilize the air sucked in and then emitted into the room.",
      "In the future, the researchers will test their unique combination of integrated damage mechanisms and more ideas they recently developed on combined efficient direct and indirect damage to bacteria and viruses on different surfaces, air, and water."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that the technology can be installed in air conditioning, vacuum, and water systems for disinfection purposes.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.08689385652542114,
    "x2e_entail_prob": 0.018167132511734962
  },
  {
    "id": "covid_fact-000852",
    "statement": "Finding suggests technology cannot be installed in air conditioning, vacuum, and water systems",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eventually, as the science develops, the industry will be able to make the necessary adjustments and install the bulbs in robotic systems or air conditioning, vacuum, and water systems, and thereby be able to efficiently disinfect large surfaces and spaces.",
      "Disinfection systems based on LED bulbs, however, can be installed in the ventilation system and air conditioner, for example, and sterilize the air sucked in and then emitted into the room.",
      "In the future, the researchers will test their unique combination of integrated damage mechanisms and more ideas they recently developed on combined efficient direct and indirect damage to bacteria and viruses on different surfaces, air, and water."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that technology can be installed in air conditioning systems and mentions future plans for vacuum and water systems, contradicting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.011408752761781216,
    "x2e_entail_prob": 0.012427505105733871
  },
  {
    "id": "covid_fact-000853",
    "statement": "Oxford university vaccine shows 70 % protection - bbc news",
    "label": "SUPPORTED",
    "evidences": [
      "The researchers said it worked out at 70% protection, which is better than the seasonal flu jab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that Oxford University's vaccine shows 70% protection aligns with the evidence provided. The evidence confirms a 70% protection rate, which is consistent with the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.5134915709495544,
    "x2e_entail_prob": 0.0014437715290114284
  },
  {
    "id": "covid_fact-000854",
    "statement": "Oxford university vaccine shows 70 % protection -19 news",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The researchers said it worked out at 70% protection, which is better than the seasonal flu jab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that the Oxford University vaccine shows 70% protection, confirming the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.012903599999845028,
    "x2e_entail_prob": 0.0016251960769295692
  },
  {
    "id": "covid_fact-000855",
    "statement": "Mast cells activated by sars-cov-2 release histamine which increases il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While mast cells do release histamine upon activation, the evidence does not explicitly state that histamine increases IL-1 levels or directly causes cytokine storm in COVID-19.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.011959933675825596,
    "x2e_entail_prob": 0.07432067394256592
  },
  {
    "id": "covid_fact-000856",
    "statement": "Mast cells activated by sars-cov-2 release histamine which reduces il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that mast cells activated by SARS-CoV-2 release histamine, which contributes to inflammation. However, it does not support the claim that histamine reduces IL-1 levels or causes a cytokine storm. Instead, the evidence indicates that IL-1 induces thromboxane-A2 and plays a role in inflammation.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.9467753767967224,
    "x2e_entail_prob": 0.26259952783584595
  },
  {
    "id": "covid_fact-000857",
    "statement": "Mast cells activated by sars-cov-2 release histamine which decreases il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms mast cell activation leads to histamine release contributing to inflammation but does not support that histamine decreases IL-1 levels or causes cytokine storms.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.008966325782239437,
    "x2e_entail_prob": 0.1390274167060852
  },
  {
    "id": "covid_fact-000858",
    "statement": "Mast cells activated by sars-cov-2 release histamine which inhibits il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that mast cells release histamine and contribute to inflammation but does not mention histamine inhibiting IL-1 levels or causing cytokine storms.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.006253461819142103,
    "x2e_entail_prob": 0.2796424925327301
  },
  {
    "id": "covid_fact-000859",
    "statement": "The furin cleavage site of sars-cov-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells .",
    "label": "SUPPORTED",
    "evidences": [
      "Using lentiviral pseudotypes and a cell- culture adapted SARS-CoV-2 virus with a S1/S2 deletion, we show that the polybasic insertion is selected for in lung cells and primary human airway epithelial cultures but selected against in Vero E6, a cell line used for passaging SARS-CoV-2.",
      "The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission",
      "We find this selective advantage depends on expression of the cell surface protease, TMPRSS2, that allows virus entry independent of endosomes thus avoiding antiviral IFITM proteins.",
      "SARS-CoV-2 has a unique polybasic insertion at the S1/S2 CS, which we demonstrate can be cleaved by furin."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the furin cleavage site enhances replication in airway cells and is a key determinant for transmission due to its interaction with TMPRSS2, which aids virus entry and avoids antiviral proteins.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7920422554016113,
    "x2e_entail_prob": 0.03706737607717514
  },
  {
    "id": "covid_fact-000860",
    "statement": "The furin cleavage site of sars-cov-2 spike protein is a key determinant for transmission due to enhanced infection in airway cells.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using lentiviral pseudotypes and a cell- culture adapted SARS-CoV-2 virus with a S1/S2 deletion, we show that the polybasic insertion is selected for in lung cells and primary human airway epithelial cultures but selected against in Vero E6, a cell line used for passaging SARS-CoV-2.",
      "The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission",
      "We find this selective advantage depends on expression of the cell surface protease, TMPRSS2, that allows virus entry independent of endosomes thus avoiding antiviral IFITM proteins.",
      "SARS-CoV-2 has a unique polybasic insertion at the S1/S2 CS, which we demonstrate can be cleaved by furin."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that the furin cleavage site enhances infection in airway cells and is crucial for viral transmission.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.01995110884308815,
    "x2e_entail_prob": 0.09356649965047836
  },
  {
    "id": "covid_fact-000861",
    "statement": "Is there an airborne component to the transmission of covid-19 ?",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that SARS-CoV-2 can be transmitted through airborne aerosols, especially in enclosed spaces, supporting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.9566089510917664,
    "x2e_entail_prob": 0.1264755129814148
  },
  {
    "id": "covid_fact-000862",
    "statement": "Is there an airborne component to the entry of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 is shed in high concentrations from the nasal cavity and can be transmitted via aerosols, even with social distancing in enclosed spaces.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9876859188079834,
    "x2e_entail_prob": 0.6617676019668579
  },
  {
    "id": "covid_fact-000863",
    "statement": "Is there an airborne component to the development of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 virions are shed in high concentrations from infected individuals and can pose a risk of transmission through aerosols in enclosed spaces, even with social distancing.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9904600381851196,
    "x2e_entail_prob": 0.711097240447998
  },
  {
    "id": "covid_fact-000864",
    "statement": "Is there an airborne component to the use of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence discusses the shedding of SARS-CoV-2 virions and the potential for aerosol transmission, even with social distancing. A study on enclosed spaces further supports this airborne risk.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9045537710189819,
    "x2e_entail_prob": 0.5299866795539856
  },
  {
    "id": "covid_fact-000865",
    "statement": "Saliva-based antigen testing is better than the pcr swab",
    "label": "SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence highlights several advantages of saliva-based antigen testing over PCR, including practicality, cost-effectiveness, speed, and convenience. While it doesn't mention sensitivity, the provided benefits strongly support the claim in specific contexts.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.009615311399102211,
    "x2e_entail_prob": 0.0036120021250098944
  },
  {
    "id": "covid_fact-000866",
    "statement": "Saliva-based antigen testing is lower than the pcr swab",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the specificity, cost, and practicality of saliva-based antigen testing but does not explicitly compare its sensitivity or accuracy to PCR swab tests. While it implies that antigen tests may have lower sensitivity by not detecting lingering viral matter, the claim's vagueness about what aspect is being compared (accuracy vs. cost) makes it difficult to fully support.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.007109917234629393,
    "x2e_entail_prob": 0.02941843494772911
  },
  {
    "id": "covid_fact-000867",
    "statement": "Saliva-based antigen testing is less than the pcr swab",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence highlights that saliva-based antigen testing is less expensive (as low as $1 per test), quicker to provide results, requires fewer resources, and is more accessible than PCR swab tests. This supports the claim that saliva-based antigen testing is less resource-intensive compared to PCR swab.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9204031825065613,
    "x2e_entail_prob": 0.004399145022034645
  },
  {
    "id": "covid_fact-000868",
    "statement": "10 % of stockholmers infected",
    "label": "SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by stating that 10% of Stockholm's population had been infected with COVID-19 based on a sample of 1,000 residents.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.414838582277298,
    "x2e_entail_prob": 0.000989799969829619
  },
  {
    "id": "covid_fact-000869",
    "statement": "10 % of authorers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention anything about authors being infected. It discusses the infection rate in Stockholm's general population.",
    "confidence": 1,
    "e2x_entail_prob": 0.009757247753441334,
    "x2e_entail_prob": 0.0012003042502328753
  },
  {
    "id": "covid_fact-000870",
    "statement": "10 % of readers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that 10% of Stockholm's residents were infected with COVID-19 but does not provide information about 'readers' being infected.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.025885028764605522,
    "x2e_entail_prob": 0.0010733685921877623
  },
  {
    "id": "covid_fact-000871",
    "statement": "10 % of allers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that by early April, approximately 10% of Stockholm's population had been infected with the coronavirus and developed antibodies based on a sample of 1,000 residents. This directly supports the claim regarding the infection rate in Stockholm.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8100197315216064,
    "x2e_entail_prob": 0.0008722843485884368
  },
  {
    "id": "covid_fact-000872",
    "statement": "Sars-cov-2 d614g variant exhibits enhanced replication ex vivo and earlier transmission in vivo",
    "label": "SUPPORTED",
    "evidences": [
      "Our study demonstrated the SARS-CoV2 D614G substitution enhances infectivity, replication fitness, and early transmission.",
      "This article has been published \"SARS-CoV-2 D614G Variant Exhibits Efficient Replication ex vivo and Transmission in vivo\" in Science."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by confirming enhanced replication ex vivo and efficient transmission in vivo for the D614G variant.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9294530153274536,
    "x2e_entail_prob": 0.0075425151735544205
  },
  {
    "id": "covid_fact-000873",
    "statement": "Sars-cov-2 d614g variant inhibited enhanced replication ex vivo and earlier transmission in vivo",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our study demonstrated the SARS-CoV2 D614G substitution enhances infectivity, replication fitness, and early transmission.",
      "This article has been published \"SARS-CoV-2 D614G Variant Exhibits Efficient Replication ex vivo and Transmission in vivo\" in Science."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence contradicts the claim by stating that the D614G variant enhances replication and transmission rather than inhibiting them.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.029235905036330223,
    "x2e_entail_prob": 0.0036108046770095825
  },
  {
    "id": "covid_fact-000874",
    "statement": "Orf8 and orf3b antibodies are accurate serological markers of early and late sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses.",
      "We have identified ORF8 antibodies as a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection because of its immunodominance and specificity, in addition to N protein."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports ORF8 as an accurate marker for both early and late infection due to its immunodominance and specificity. While ORF3b antibodies are noted, their role across all stages isn't explicitly detailed, but they are confirmed as strong markers.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.792432427406311,
    "x2e_entail_prob": 0.23198707401752472
  },
  {
    "id": "covid_fact-000875",
    "statement": "Orf8 and orf3b antibodies are accurate serological markers of early and acute sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses.",
      "We have identified ORF8 antibodies as a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection because of its immunodominance and specificity, in addition to N protein."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that ORF8 antibodies are a major marker for acute SARS-CoV-2 infection, but it does not specifically mention ORF3b as an accurate marker for early or acute infection.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.011272097937762737,
    "x2e_entail_prob": 0.1358073651790619
  },
  {
    "id": "covid_fact-000876",
    "statement": "Plasma from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that plasma from COVID-19 recovered subjects inhibits spike protein binding to ACE2 using a microsphere-based assay, as described in the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.7371615767478943,
    "x2e_entail_prob": 0.0016653980128467083
  },
  {
    "id": "covid_fact-000877",
    "statement": "Blood from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that plasma from recovered COVID-19 subjects inhibited spike protein binding to ACE2 in a microsphere-based assay, which fully supports the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.20415098965168,
    "x2e_entail_prob": 0.0017254040576517582
  },
  {
    "id": "covid_fact-000878",
    "statement": "Rna from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to RNA inhibiting spike protein binding, while the evidence discusses antibodies in plasma. There's no mention of RNA in the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0014463451225310564,
    "x2e_entail_prob": 0.0059370012022554874
  },
  {
    "id": "covid_fact-000879",
    "statement": "Cdna from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses plasma from recovered subjects inhibiting spike-ACE2 binding but does not mention cDNA. The claim specifically refers to cDNA, which is not supported by the provided evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.032500188797712326,
    "x2e_entail_prob": 0.004205182194709778
  },
  {
    "id": "covid_fact-000880",
    "statement": "Dana-farber to test blood cancer drug in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Dana-Farber is testing a blood cancer drug, specifically BTK-inhibitors, in COVID-19 patients to study the immune response and potential benefits.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.37665802240371704,
    "x2e_entail_prob": 0.0015492587117478251
  },
  {
    "id": "covid_fact-000881",
    "statement": "Dana-farber to test breast cancer drug in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows Dana-Farber will test BTK-inhibitors in COVID-19 patients but does not confirm that these are breast cancer drugs.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.009485292248427868,
    "x2e_entail_prob": 0.001078526140190661
  },
  {
    "id": "covid_fact-000882",
    "statement": "Dana-farber to test human cancer drug in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.004802224226295948,
    "x2e_entail_prob": 0.004191942047327757
  },
  {
    "id": "covid_fact-000883",
    "statement": "Hydroxychloroquine improves airflow and lowers circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that hydroxychloroquine has immunomodulating effects and potential utility in asthma but does not provide specific data on improved airflow or reduced IgE levels in moderate symptomatic asthma.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.0011505048023536801,
    "x2e_entail_prob": 0.060902807861566544
  },
  {
    "id": "covid_fact-000884",
    "statement": "Hydroxychloroquine improves airflow and increases circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that hydroxychloroquine has potential utility in treating asthma but does not provide specific information about improving airflow or increasing IgE levels. Without explicit data on these outcomes, the claim cannot be supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.004103256855159998,
    "x2e_entail_prob": 0.13254964351654053
  },
  {
    "id": "covid_fact-000885",
    "statement": "Hydroxychloroquine decreases airflow and lowers circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not provide specific data about hydroxychloroquine affecting airflow or IgE levels in asthmatic subjects, only suggesting potential utility without details.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.004845059011131525,
    "x2e_entail_prob": 0.009608278051018715
  },
  {
    "id": "covid_fact-000886",
    "statement": "Hydroxychloroquine improves airflow and increased circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specifically mention hydroxychloroquine improving airflow or increasing IgE levels in asthma subjects. It only states that HCQ has immunomodulating properties and potential utility in treating asthma, without supporting the two specific claims.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.005225849337875843,
    "x2e_entail_prob": 0.08607332408428192
  },
  {
    "id": "covid_fact-000887",
    "statement": "Moderna has completed case accrual for first planned interim analysis of its mrna vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the early development and shipment of the mRNA-1273 vaccine but does not mention anything about case accrual or interim analyses, which are related to clinical trial phases conducted later.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.006072606425732374,
    "x2e_entail_prob": 0.6778345704078674
  },
  {
    "id": "covid_fact-000888",
    "statement": "Moderna has no case accrual for first planned interim analysis of its mrna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention any details about the clinical trial progress or outcomes, including case accrual or interim analyses. It only provides information about the development of the mRNA-1273 vaccine up to February 2020.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.017881549894809723,
    "x2e_entail_prob": 0.7172476053237915
  },
  {
    "id": "covid_fact-000889",
    "statement": "Moderna has completed case accrual for first planned interim analysis of its dna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes mRNA-1273 as an mRNA vaccine, not a DNA vaccine, and does not mention case accrual for interim analysis.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.06653828173875809,
    "x2e_entail_prob": 0.6032392978668213
  },
  {
    "id": "covid_fact-000890",
    "statement": "Amplicon contamination in labs masquerades as covid19 in surveillance tests",
    "label": "SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses minimizing amplicon contamination and handling suspected cases but does not explicitly state that such contamination is masquerading as COVID-19 in surveillance tests. It focuses on resource management rather than misdiagnosis.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0032473127357661724,
    "x2e_entail_prob": 0.00401230389252305
  },
  {
    "id": "covid_fact-000891",
    "statement": "Amplicon contamination in human masquerades as covid19 in surveillance tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the importance of minimizing amplicon contamination and its impact on resource allocation but does not provide specific information that amplicon contamination is masquerading as COVID-19 in surveillance tests.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0009102672338485718,
    "x2e_entail_prob": 0.010504408739507198
  },
  {
    "id": "covid_fact-000892",
    "statement": "Amplicon contamination in labs masquerades as covid19 in preparation tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence discusses amplicon contamination's impact on research and resource allocation, it doesn't explicitly confirm that contamination is mistaken for COVID-19 in tests.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.002310095587745309,
    "x2e_entail_prob": 0.006456709932535887
  },
  {
    "id": "covid_fact-000893",
    "statement": "Amplicon contamination in labs masquerades as covid19 in children tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses amplicon contamination and its impact on research and resource allocation but does not specifically mention that it masquerades as COVID-19 in children's tests.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0007374578854069114,
    "x2e_entail_prob": 0.006237333174794912
  },
  {
    "id": "covid_fact-000894",
    "statement": "Male sex hormones appear to help the coronavirus infiltrate human cells",
    "label": "SUPPORTED",
    "evidences": [
      "Her studies at the UCSF stem cell laboratory found that androgens -- male hormones, including testosterone -- actually help SARS-CoV-2, the specific coronavirus that causes COVID-19, infiltrate human cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by showing that male hormones, including testosterone, aid SARS-CoV-2 in infiltrating human cells.",
    "confidence": 1,
    "e2x_entail_prob": 0.4790325164794922,
    "x2e_entail_prob": 0.0014944082358852029
  },
  {
    "id": "covid_fact-000895",
    "statement": "Male sex hormones fail to help the coronavirus infiltrate human cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Her studies at the UCSF stem cell laboratory found that androgens -- male hormones, including testosterone -- actually help SARS-CoV-2, the specific coronavirus that causes COVID-19, infiltrate human cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that male hormones help SARS-CoV-2 infiltrate human cells, which contradicts the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.04307574778795242,
    "x2e_entail_prob": 0.0029751171823590994
  },
  {
    "id": "covid_fact-000896",
    "statement": "Il-6 : a novel signature associated with covid-19 disease progression and development of anti-sars-cov-2 antibodies",
    "label": "SUPPORTED",
    "evidences": [
      "Findings IL-6 and sMAdCAM expressed as a novel integrative marker (sMIL index) are associated both with disease-states (early infection and convalescence) as well as development of antiviral humoral responses.",
      "Share sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 Share This Article: Copy Citation Tools sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 "
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that IL-6 is part of a novel signature (sMIL index) associated with COVID-19 progression and anti-SARS-CoV-2 antibody development.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7384049296379089,
    "x2e_entail_prob": 0.2860126197338104
  },
  {
    "id": "covid_fact-000897",
    "statement": "Il-6 : a common signature associated with covid-19 disease progression and development of anti-sars-cov-2 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Findings IL-6 and sMAdCAM expressed as a novel integrative marker (sMIL index) are associated both with disease-states (early infection and convalescence) as well as development of antiviral humoral responses.",
      "Share sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 Share This Article: Copy Citation Tools sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 "
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that IL-6 is part of a novel marker associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies, directly supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.14462722837924957,
    "x2e_entail_prob": 0.15115992724895477
  },
  {
    "id": "covid_fact-000898",
    "statement": "Slovakia to test all adults for sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Slovakia has initiated a large-scale testing operation for all adults due to an increase in virus spread, directly supporting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.016439346596598625,
    "x2e_entail_prob": 0.0068286932073533535
  },
  {
    "id": "covid_fact-000899",
    "statement": "He to test all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim incorrectly refers to an individual ('he') testing all adults, while the evidence states it's Slovakia's government conducting the tests.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.00612179609015584,
    "x2e_entail_prob": 0.001315455068834126
  },
  {
    "id": "covid_fact-000900",
    "statement": "Slovakia to represent all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Slovakia has initiated a nationwide testing operation targeting its entire adult population for SARS-CoV-2. This aligns with the claim, confirming it is supported.",
    "confidence": 1,
    "e2x_entail_prob": 0.08336770534515381,
    "x2e_entail_prob": 0.0017503491835668683
  },
  {
    "id": "covid_fact-000901",
    "statement": "failed to test all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows Slovakia began testing its entire adult population, contradicting the claim of failing to test all adults.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1024828553199768,
    "x2e_entail_prob": 0.0013078467454761267
  },
  {
    "id": "covid_fact-000902",
    "statement": "Extra doses found in pfizer 's coronavirus vaccine.",
    "label": "SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly mentions that Pfizer's coronavirus vaccine vials had extra doses, and the FDA approved their use.",
    "confidence": 1,
    "e2x_entail_prob": 0.40489277243614197,
    "x2e_entail_prob": 0.04298320412635803
  },
  {
    "id": "covid_fact-000903",
    "statement": "No doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that Pfizer's vaccine vials contained extra doses, directly contradicting the claim of 'no doses found.'",
    "confidence": 1,
    "e2x_entail_prob": 0.01760699227452278,
    "x2e_entail_prob": 0.0378122441470623
  },
  {
    "id": "covid_fact-000904",
    "statement": "One doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Pfizer's coronavirus vaccine vials contain extra doses beyond the initial expectation of five doses per vial, which aligns with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5611636638641357,
    "x2e_entail_prob": 0.028295883908867836
  },
  {
    "id": "covid_fact-000905",
    "statement": "Low doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Pfizer's vaccine vials had extra doses beyond the intended five per vial, which expanded the supply. This contradicts the claim of low doses being found.",
    "confidence": 1,
    "e2x_entail_prob": 0.08275118470191956,
    "x2e_entail_prob": 0.16743871569633484
  },
  {
    "id": "covid_fact-000906",
    "statement": "Bradykinin initiates cytokine-mediated inflammatory hyperalgesia",
    "label": "SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim by showing that bradykinin initiates cytokine release, specifically TNF-alpha, which mediates inflammatory hyperalgesia.",
    "confidence": 1,
    "e2x_entail_prob": 0.9091611504554749,
    "x2e_entail_prob": 0.0025215339846909046
  },
  {
    "id": "covid_fact-000907",
    "statement": "Bradykinin initiates cytokine-independent inflammatory hyperalgesia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that bradykinin initiates a cascade involving cytokine release (e.g., TNF-alpha) to mediate hyperalgesia, which contradicts the claim of being cytokine-independent.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0017628142377361655,
    "x2e_entail_prob": 0.0013197241351008415
  },
  {
    "id": "covid_fact-000908",
    "statement": "Bradykinin cans cytokine-mediated inflammatory hyperalgesia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that bradykinin initiates cytokine release, particularly TNF-alpha, which mediates inflammatory hyperalgesia.",
    "confidence": 1,
    "e2x_entail_prob": 0.9888733625411987,
    "x2e_entail_prob": 0.004324787296354771
  },
  {
    "id": "covid_fact-000909",
    "statement": "Potently neutralizing human antibodies that block sars-cov-2 receptor binding and protect animals",
    "label": "SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes potent neutralizing monoclonal antibodies against SARS-CoV-2 but does not provide information about protection in animals.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.001243887934833765,
    "x2e_entail_prob": 0.005889755208045244
  },
  {
    "id": "covid_fact-000910",
    "statement": "Potently neutralizing mouse antibodies that block sars-cov-2 receptor binding and protect animals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes potent neutralizing monoclonal antibodies but does not specify that they are mouse-derived. Without confirmation of their origin, the claim about mouse antibodies is unsupported.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.022461753338575363,
    "x2e_entail_prob": 0.007628418039530516
  },
  {
    "id": "covid_fact-000911",
    "statement": "Potently neutralizing human antibodies that block sars-cov-2 receptor binding and neutralization animals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that the antibodies have potent neutralizing activity against SARS-CoV-2 in vitro but does not mention animal studies, leaving part of the claim unsupported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0014679438900202513,
    "x2e_entail_prob": 0.005037272814661264
  },
  {
    "id": "covid_fact-000912",
    "statement": "Persistence of viral rna , pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from two studies supports each part of the claim: persistence of viral RNA, presence of pneumocyte syncytia in autopsy findings, and thrombosis as a complication in severe COVID-19 cases.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.04305998608469963,
    "x2e_entail_prob": 0.12511926889419556
  },
  {
    "id": "covid_fact-000913",
    "statement": "Persistence of viral dna, pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that viral DNA and thrombosis are present in advanced COVID-19 cases. Pneumocyte syncytia is a known feature of severe COVID-19 pathology.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.13787515461444855,
    "x2e_entail_prob": 0.10481511801481247
  },
  {
    "id": "covid_fact-000914",
    "statement": "Persistence of viral replication, pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions three hallmarks: viral replication, pneumocyte syncytia, and thrombosis. The evidence supports viral presence (implying replication) and thrombosis but does not explicitly mention pneumocyte syncytia, leaving one component unsupported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.020184924826025963,
    "x2e_entail_prob": 0.03584927320480347
  },
  {
    "id": "covid_fact-000915",
    "statement": "The novel severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that SARS-CoV-2 directly causes severe tissue damage to human spleens and lymph nodes, including depletion of lymph follicles and reductions in lymphocytes.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.45093613862991333,
    "x2e_entail_prob": 0.9602888226509094
  },
  {
    "id": "covid_fact-000916",
    "statement": "The primary severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, and lymphocyte reductions, which directly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.13259363174438477,
    "x2e_entail_prob": 0.9543638229370117
  },
  {
    "id": "covid_fact-000917",
    "statement": "The first severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that SARS-CoV-2 directly causes severe damage to human spleens and lymph nodes, including specific tissue changes as mentioned in the study.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.11425632983446121,
    "x2e_entail_prob": 0.8294283747673035
  },
  {
    "id": "covid_fact-000918",
    "statement": "Researchers discover new variant of covid-19 virus in columbus , ohio.",
    "label": "SUPPORTED",
    "evidences": [
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- Cov-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus.",
      "Doctors at Ohio State talked about the COVID-19 vaccine and the new variant of the coronavirus in the briefing below.",
      "Scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19.",
      "> OSU COVID variant > > Researchers at Ohio State discuss COVID-19 vaccinations and a new variant of > the virus discovered in Columbus.",
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- CoV-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that scientists at The Ohio State University Wexner Medical Center and College of Medicine discovered a new strain of COVID-19 and mentions the variant being discussed in Columbus.",
    "confidence": 1,
    "e2x_entail_prob": 0.7262134552001953,
    "x2e_entail_prob": 0.07916930317878723
  },
  {
    "id": "covid_fact-000919",
    "statement": "Researchers no new variant of covid-19 virus in columbus, ohio.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- Cov-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus.",
      "Doctors at Ohio State talked about the COVID-19 vaccine and the new variant of the coronavirus in the briefing below.",
      "Scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19.",
      "> OSU COVID variant > > Researchers at Ohio State discuss COVID-19 vaccinations and a new variant of > the virus discovered in Columbus.",
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- CoV-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that researchers at Ohio State discovered a new COVID-19 variant, and mentions Columbus as the location.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.11275120824575424,
    "x2e_entail_prob": 0.10681997239589691
  },
  {
    "id": "covid_fact-000920",
    "statement": "Coronavirus vaccine shows promising early results in china",
    "label": "SUPPORTED",
    "evidences": [
      "Lab research at CanSino Biologics in Tianjin, China, in 2018.Credit...China Stringer Network/Reuters By Apoorva Mandavilli Published May 22, 2020Updated July 16, 2020 A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.",
      "A vaccine for the new coronavirus is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy.",
      "That vaccine has now entered mid-stage human trials, the manufacturer, Sinovac Biotech Ltd., said on Friday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a coronavirus vaccine developed in China is safe and has potential protective effects, with mid-stage trials initiated. These details support the claim of promising early results.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6266946196556091,
    "x2e_entail_prob": 0.044244978576898575
  },
  {
    "id": "covid_fact-000921",
    "statement": "Coronavirus vaccine shows no early results in china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Lab research at CanSino Biologics in Tianjin, China, in 2018.Credit...China Stringer Network/Reuters By Apoorva Mandavilli Published May 22, 2020Updated July 16, 2020 A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.",
      "A vaccine for the new coronavirus is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy.",
      "That vaccine has now entered mid-stage human trials, the manufacturer, Sinovac Biotech Ltd., said on Friday."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Chinese vaccines have entered trials and shown potential efficacy, contradicting the claim of no early results.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.21141009032726288,
    "x2e_entail_prob": 0.05527299642562866
  },
  {
    "id": "covid_fact-000922",
    "statement": "Sars-cov-2 triggers inflammatory responses and cell death through caspase-8 activation",
    "label": "SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports that SARS-CoV-2 infection triggers caspase-8 activation, leading to cell death (apoptosis) and inflammatory cytokine processing, such as pro-IL-1\u03b2.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.4594309628009796,
    "x2e_entail_prob": 0.3891865015029907
  },
  {
    "id": "covid_fact-000923",
    "statement": "Sars-cov-2 suppress inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infection activates caspase-8, leading to apoptosis and inflammation, not suppression.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5831026434898376,
    "x2e_entail_prob": 0.49788230657577515
  },
  {
    "id": "covid_fact-000924",
    "statement": "Sars-cov-2 inhibits inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows SARS-CoV-2 activates caspase-8 to induce cell death and inflammatory cytokine processing, contradicting the claim that it inhibits these processes.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.21701207756996155,
    "x2e_entail_prob": 0.34966981410980225
  },
  {
    "id": "covid_fact-000925",
    "statement": "Sars-cov-2 inhibited inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 infection activates caspase-8, which triggers apoptosis (cell death) and processes pro-inflammatory cytokines like IL-1\u03b2, thereby promoting inflammation rather than inhibiting it.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5356297492980957,
    "x2e_entail_prob": 0.3386892080307007
  },
  {
    "id": "covid_fact-000926",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks.",
    "label": "SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms a study of approximately 43,000 antibody-positive individuals followed for up to 35 weeks, where 0.7% experienced SARS-CoV-2 reinfection.",
    "confidence": 1,
    "e2x_entail_prob": 0.4884311854839325,
    "x2e_entail_prob": 0.903093695640564
  },
  {
    "id": "covid_fact-000927",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 years.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows a follow-up period of up to approximately 8 months (34.6 weeks), not 35 years as claimed.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.008560136891901493,
    "x2e_entail_prob": 0.9504547119140625
  },
  {
    "id": "covid_fact-000928",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 days.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states a follow-up period of up to 35 days, but the evidence shows a median follow-up of 16.3 weeks (approximately 114 days), which is significantly longer. While the evidence supports that reinfections occurred among antibody-positive individuals, the specific time frame mentioned in the claim is not accurate.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.03069511614739895,
    "x2e_entail_prob": 0.8455770611763
  },
  {
    "id": "covid_fact-000929",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 hours.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a follow-up period of weeks to months (median 16.3 weeks), not 35 hours as claimed.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.010878217406570911,
    "x2e_entail_prob": 0.9474561214447021
  },
  {
    "id": "covid_fact-000930",
    "statement": "Anakinra to prevent respiratory failure in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that early suPAR-guided anakinra treatment is associated with a decrease in severe respiratory failure risk and improved outcomes, supporting its use to prevent respiratory failure in COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.29355698823928833,
    "x2e_entail_prob": 0.5633355975151062
  },
  {
    "id": "covid_fact-000931",
    "statement": "Anakinra to prevent neurological failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the benefits of Anakinra in reducing severe respiratory failure and inflammation markers but does not mention any impact on neurological outcomes or failures.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.002262900583446026,
    "x2e_entail_prob": 0.5286548137664795
  },
  {
    "id": "covid_fact-000932",
    "statement": "Anakinra to cause respiratory failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Anakinra reduces the risk of severe respiratory failure (SRF) and improves outcomes in COVID-19 patients, contradicting the claim that it causes respiratory failure.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.26722535490989685,
    "x2e_entail_prob": 0.5921706557273865
  },
  {
    "id": "covid_fact-000933",
    "statement": "Anakinra to causes respiratory failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that Anakinra treatment is associated with a decrease in the risk of severe respiratory failure (SRF) and improvement in inflammatory markers, indicating it prevents rather than causes respiratory failure.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.38466301560401917,
    "x2e_entail_prob": 0.6429439783096313
  },
  {
    "id": "covid_fact-000934",
    "statement": "Hadassah doctors crack the cause of fatal corona blood clots",
    "label": "SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Hadassah researchers discovered that increased levels of alpha defensin protein contribute to fatal corona-related blood clots, aligning with the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.07719148695468903,
    "x2e_entail_prob": 0.0027298240456730127
  },
  {
    "id": "covid_fact-000935",
    "statement": "Hadassah virus crack the cause of fatal corona blood clots",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Hadassah researchers identified increased levels of alpha defensin protein linked to fatal blood clots, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8193385004997253,
    "x2e_entail_prob": 0.0022475270088762045
  },
  {
    "id": "covid_fact-000936",
    "statement": "Hadassah doctors remain the cause of fatal corona blood clots",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses Hadassah researchers identifying a biomarker (alpha defensin) linked to blood clots but does not suggest that Hadassah doctors caused the clots.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.02561083808541298,
    "x2e_entail_prob": 0.0018440485000610352
  },
  {
    "id": "covid_fact-000937",
    "statement": "Virus can infect heart cells in lab dish",
    "label": "SUPPORTED",
    "evidences": [
      "The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular \"defense mechanisms\" in an effort to help clear out the virus.",
      "A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly confirms that SARS-CoV-2 can infect heart cells in a laboratory setting, supporting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.9325578808784485,
    "x2e_entail_prob": 0.0010760915465652943
  },
  {
    "id": "covid_fact-000938",
    "statement": "Virus cannot infect heart cells in lab dish",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular \"defense mechanisms\" in an effort to help clear out the virus.",
      "A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly shows that SARS-CoV-2 can infect heart cells in a lab dish. One study demonstrates changes in gene expression and activation of defense mechanisms, while another explicitly states the virus's ability to infect these cells.",
    "confidence": 1,
    "e2x_entail_prob": 0.5281991362571716,
    "x2e_entail_prob": 0.02499094046652317
  },
  {
    "id": "covid_fact-000939",
    "statement": "Alpha-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that alpha-1 antitrypsin (\u03b11-AT) inhibits SARS-CoV-2 infection by targeting the viral spike protein, which supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7180071473121643,
    "x2e_entail_prob": 0.017761653289198875
  },
  {
    "id": "covid_fact-000940",
    "statement": "Cox-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim incorrectly references 'Cox-1 antitrypsin,' which is not mentioned in the evidence. The evidence supports \u03b11-antitrypsin (\u03b11-AT) inhibiting SARS-CoV-2, but not Cox-1.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.17426323890686035,
    "x2e_entail_prob": 0.08722342550754547
  },
  {
    "id": "covid_fact-000941",
    "statement": "Mcp-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to 'Mcp-1 antitrypsin,' but the evidence provided discusses '\u03b11-antitrypsin (\u03b11-AT),' which is a different protein. There is no mention of MCP-1 in the evidence, so the claim about Mcp-1 is unsupported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.3093073070049286,
    "x2e_entail_prob": 0.06559120118618011
  },
  {
    "id": "covid_fact-000942",
    "statement": "Il-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that alpha-1 antitrypsin (\u03b11-AT) inhibits SARS-CoV-2 by targeting the viral spike protein and blocking infection in human airway epithelium at physiological concentrations.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9397193789482117,
    "x2e_entail_prob": 0.00565320672467351
  },
  {
    "id": "covid_fact-000943",
    "statement": "New study suggests children may carry covid-19 at high levels",
    "label": "SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence partially supports the claim but not universally for all children. While children aged 10-19 can spread COVID-19 as effectively as adults, younger children do so much less. The claim doesn't specify age groups, leading to a partial support.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.3810880184173584,
    "x2e_entail_prob": 0.005062656011432409
  },
  {
    "id": "covid_fact-000944",
    "statement": "New study suggests cats may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses children's transmission of SARS-CoV-2 but does not mention cats or any findings related to feline carriers of COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.005028040148317814,
    "x2e_entail_prob": 0.008326273411512375
  },
  {
    "id": "covid_fact-000945",
    "statement": "New study suggests bats may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses human transmission of SARS-CoV-2 among different age groups and does not mention bats or their role in carrying COVID-19. Therefore, it does not support the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0028775501996278763,
    "x2e_entail_prob": 0.006368483416736126
  },
  {
    "id": "covid_fact-000946",
    "statement": "New study suggests coronaviruses may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses transmission rates among children and teenagers but does not address whether coronaviruses carry COVID-19 at high levels.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0016570516163483262,
    "x2e_entail_prob": 0.006713461596518755
  },
  {
    "id": "covid_fact-000947",
    "statement": "In the coronavirus pandemic , we 're making decisions without reliable data",
    "label": "SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that decisions were made without reliable data during the coronavirus pandemic.",
    "confidence": 1,
    "e2x_entail_prob": 0.12971113622188568,
    "x2e_entail_prob": 0.06711827963590622
  },
  {
    "id": "covid_fact-000948",
    "statement": "In the coronavirus pandemic, we're making decisions with reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that decisions were made without reliable data during the pandemic, contradicting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.03954092040657997,
    "x2e_entail_prob": 0.056814465671777725
  },
  {
    "id": "covid_fact-000949",
    "statement": "In the coronavirus pandemic, we're making decisions and reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that decisions were being made without reliable data during the pandemic, contradicting the claim that decisions were based on reliable data.",
    "confidence": 1,
    "e2x_entail_prob": 0.06145405396819115,
    "x2e_entail_prob": 0.022404855117201805
  },
  {
    "id": "covid_fact-000950",
    "statement": "In the coronavirus pandemic, we're making decisions in reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that decisions were made without reliable data during the pandemic, contradicting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.0072999498806893826,
    "x2e_entail_prob": 0.05551053211092949
  },
  {
    "id": "covid_fact-000951",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly decreased mortality",
    "label": "SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that early transfusion with high-titer convalescent plasma reduces mortality in COVID-19 patients.",
    "confidence": 1,
    "e2x_entail_prob": 0.9898539185523987,
    "x2e_entail_prob": 0.15584760904312134
  },
  {
    "id": "covid_fact-000952",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly increased mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that early transfusion with high-titer convalescent plasma reduces mortality, contradicting the claim of increased mortality.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.2789367437362671,
    "x2e_entail_prob": 0.23237627744674683
  },
  {
    "id": "covid_fact-000953",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly increase mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that early transfusion with high-titer anti-spike protein IgG convalescent plasma reduces mortality in COVID-19 patients, contradicting the claim of increased mortality.",
    "confidence": 1,
    "e2x_entail_prob": 0.5203883051872253,
    "x2e_entail_prob": 0.25453677773475647
  },
  {
    "id": "covid_fact-000954",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly higher mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that early transfusion of convalescent plasma with high titer anti-spike protein IgG reduces mortality among COVID-19 patients, contradicting the claim of significantly higher mortality.",
    "confidence": 1,
    "e2x_entail_prob": 0.38744989037513733,
    "x2e_entail_prob": 0.2682560682296753
  },
  {
    "id": "covid_fact-000955",
    "statement": "Egyptian doctors are speaking out against health authorities over increasing coronavirus infections and deaths among medical staff across the country .",
    "label": "SUPPORTED",
    "evidences": [
      "Another Egyptian doctor told Amnesty International that doctors who speak out are subjected to threats, interrogations by the National Security Agency (NSA), administrative questioning, and penalties.",
      "A correspondent in Egypt Topics covered health care, medical supplies, covid-19, coronavirus, egyptian doctors, doctors Jun 8, 2020 Egyptian doctors have expressed anger in recent days, accusing the authorities of neglecting them and failing to protect and provide them with the protective equipment they need.",
      "Egypts arrests of medical professionals who criticized its Covid-19 policies warrant unambiguous opposition from the World Bank, in line with its commitment not to tolerate reprisals, said Amr Magdi, Middle East and North Africa researcher at Human Rights Watch."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows Egyptian doctors speaking out against health authorities regarding inadequate protection and increasing infections/deaths among medical staff. Doctors face repercussions like threats and interrogations, aligning with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6291895508766174,
    "x2e_entail_prob": 0.008877009153366089
  },
  {
    "id": "covid_fact-000956",
    "statement": "Egyptian doctors are ruled out against health authorities over increasing coronavirus infections and deaths among medical staff across the country.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Another Egyptian doctor told Amnesty International that doctors who speak out are subjected to threats, interrogations by the National Security Agency (NSA), administrative questioning, and penalties.",
      "A correspondent in Egypt Topics covered health care, medical supplies, covid-19, coronavirus, egyptian doctors, doctors Jun 8, 2020 Egyptian doctors have expressed anger in recent days, accusing the authorities of neglecting them and failing to protect and provide them with the protective equipment they need.",
      "Egypts arrests of medical professionals who criticized its Covid-19 policies warrant unambiguous opposition from the World Bank, in line with its commitment not to tolerate reprisals, said Amr Magdi, Middle East and North Africa researcher at Human Rights Watch."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Egyptian doctors are criticizing health authorities for neglecting them and failing to provide necessary protection against COVID-19, leading to increased infections and deaths among medical staff. Additionally, there are reports of doctors being threatened or interrogated for speaking out, supporting the claim of conflict between doctors and health authorities.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.730815589427948,
    "x2e_entail_prob": 0.0034713377244770527
  },
  {
    "id": "covid_fact-000957",
    "statement": "High sars-cov-2 viral load is associated with a worse clinical outcome of covid-19 disease",
    "label": "SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a statistically significant correlation between high viral load and worse clinical outcomes, independent of other risk factors.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9848363995552063,
    "x2e_entail_prob": 0.19203606247901917
  },
  {
    "id": "covid_fact-000958",
    "statement": "High sars-cov-2 viral load is associated with a greater clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that there is a statistically significant correlation between high SARS-CoV-2 viral load and worse clinical outcomes in COVID-19 patients, even after accounting for other risk factors. This directly supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7204980254173279,
    "x2e_entail_prob": 0.7379372715950012
  },
  {
    "id": "covid_fact-000959",
    "statement": "High sars-cov-2 viral load is associated with a better clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly indicates a correlation between high sars-cov-2 viral load and worse clinical outcomes, contradicting the claim that it is associated with better results.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6822543740272522,
    "x2e_entail_prob": 0.3315129578113556
  },
  {
    "id": "covid_fact-000960",
    "statement": "High sars-cov-2 viral load is associated with a higher clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a statistically significant correlation between high SARS-CoV-2 viral load and worse clinical outcomes, independent of other risk factors.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9897152781486511,
    "x2e_entail_prob": 0.4617164433002472
  },
  {
    "id": "covid_fact-000961",
    "statement": "In silico mutagenesis of human ace2 with s protein and translational efficiency explain sars-cov-2 infectivity in different species",
    "label": "SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that ACE2 variability and translational efficiency influence SARS-CoV-2 infectivity across species, aligning with the claim despite not explicitly mentioning in silico methods.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.006882854271680117,
    "x2e_entail_prob": 0.08352597057819366
  },
  {
    "id": "covid_fact-000962",
    "statement": "In silico mutagenesis of bat ace2 with s protein and translational efficiency explain sars-cov-2 infectivity in different species",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence supports that ACE2 variability and translational efficiency influence SARS-CoV-2 infectivity across species but does not mention in silico mutagenesis of bat ACE2.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0036674386356025934,
    "x2e_entail_prob": 0.10382095724344254
  },
  {
    "id": "covid_fact-000963",
    "statement": "In silico mutagenesis of human ace2 with s protein and translational efficiency inhibited sars-cov-2 infectivity in different species",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that ACE2 variants affect SARS-CoV-2 infectivity through interactions with the S protein and translational efficiency, supporting the claim about in silico mutagenesis.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.011817163787782192,
    "x2e_entail_prob": 0.19161149859428406
  },
  {
    "id": "covid_fact-000964",
    "statement": "Plasmin cascade mediates thrombolytic events in sars-cov-2 infection via complement and platelet-activating systems",
    "label": "SUPPORTED",
    "evidences": [
      "Our results indicate that plasmin is a crucial mediator which primes interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection, with a potential for therapeutic intervention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that plasmin mediates interactions between complement and platelet-activating systems during SARS-CoV-2 infection, aligning with the claim about its role in thrombolytic events.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.002991252113133669,
    "x2e_entail_prob": 0.02032567374408245
  },
  {
    "id": "covid_fact-000965",
    "statement": "Plasmin cascade mediates thrombolytic events in sars-cov-2 production via complement and platelet-activating systems",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results indicate that plasmin is a crucial mediator which primes interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection, with a potential for therapeutic intervention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that plasmin plays a role in mediating interactions between complement and platelet systems during SARS-CoV-2 infection, which relates to thrombolytic events. However, the claim's mention of 'sars-cov-2 production' might be misleading as plasmin's role is more about infection processes rather than virus production.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0018595348810777068,
    "x2e_entail_prob": 0.14544202387332916
  },
  {
    "id": "covid_fact-000966",
    "statement": "Private firm running uk ppe stockpile was sold in middle of pandemic .",
    "label": "SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a shift in management from a German to an American firm but does not explicitly confirm that the private firm was sold during the pandemic.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.0027424865402281284,
    "x2e_entail_prob": 0.024846302345395088
  },
  {
    "id": "covid_fact-000967",
    "statement": "Private firm running uk ppe stockpile was established in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a transfer of management responsibility but does not provide information about when the private firm was established or whether it was during the pandemic.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.001016291556879878,
    "x2e_entail_prob": 0.0025505295488983393
  },
  {
    "id": "covid_fact-000968",
    "statement": "No firm running uk ppe stockpile was sold in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a transfer of management from a German-owned company to an American one but does not provide information about any firm being sold during the pandemic.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.003134605474770069,
    "x2e_entail_prob": 0.011658580973744392
  },
  {
    "id": "covid_fact-000969",
    "statement": "Private firm running uk ppe stockpile was developed in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates a shift in management but doesn't specify whether this occurred during the pandemic.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.001805068925023079,
    "x2e_entail_prob": 0.002023376291617751
  },
  {
    "id": "covid_fact-000970",
    "statement": "A systematic review uncovers a wide-gap between covid-19 in humans and animal models",
    "label": "SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that no severe illness or mortality was observed in animal models, indicating a wide gap compared to humans.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9534434676170349,
    "x2e_entail_prob": 0.2617430090904236
  },
  {
    "id": "covid_fact-000971",
    "statement": "A systematic review focuseds a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates no severe illness with mortality in animal models, supporting the claim of a wide gap between human and animal responses to COVID-19.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9917425513267517,
    "x2e_entail_prob": 0.24085643887519836
  },
  {
    "id": "covid_fact-000972",
    "statement": "A systematic review focusess a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates no severe illness or mortality in animal models, supporting a significant gap compared to humans.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9895153045654297,
    "x2e_entail_prob": 0.20262233912944794
  },
  {
    "id": "covid_fact-000973",
    "statement": "A systematic review focuss a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows no severe illness or mortality in various animal models, indicating a gap between human and animal responses to COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9885835647583008,
    "x2e_entail_prob": 0.4827623665332794
  },
  {
    "id": "covid_fact-000974",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the heart.",
    "label": "SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses damage to the heart from SARS-CoV-2 but does not mention transcriptomic changes, so it doesn't support the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0026949397288262844,
    "x2e_entail_prob": 0.014263161458075047
  },
  {
    "id": "covid_fact-000975",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the lung.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses SARS-CoV-2's impact on the heart but does not mention any transcriptomic changes in the lungs, making the claim unsupported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0024291754234582186,
    "x2e_entail_prob": 0.023453721776604652
  },
  {
    "id": "covid_fact-000976",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the lungs.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention any transcriptomic changes within the lungs associated with cardiac SARS-CoV-2 infection.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.00300405896268785,
    "x2e_entail_prob": 0.03296928480267525
  },
  {
    "id": "covid_fact-000977",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the liver.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses cardiac replication and effects of SARS-CoV-2 but does not mention any transcriptomic changes in the liver.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0037620277144014835,
    "x2e_entail_prob": 0.013185367919504642
  },
  {
    "id": "covid_fact-000978",
    "statement": "'in a few weeks , we will have coronavirus vaccine '",
    "label": "SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "While most statements indicate hope for a vaccine in a few weeks, some mention a longer 90-day approval process.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0842655673623085,
    "x2e_entail_prob": 0.010914111509919167
  },
  {
    "id": "covid_fact-000979",
    "statement": "'in a few years, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions timelines of weeks and 90 days, not years, contradicting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.01358687411993742,
    "x2e_entail_prob": 0.06313250213861465
  },
  {
    "id": "covid_fact-000980",
    "statement": "'in a few hours, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions timeframes of a few weeks to 90 days for vaccine approval and development, which contradicts the claim of having the vaccine available in a few hours.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.38537126779556274,
    "x2e_entail_prob": 0.009620255790650845
  },
  {
    "id": "covid_fact-000981",
    "statement": "'in a few decades, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the vaccine is expected to be available in a few weeks or months, not in a few decades. The quotes from the evidence mention timelines of 'a few weeks' and '90 days,' which are much shorter than the decades suggested in the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3936845362186432,
    "x2e_entail_prob": 0.004855981096625328
  },
  {
    "id": "covid_fact-000982",
    "statement": "Indiana bans all non-essential gatherings over 250 people",
    "label": "SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that Indiana has banned non-essential gatherings of more than 250 people, which aligns with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.28751930594444275,
    "x2e_entail_prob": 0.008582815527915955
  },
  {
    "id": "covid_fact-000983",
    "statement": "Indiana bans all non-essential gatherings over 15 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Indiana banned non-essential gatherings over 250 people, not 15.",
    "confidence": 1,
    "e2x_entail_prob": 0.042216941714286804,
    "x2e_entail_prob": 0.7532209157943726
  },
  {
    "id": "covid_fact-000984",
    "statement": "Indiana bans all non-essential gatherings over 10 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence specifies that non-essential gatherings are limited to fewer than 250 people, not over 10 as claimed.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0038991475012153387,
    "x2e_entail_prob": 0.1357485055923462
  },
  {
    "id": "covid_fact-000985",
    "statement": "Indiana bans all non-essential gatherings over 20 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence specifies that non-essential gatherings are limited to fewer than 250 people, not over 20. There is no mention of a ban on gatherings over 20 people.",
    "confidence": 1,
    "e2x_entail_prob": 0.22789698839187622,
    "x2e_entail_prob": 0.08544010668992996
  },
  {
    "id": "covid_fact-000986",
    "statement": "Evaluation of four commercial , fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the Siemens COV2G assay has impaired sensitivity and suggests switching to a new IgG assay, supporting the claim of a needed revision.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8330779075622559,
    "x2e_entail_prob": 0.324646919965744
  },
  {
    "id": "covid_fact-000987",
    "statement": "Evaluation of two commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence discusses evaluations of commercial antibody tests and suggests changes to the Siemens COV2G assay, such as switching to a new assay and adjusting the cut-off index.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.970529317855835,
    "x2e_entail_prob": 0.08700338006019592
  },
  {
    "id": "covid_fact-000988",
    "statement": "Evaluation of each commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that thorough evaluation of serologic tests, including Siemens' COV2G, revealed impaired sensitivity and recommended a switch to a new IgG assay (sCOVG), supporting the need for revision.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8476231694221497,
    "x2e_entail_prob": 0.31407520174980164
  },
  {
    "id": "covid_fact-000989",
    "statement": "Evaluation of both commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that evaluations of commercial antibody tests led to revisions in the Siemens assay, including switching to a new version and adjusting parameters like the cut-off index.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6429197192192078,
    "x2e_entail_prob": 0.07397536188364029
  },
  {
    "id": "covid_fact-000990",
    "statement": "Global covid-19 cases surpass 75 million.",
    "label": "SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that global COVID-19 cases have topped 75 million, which aligns with the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.09248478710651398,
    "x2e_entail_prob": 0.14808706939220428
  },
  {
    "id": "covid_fact-000991",
    "statement": "Global covid-19 cases surpass 75 days.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states 'Global covid-19 cases surpass 75 days,' which is nonsensical as cases are counted, not measured in days. The evidence mentions 75 million cases and 1.7 million deaths but does not relate to the timeframe of 75 days. There's a possible typo, but without clarification, the claim isn't supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.03128981590270996,
    "x2e_entail_prob": 0.29614385962486267
  },
  {
    "id": "covid_fact-000992",
    "statement": "Global covid-19 cases surpass 75 persons.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that global COVID-19 cases surpassed 75 persons, but the evidence indicates over 75 million cases, which does not align with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.03392178192734718,
    "x2e_entail_prob": 0.07890472561120987
  },
  {
    "id": "covid_fact-000993",
    "statement": "Global covid-19 cases surpass 75 deaths.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim incorrectly states that global COVID-19 cases surpassed 75 deaths. According to the evidence, as of January 2021, global cases topped 75 million and deaths surpassed 1.7 million. The numbers in the evidence do not support the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.22385908663272858,
    "x2e_entail_prob": 0.46233469247817993
  },
  {
    "id": "covid_fact-000994",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in women.",
    "label": "SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly contradicts the false post by labeling the claim as NOT TRUE and provides scientific reasoning to refute it.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.022151147946715355,
    "x2e_entail_prob": 0.023501567542552948
  },
  {
    "id": "covid_fact-000995",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in dogs.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided addresses the incorrect suggestion that COVID-19 vaccines cause infertility in humans but does not provide any information regarding dogs. Therefore, it cannot support or refute the claim about dogs.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.002480778144672513,
    "x2e_entail_prob": 0.07587098330259323
  },
  {
    "id": "covid_fact-000996",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in children.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence refutes the claim that COVID-19 vaccines cause infertility, confirming it as false misinformation on social media.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.007479502819478512,
    "x2e_entail_prob": 0.012757374905049801
  },
  {
    "id": "covid_fact-000997",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in adults.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that the claim of COVID-19 vaccines causing infertility is NOT TRUE and explains it as a misunderstanding based on a very short amino acid sequence shared with syncytin-1, which does not lead to infertility.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.07976295799016953,
    "x2e_entail_prob": 0.003287126077339053
  },
  {
    "id": "covid_fact-000998",
    "statement": "Expert reaction to people being re-tested positive for coronavirus after initial recovery",
    "label": "SUPPORTED",
    "evidences": [
      "Clearly we need more information about these patients, such as were there underlying medical conditions or a change in circumstances that might have allowed the virus to escape immune control?",
      "However, the report reinforces the fact that we have to investigate all such findings really thoroughly and report such information if we are to make the best decisions based on sound scientific evidence.",
      "She has a prolonged excretion of virus from her initial infection and tests were either not done or were not done sufficiently well or enough to confirm clearance.",
      "Although coronaviruses generally cause short- term self-limiting infections which are cleared, there is some evidence in the scientific literature for persistent infections of animal coronaviruses (mainly in bats).",
      "This highlights the need for more research into the biology of the new coronavirus, it is very much early days in our efforts to understand it. On case in Japan: Prof Paul Hunter, Professor in Medicine, University of East Anglia (UEA), said: Regarding this reported case: There is so much we do not know about this case to give a properly informed opinion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Experts have reacted to cases where individuals tested positive again, highlighting the need for more information and thorough investigations into these occurrences.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9554806351661682,
    "x2e_entail_prob": 0.03269628435373306
  },
  {
    "id": "covid_fact-000999",
    "statement": "Expert reaction to people being re-tested positive for coronavirus before initial recovery",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Clearly we need more information about these patients, such as were there underlying medical conditions or a change in circumstances that might have allowed the virus to escape immune control?",
      "However, the report reinforces the fact that we have to investigate all such findings really thoroughly and report such information if we are to make the best decisions based on sound scientific evidence.",
      "She has a prolonged excretion of virus from her initial infection and tests were either not done or were not done sufficiently well or enough to confirm clearance.",
      "Although coronaviruses generally cause short- term self-limiting infections which are cleared, there is some evidence in the scientific literature for persistent infections of animal coronaviruses (mainly in bats).",
      "This highlights the need for more research into the biology of the new coronavirus, it is very much early days in our efforts to understand it. On case in Japan: Prof Paul Hunter, Professor in Medicine, University of East Anglia (UEA), said: Regarding this reported case: There is so much we do not know about this case to give a properly informed opinion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that experts are concerned about re-testing positive cases, calling for more research and thorough investigation. While they acknowledge uncertainties, their reactions confirm the need to address these issues.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8194337487220764,
    "x2e_entail_prob": 0.03752196207642555
  },
  {
    "id": "covid_fact-001000",
    "statement": "Il-6 inhibition could be key to covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.",
      "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence discusses how blocking IL-6 pathways could be a new treatment for severe COVID-19 and mentions Tocilizumab, an IL-6 blocker that is effective against the disease, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.41390275955200195,
    "x2e_entail_prob": 0.8803915977478027
  }
]